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ABSTRACT 
The porcine reproductive and respiratory syndrome virus (PRRSV) is a positive sense 
single-stranded RNA virus of the arteriviridae family and is one of the most 
economically devastating pathogens in the swine industry today. The PRRSV was 
discovered in the early 1990s in Europe and the United States, with strains being divided 
into Type 1 and Type 2 genotypes, respectively. Disease outcomes range from being 
asymptomatic to upwards of 100% mortality in herds, being attributable to the 
pathogenicity of the PRRSV strain, to co-infections with opportunistic pathogens, and to 
the age and breed of the pig. Animals subject to infection with PRRSV exhibit an array of 
clinical symptoms, including but not limited to, respiratory difficulty and pneumonia, 
weight loss, immune suppression leading to secondary bacterial infections, and 
spontaneous abortions/fetal mummification, from which the majority of the economic 
losses stem. Immunization with modified live vaccines are the most popular intervention 
to control disease, and although they are effective in improving health status of animals, 
the currently distributed vaccines pose a risk of reversion to virulence and afford limited 
cross protection amongst circulating strains of the virus. Thus, there is a high demand for 
a safe and effective vaccine. 
The goal of this study was to investigate the role of specific antigen-presenting cell 
(APC) subsets during the pathogenesis of PRRSV and to further understand the 
progression to T cell immunity in response to PRRSV. To accomplish this, we chose to 
investigate the susceptibility of bone marrow-derived dendritic cells (BMDCs), 
monocyte-derived dendritic cells (MoDCs), and monocyte-derived macrophages 
(MoMΦs). After successfully differentiating and characterizing BMDCs from 
hematopoietic stem cells isolated from the sternum of animals, we demonstrated that 
PRRSV infection is restricted only to APCs that express CD163. Furthermore, we 
showed that PRRSV replicates more quickly in MoMΦ cell cultures than in CD163+ 
BMDC cultures and potentially in MoDCs. We continued to investigate PRRSV infection 
of APCs and discovered that in non-infected MoDCs, the cellular protein gamma actin 1 
associates closely with MHCII. When MoDCs were infected with PRRSV, gamma actin 
1 was no longer associated with MHCII. We hypothesize that PRRSV could be 
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manipulating the actin cytoskeleton, potentially interfering with MHCII peptide 
presentation. 
Ultimately, we were interested in the interaction of APCs with T cells. In order to study 
this interaction, we developed an assay utilizing a mixed leukocyte reaction (MLR). Our 
hypothesis was confirmed in the MLR that showed M1 MoMΦs (IFN-γ stimulated) are 
more potent inducers of cytotoxic lymphocyte (CTLs) and CD4α+ T cell proliferation 
than M2 MoMΦs (IL-4 stimulated) or M0 MoMΦs (non-stimulated). In addition, our 
results indicated that gamma delta (γδ) T cells did not participate in the MLR. Next we 
proceeded with an animal trial investigating the interaction of APCs with T cells in a 
PRRSV-antigen specific manner. 
The objective of the trial was to investigate the progression to T cell immunity during a 
PRRSV infection. We used a commercial swine-influenza vaccine as a positive control 
antigen, and as a comparative measure for the T cell immune response to PRRSV. Our 
results indicated that PRRSV infection of APCs does not interfere with the ability of 
APCs to promote T cell proliferation. We detected IFN-γ secreting cells in PBMCs two 
weeks post infection, and T cell proliferation was evident in all lymphoproliferative cell 
cultures two weeks post infection. A comparison between MoMΦ-T cell co-cultures and 
MoDC-T cell co-cultures indicated that MoDCs may be more potent stimulators of 
central memory Th cell proliferation. Lastly, PRRSV infected animals showed a higher 
capacity to promote the proliferation of T cells specific for swine-influenza A virus, 
potentially signifying that the general monocyte population from PRRSV infected 
animals acquired an activated state as a result of the infection.  
 
Overall, the work in this thesis allowed us to formulate a theory regarding the 
dysregulated immune response to PRRSV. A characteristic adaptive immune response to 
PRRSV includes the early appearance of non-neutralizing antibodies (within a week), a 
delayed induction of T cell immunity (2-3 weeks post infection), with neutralizing 
antibodies becoming detectable roughly 4 weeks post infection, correlating to the 
resolution of illness. We believe that specific subsets of DCs are responsible for the 
induction of T cell immunity, and the rarity of this DC population(s) causes a delay in the 
induction of the T cell immune response. Furthermore, the delayed induction of T cell 
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immunity would affect the humoral immune response. In the absence of CD4+ follicular 
T helper cells, B cells would not be able to undergo proper somatic hypermutation and 
the result would be a state of hypergammaglobulinemia, similar to what is observed early 
during a PRRSV infection with non-neutralizing antibodies and auto-antibodies. The 
results herein support our theory, and contribute to the general knowledge surrounding 
the immunopathogenesis of PRRSV. Future work investigating the mechanisms by which 
PRRSV hinders the progression to adaptive immunity could prove to be fundamental in 
the development of a novel vaccine. 
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Chapter 1  LITERATURE REVIEW 
 
1.1  Introduction: 
 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a positive sense, single-
stranded, enveloped RNA virus that causes disease in swine worldwide. The virus is 
classified under the order Nidovirales from the Arteriviridae family and was first 
identified in the early 1990s (Shi et al., 2010). Today, PRRSV is the most significant 
pathogen in the swine industry causing yearly losses upwards of $650 million dollars in 
the United States alone (Butler et al., 2014; Holtkamp, 2012). Outcomes of disease 
include respiratory difficulty, spontaneous abortions and fetus mummification in sows, 
weight loss, and death under certain circumstances (Butler et al., 2014; Reeth, 1997; 
Tong et al., 2007). The demand for an efficacious vaccine and the development of 
strategies for disease control are top priorities for producers and consumers alike (Nan et 
al., 2017). 
 
1.1.1  PRRSV Structure and genomic organization 
Two main species of PRRSV exist, the North American (Type 1) and the European (Type 
2) between which a roughly 63% nucleotide identity is shared (Allende et al., 1999; 
Nelsen et al., 1999; Stadejek et al., 2013). The genome consists of 15.1-15.5 kb and can 
be divided into 9 open reading frames (ORF). The entire viral RNA transcript codes for 
ORF1a and ORF1b, which are translated into separate polyproteins. The polyproteins 
translate into 14 non-structural proteins (nsp) possessing protease (nsp1α, nsp1β, nsp2, 
nsp4), endonuclease (nsp11), helicase (nsp10), and RNA-dependent RNA polymerase 
(nsp9) activities. The structural proteins are encoded in ORFs 2-7. The glycosylated 
membrane proteins (GP2-GP5) are translated from ORFs 2-5, a small non-glycosylated 
protein (E) is resolved from ORF2b within ORF2, the membrane protein (M) is coded for 
in ORF6, and ORF7 codes for the nucleocapsid protein (N) (Dokland, 2010). High 
genetic variability, due to spontaneous mechanisms of mutation and recombination 
	 2	
between strains, has been observed in the Type 1 and Type 2 genotypes. As a result, 
numerous strains have been identified conferring variable levels of pathogenicity 
(Murtaugh et al., 2010; Wang et al., 2007). 
 
1.2  Transmission and pathogenesis 
1.2.1   Tropism 
The tropism of PRRSV is thought to be restricted to cells that express the 
hemoglobin/haptoglobin scavenger molecule CD163, which was identified as a necessary 
cellular receptor for viral entry into the cytoplasm (Calvert et al., 2007). In addition to 
CD163, sioladhesin 1 (CD169) and heparan sulfate residues have been identified as 
attachment factors for PRRSV (Van Breedam et al., 2010; Van Gorp et al., 2008). 
Although it has been widely accepted that porcine alveolar macrophages (PAMs) are the 
main target cells for PRRSV infection and replication, it has been proposed that certain 
dendritic cell (DC) subsets, and likely monocyte-derived macrophages, may also be prone 
to infection (Calzada-Nova et al., 2010; Calzada-Nova et al., 2011; Chang et al., 2008; 
Chaung et al., 2010; Peng et al., 2009; Rodriguez-Gomez et al., 2012; Rodriguez-Gomez 
et al., 2015; Silva-Campa et al., 2009). It is also possible that DC susceptibility to 
infection is strain dependent (Bordet et al., 2018). Thus, it remains unclear which cells 
are involved in spreading PRRSV throughout the blood and into peripheral lymphoid 
organs. Because DCs are the professional APC of the immune system, the modulation of 
their antigen-presenting ability, or their being targets of PRRSV replication, would have 
major implications on the transition from innate to adaptive immunity (Mildner and Jung, 
2014; Randolph et al., 2005). Whether or not DCs are susceptible to infection is under 
debate and must be resolved.  
 
1.2.2  Transmission and Pathogenesis 
PRRSV is highly communicable and is transmitted via aerosols, on fomites, through 
direct contact, and in seminal fluids (Kristensen et al., 2004; Pitkin et al., 2009; Swenson 
et al., 1994; Wills et al., 1997). Different stages of illness have been described in pigs; 
acute with resolution of viremia, viremia and persistence in lymphoid organs, or a 
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resolution of viremia with a rebound and re-established viremic state as a result of viral 
persistence in peripheral lymphoid organs (Chen et al., 2016; Petry et al., 2007). The 
course of disease is likely dependent on the pathogenicity of the virus in addition to the 
immune status, age, and genetics of the pig. Age seems to be a significant contributor to 
the outcome of an infection as older animals seem to fare better than younger animals 
potentially being attributable to a more developed immune response in adults (Butler et 
al., 2014). In the field, the most likely routes of a PRRSV infection would be intranasally, 
via direct contact and from respiratory droplets, or through semen during intercourse. The 
initial targets of PRRSV infection are likely PAMs, which reside in the alveolar space in 
the lungs. After replicating in PAMs, PRRSV becomes viremic roughly 6-12 hours post 
infection, allowing it to spread to peripheral lymphoid organs, infecting and replicating in 
macrophages and potentially dendritic cells (DCs). The immunosuppressive qualities of 
the PRRSV and compromisation of the macrophage population render animals 
susceptible to secondary bacterial and viral infections (porcine circovirus, swine-
influenza A virus (swIAV), S. suis, H. parasuis, Actinobacillus suis), which lead to an 
exacerbation of the disease resulting in the porcine respiratory disease complex. 
Pathology associated with disease includes pneumonia, respiratory difficulty, and weight 
loss (Brockmeier et al., 2017b; Lunney et al., 2016). Additionally, PRRSV infection of 
tissue macrophages in peripheral lymphoid organs and the thymus leads to the apoptosis 
of bystander lymphocyte populations. It’s possible that the apoptosis and atrophy that has 
been documented in these peripheral lymphoid organs could lead to an overall depletion 
of the lymphocyte population, resulting in a delayed induction of immunity (Gomez-
Laguna et al., 2013a; He et al., 2012).  
The majority of economic losses associated with PRRSV stem from the complications 
that arise during gestation. Rowland showed that late during gestation (70-90 days), if a 
sow becomes infected, PRRSV is able to cross the maternal/fetal barrier and productively 
infect the fetus (Rowland et al., 2003). Viral replication primarily occurs in the thymus, 
but virus is also detectable in the heart, lungs, kidney, spleen, and liver. Furthermore, it 
appeared that the fetus was able to launch an independent immune response, in which 
elevated pro-inflammatory cytokines (IFN-γ and TNFα) were detected in the placenta 
(Rowland, 2010). Until recently, the mechanism by which PRRSV crossed the maternal-
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fetal interface was unknown. Karniychuk et al. hypothesized that infection of the fetus 
being restricted to late gestation is attributable to the level of CD163+/Sn+ cells 
(endometrial macrophages) during late gestation, otherwise present in lower numbers 
throughout earlier periods. This led to their theory that PRRSV most likely enters the 
placenta via infected endometrial macrophages, which are able to traverse the 
maternal/fetal interface. Although replication occurred in the fetus, there was a lack of 
lesions surrounding internal organs, leading the authors to believe that pathological 
effects are of maternal origin. Overall, it seems that maternal CD8β+ and NK T cell 
mediated immunity at the endometrium, in addition to PRRSV replication within the 
placenta and fetal mesenchyme, which would result in apoptosis of surrounding cells, 
lead to the detachment of the trophoblast layer and ultimately the degradation of the 
placenta (Nauwynk, 2013). There have been few investigations surrounding the PRRSV 
infection of the fetus. Focusing future research efforts on both the fetal and the maternal 
response to infection in the placenta could prove to be beneficial in developing a vaccine. 
 
1.3  PRRSV pathogenicity characteristics 
 
The outcome of a PRRSV infection is largely dependent on the pathogenicity of the 
causative strain. Strains of Type 2 PRRSV can be categorized as being 
avirulent/moderately virulent, North American highly pathogenic (NA-HP), or Chinese 
HP (Ch-HP). Observations under lab conditions are subject to variation and are 
dependent on, but not limited to, route of inoculation, dosage, age, strain and sex of the 
pig. But for the most part, the syndromes of the animals subjected to RPRSV infection 
under controlled conditions correlate to those in the field.  
 
1.3.1  Low virulent strains 
Two of the first isolated strains of PRRSV became the prototypes for the Type 1 and 
Type 2 genotype designation, they were VR-2332 and Lelystad (LV), respectively 
(Murtaugh et al., 2010). Although significant genetic variation exists between the two 
strains (40%), the clinical signs and outcome of infection are fairly similar (Guo et al., 
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2013; Hanada et al., 2005; Weesendorp et al., 2013). Generally, pigs are asymptomatic in 
response to infection with either strain. Fever development and weight loss are minimal, 
if they occur at all, and symptoms occur later during infection in comparison to virulent 
strains. Mortality in response to infection with either strain is attributable to secondary 
co-infections (Guo et al., 2013; Weesendorp et al., 2013).  
 
1.3.2  High virulent strains 
Highly virulent strains of PRRSV have arisen in North America and Europe causing rates 
of mortality ranging from 50-100% in herds (Zhou and Yang, 2010). Clinical symptoms 
in pigs are more pronounced and occur early during infections with the virulent strains 
upon comparison to the Type 1 and Type 2 prototypes. Classical symptoms indicating 
PRRSV infection such as blue ears, respiratory difficulty, and weight loss have been 
observed amongst the experimentally infected pigs. Strains typically studied include Type 
1 VR-2385, MN184, SDSU73, VFL-12, SD-23983, SD01-08 and Type 2 Lena. (Guo et 
al., 2013; Karniychuk et al., 2010; Miguel et al., 2010; Weesendorp et al., 2013). The 
previously listed strains have been placed into the NA-HP category. Lastly, we are left 
with the highly pathogenic Chinese strains, which have been documented to cause 
upwards of 100% mortality in herds as well as under laboratory conditions. Infected 
animals have similar symptoms to the NA-HP challenged pigs except more acute and 
pronounced (Guo et al., 2013; Tong et al., 2007). 
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Table 1.1: Strains of PRRSV according to pathogenicity. 
Strain Virulence Genotype 
VR2332 Avirulent Type 2 
LV Avirulent Type 1 
01NP1 Avirulent Type 2 
BS/AL2011 Avirulent Type 2 
HF6-2 Moderate Type 2 
NVSL-97-7895 Moderate Type 2 
SD-23983 Moderate Type 2  
VR2385 High Type 2 
HuN4 High Type 2 
MN184 High Type 2 
Lena High Type 1 
vFL12 High  Type 2 
SD01-08 High Type2 
rJXwn06 Ch High Type 2 
CH-1a Ch High Type 2 
07HBEZ  Ch High Type 2 
WUH3 Ch High Type 2 
SY0608 Ch High Type 2 
 
List of the various strains mentioned in the review according to their genotype and 
pathogenicity. 
 
1.4  Innate immunity 
1.4.1  Innate Immune Response 
The innate immune response is critical for not only host defense, but also in providing a 
foundation for and influencing the adaptive immune response. In regards to PRRSV, the 
RNA genome is recognized by endosome bound TLR-3, TLR-7, and TLR-8 and by RIG-
I/MDA-5 in the cytoplasm (Calzada-Nova et al., 2010; Chaung et al., 2010; Miguel et al., 
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2010; Miller et al., 2009; Sang et al., 2011). Detection of the viral genome leads to the 
stimulation of type 1 interferons (IFN-α, IFN-β) and other pro-inflammatory cytokines 
(TNFα, IL-6, IL-8, IL-1β, etc) resulting in the establishment of an anti-viral state in 
neighboring cells, in addition to recruiting other immune cells to the site of infection. One 
of the more important cells recruited are DCs, the professional antigen-presenting cells 
(APC) of the immune system (Akira et al., 2006). It comes as no surprise that PRRSV is 
able to regulate the expression of the innate cytokines, and may also play a role in 
altering the activity of DCs, which would have dramatic implications on the progression 
of the adaptive response (Yoo et al., 2010). There has not been any clear correlation 
attributing increased pathogenicity to differential levels/mechanisms of immune 
regulation. 
 
1.4.1.1  Cytokines associated with PRRSV infection 
The activation of pro-inflammatory cytokine expression and type 1 IFNs occurs as a 
result of the recognition of pathogen associated molecular patterns (PAMPs). In regards 
to PRRSV, viral RNA would trigger a response. As a result, levels of type 1 IFNs and 
TLR expression have been analyzed in PAMs upon challenge with different strains of 
PRRSV. Miller et al. analyzed the induction of IFN-α in porcine alveolar macrophages 
(PAMs) infected with VR2332 upon stimulation with poly IC. Their results indicated that 
the low virulent PRRSV strain was able to inhibit the synthesis of IFN-α over the 48 hour 
time period. Although IFN-α was detected 20 and 48 hours post stimulation, the 
concentration was negligible (Miller et al., 2009). In a later study, PRRSV VR-2332 
infected pigs were shown to suppress pro-inflammatory cytokines in both the lungs and 
the serum (Guo et al., 2013). Chaung et al. infected AMs with a moderately virulent 
PRRSV strain (HF6-2) and assessed the level of TLR expression 6 and 24 hours post 
infection, and in response to poly IC (a TLR3 agonist) 24 hours post infection (PI). Their 
results indicate that TLR4 and TLR7 were downregulated upon poly IC stimulation while 
TLR3 expression was upregulated. In non-stimulated cells, TLR3 and TLR7 were 
consistently downregulated at 6 and 24 hours PI, on the other hand TLR8 was 
downregulated at 6 hours PI but returned to normal after 24 hours. No difference was 
observed in TLR2, TLR3, TLR4, or TLR9 (Chaung et al., 2010). Miguel et al. were 
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interested in TLR and cytokine expression in response to the high virulent VR2385 strain. 
Interestingly, they found that TLR3, TLR4, and TLR7 expression were downregulated in 
the lungs of infected pigs, which coincided with suppressed IL-1β, TNFα, and IL-6. But 
the opposite was observed in the tracheobronchial lymph nodes, in which all of the TLRs 
and pro-inflammatory cytokines were induced (Miguel et al., 2010). Guo et al. pigs 
infected with an Ch-HP strain showed high levels of IFN-α, TNFα, IL-6, IL-8, IL-2, IL-
12, IL-10, and IFN-γ in both the lungs and serum, which seems to indicate that a cytokine 
storm could potentially provide an explanation for the HP-PRRSV increased mortality 
rates (Guo et al., 2013). Overall, there appears to be a correlation between increased 
pathogenicity and the induction of pro-inflammatory cytokines. Lastly, although PRRSV 
seems to inhibit type 1 IFN synthesis, it has been shown that administration of IFN-α 
inhibits PRRSV replication in vivo, lending to the potential therapeutic applications of 
administered IFN-α as a resolution for PRRSV infection (Brockmeier et al., 2017a). For 
the most part, mechanisms by which PRRSV modulates the innate immune response have 
been elucidated. 
 
1.4.1.2  PRRSV mechanisms of innate immune regulation 
Non-structural protein 1 (nsp1) is a polyprotein that possesses a papain-like cysteine 
protease domain, which is responsible for its resolution into its two separate components, 
nsp1α and nsp1β. In addition to participating in viral replication, nsp1 is responsible for a 
significant portion of type 1 IFN inhibition. Song et al. investigated the properties of 
nsp1α, derived from VR-2332, in HeLa cells. They observed that nsp1α was able to 
localize to both the nucleus and the cytoplasm. Upon further analysis, they determined 
that nsp1α acted by suppressing IkB phosphorylation, inhibiting NF-κB translocation to 
the nucleus (Song et al., 2010). Conflicting results were obtained later that year by Kim et 
al. when they were unable to replicate the inhibition of IRF3 phosphorylation. This may 
have been attributable to their using MARC-145 and HeLa cells or that nsp1 was derived 
from VR-2332. They concluded that nsp1β was able to translocate into the nucleus and 
stimulate the poly-ubiquitination of CBP, which prevents the stabilization and transport 
of IRF3 to the IFN-β promoter (Kim et al., 2010). Nsp1β has been shown to possess 
multiple mechanisms by which it regulates both the expression of type 1 IFNs and IFN 
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regulatory factors (IRFs). Beura et al. observed that IRF3 phosphorylation was inhibited 
in HEK293-TLR3 cells that were transfected with PRRSV nsp1β (vFL-12) and 
subsequently challenged with dsRNA. Inhibition of IRF3 phosphorylation would prevent 
its nuclear translocation, thus inhibiting the activation of IFN-β (Beura et al., 2010). Patel 
et al. continued to research the activity of nsp1β in which they observed a completely 
different mechanism. Patel et al. observed the inhibition of STAT1 transportation to the 
nucleus in HEK293 and HeLa cells, but were unable to deduce the exact mechanism by 
which its translocation is inhibited (although they proved that it was not due to 
suppressed phosphorylation). Unlike the previous two studies, they went on to 
demonstrate STAT1 translocation inhibition in primary PAMs by infecting cells with 
VR-2385 and the MLV. Interestingly, the MLV was not able to suppress STAT1 
translocation (Patel et al., 2010). Although conflicting results exist, it is apparent that 
nsp1β plays a role in type 1 IFN regulation. Once again, it seems that the activity is strain 
dependent. In addition to nsp1β inhibition of type 1 IFN expression, nsp2 has also been 
implicated in its inhibition. 
Highly pathogenic strains of PRRSV that have arisen in China all have a similar 90 base 
pair deletion in nsp2, which is a unique feature not observed in North American or 
European strains. Nsp2 is the largest viral protein and possesses a papain like cysteine 
protease domain, typically associated with deubiquitinase activity (Dokland, 2010). Sun 
et al. were able to demonstrate that the cysteine protease domain of nsp2 from the 
avirulent SD01-08 strain is able to prevent the polyubiquitination of IκBα, which in turn 
prevents the translocation of NF-κB to the nucleus. The end result is an inhibition of type 
1 IFN stimulated genes (ISGs), pro-inflammatory cytokines, and may also play a role in 
the inhibition of apoptosis (Sun et al., 2010). In addition to preventing IRF3 and NF-κB 
translocation, nsp2 has been shown to antagonize IFN stimulated gene 15 (ISG15) 
activity. ISG15 is an important innate antiviral response protein and its activity is referred 
to posses “ISGylation” activity. Although its exact mechanism is being investigated, the 
conjugation of ISG15 to viral proteins has been hypothesized to either target viral 
proteins for degradation or disrupt protein activity (Durfee and Huibregtse, 2010). It has 
been theorized that the 30 amino acid deletion present in the HP-PRRSV strains does not 
contribute to virulence (Zhou et al., 2009). Zhi Sun et al. demonstrated that PRRSV strain 
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SD01-08 inhibits ISGylation in PAMs and more specifically, nsp2 inhibition of 
ISGylation in HeLa cells (Sun et al., 2012). Another study found that nsp2 (Ch-HP) was 
also able to inhibit the translocation of IRF3 across the nucleus, preventing the 
transcription of ISGs. Whether this inhibition is due to deubiqutinase activity or not 
remains to be determined (Li et al., 2010). Ying Fang et al. observed that the nsp2 from 
Ch-HP strains induces the degradation of IκBα in HeLa cells, thus activating the NF-κB 
pathway. They were able to determine that the hypervariable region in nsp2 is responsible 
for the NF-κB translocation and that the 30-amino acid deletion has no influence on 
activity (Fang et al., 2012). Recently, nsp2 was identified as being a structural component 
of the PRRSV virion, likely integrating into the viral envelope. This provides a potential 
explanation for high antibody titres against nsp2 in vivo. Furthermore, the study 
highlights the potential significance that nsp2 variation amongst strains could be playing 
a further role in immune evasion than what had been considered in the past (Kappes et 
al., 2013). Overall, past studies indicate that more than one domain exists in nsp2, 
resulting in multiple immunoregulatory properties such as interfering with 
proinflammatory cytokine synthesis, preventing IFN stimulated gene expression, and 
potentially having a structural role.  Although nsp2 mechanisms have only been 
demonstrated in continuous cells lines, it’s possible that nsp2 could play a significant role 
in determining virulence. In addition to the a-fore mentioned nsps, the nucleocapsid 
protein (N), nsp4, and nsp11 appear to participate in modifying the innate response as 
well. 
PRRSV nsp11 contains an endoribonuclease (NendoU) domain, which is also found in 
other Nidoviruses (Ulferts and Ziebuhr, 2011). Xibao Shi et al. investigated the properties 
of nsp11 and compared its NendoU domain sequence to those of SARS-CoV and EAV. 
The amino acids essential for the NendoU activity (His-129, His-144, Lys-173) were 
subjected to mutagenesis to elucidate the properties of the domain. They found that nsp11 
was able to inhibit the phosphorylation of IRF3 in MARC-145 cells, preventing its 
nuclear translocation. This resulted in the suppression of IFN-β induction. Knocking out 
the amino acids listed previously dramatically decreased the IRF3 suppression (Shi et al., 
2011). Zhitao Ma et al. were able to demonstrate in both MARC-145 cells and PAMs, 
that nsp4 is able to induce apoptosis, which is highly dependent on its serine protease 
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activity. Previously, GP5 had been associated with the potential induction of apoptosis, 
but this activity was not observed during their study (Ma et al., 2013). In regards to the N 
protein, its translocation to the nucleus and nucleolus during infection has been 
documented (Rowland et al., 1999; Rowland and Yoo, 2003). Rui Luo et al. investigated 
the potential activity of the N protein and discovered that it activated the NF-κB pathway. 
Their study was performed in MARC-145 cells and they observed that the DNA binding 
activity of NF-κB increased in a dose dependent manner (Luo et al., 2011). Overall 
PRRSV has multiple mechanisms by which it suppresses type 1 IFNs and ISGs and is 
able to suppress or activate the induction NF-κB associated genes. 
 
 
 
Figure 1-1: Mechanisms of innate immune regulation by PRRSV. The strains have been 
color coordinated according to their virulence. Stars with numbers = steps of PRRSV 
entry into the cell. Red = Highly Pathogenic.  Green = Avirulent.  Purple = Chine Highly 
Pathogenic. Red X = inhibition. Green arrow = activation. 
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There appears to be a significant amount of information indicating that mechanisms of 
innate immune regulation act in either a synergistic or antagonistic manner (Figure 1-2). 
The activities of specific viral proteins are highly dependent on individual strain 
pathogenicity. A prime example of this can be seen in studies performed on nsp2. Nsp2 
derived from a low virulent strain (SD01-08) was observed to deubiquitinate IκBα, 
preventing NF-κB activation, whereas nsp2 from a HP-PRRSV strain activates the 
translocation of NF-κB. The question then arises as to whether the former activity of nsp2 
is abolished or whether there is a secondary interaction with a different PRRSV protein 
that causes the phenomenon to occur.  
 
1.5  Dendritic cells 
1.5.1  PRRSV and dendritic cells 
Dendritic cells are the professional APCs of the immune system, providing a direct link 
between innate and adaptive immunity. They are responsible for transporting antigen to 
peripheral lymphoid organs to directly stimulate naïve T cells to mount a specific 
response. Cytokines produced during this process influence the type of response 
subsequently raised (Bousso, 2008). In 2007, Wang et al. were one of the first groups to 
demonstrate DC infection in vitro. Their results indicated that a moderately virulent strain 
of PRRSV (SD-23983) targeted monocyte-derived DCs (MoDCs) specifically and the 
rates at which PRRSV replication was detected was similar to those observed in MARC-
145 cells. They went on to demonstrate that SD-23983 kills DCs by both necrosis and 
apoptosis. More importantly, they observed a decrease in antigen-presenting ability in the 
infected DC population. Lastly, infected MoDCs did not produce Th1 cytokines or IL-10 
but low levels of TNFα were present (Wang et al., 2007). Later, Zhang et al. infected 
MoDCs with the moderately virulent strain SD-23983. Their results indicate that PRRSV 
is able to induce the transcription of IFN-α via the phosphoiositide 3-Kinase (PI3K) 
pathway. But, levels of IFN-α in the supernatant were negligible upon ELISA analysis. 
They concluded that PRRSV possesses a post-transcriptional method of IFN-α inhibition 
that is replication dependent, as heat inactivated virus did not possess the same 
immunomodulatory capability (Zhang et al., 2012). Mendoza et al. obtained different 
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results upon analyzing the infection of mature MoDCs (mDCs) with a NA virulent strain 
of PRRSV (vFL12). Similar to the previous study, PRRSV was able to infect and achieve 
similar rates of replication in the mDCs as those in observed in PAMs. Apoptosis was 
detected in the cells 24 hours PI and a downregulation of MHCII occurred. On the other 
hand, they observed a major upregulation of IL-10 and little IFN-α (Flores-Mendoza et 
al., 2008). In 2011, Subramaniam et al. published a paper utilizing the same viral strain as 
Mendoza that showed levels of IL-10 were not up-regulated in DCs. A potential 
explanation for the difference to Mendoza’s past results could be attributable to LPS 
treatment (stimulating DC maturation) inducing high levels of IL-10 production in 
MoDCs before infecting the DCs (Subramaniam et al., 2011). PRRSV strain HF6-2 was 
utilized to infect GM-CSF/IL-4 derived BMDCs. The results were consistent in 
demonstrating decreased levels of MHC-I and CD80/86 expression in infected cells and 
apoptosis in cell cultures. Interestingly, bystander, uninfected cells showed an 
upregulation of CD80/86. There appeared to be a significant induction of IL-1, IL-6, IL-
8, and more importantly IL-10. Levels of TNFα and IL-12 were negligible (Chang et al., 
2008; Peng et al., 2009). More recently, Rodriguez-Gomez et al. found that MoDCs 
infected with either Type 1 or Type 2 PRRSV showed an upregulation of SLA-DR and 
CD80/86. They investigated whether IL-10 secretion resulted in the induction of 
regulatory T cells and determined that PRRSV infection of MoDCs did not result in the 
stimulation of regulatory T cells (Rodriguez-Gomez et al., 2015). The variable results 
obtained from different studies could be attributable to the strain of virus used, the MOI 
of the infection, and the breed or age of the pigs. 
 
1.5.2    Plasmacytoid dendritic cells 
Plasmacytoid DCs (pDCs) have been identified in humans to be a specific subset of DCs 
responsible for the majority of the IFN-α production observed in vivo. Calzada-Nova et 
al. were able to isolate and characterize a pDC population from pigs based on their 
CD4αhiCD172alo cell surface morphology utilizing cell sorting (Calzada-Nova et al., 
2010). They went on to investigate whether pDCs were susceptible to PRRSV infection 
in vitro. Plasmacytoid DCs were treated with PRRSV 4468 and subsequently challenged 
with ODN D19 (TLR9 agonist) or transmissible gastroenteritis virus (TGEV), which on 
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their own induce IFN-α, TNFα, IL-8, IL-6, and IL-2. The cells were found to be non-
permissive to PRRSV infection, but only moderate levels of IL-2 were detected. Upon 
closer examination, they found that PRRSV (live or inactivated) suppressed levels of 
IRF7 upon challenge with ODN D19 or TGEV. Similarly, they observed a decrease in 
STAT1 translocation to the nucleus. Although the exact mechanism by which PRRSV 
acts to modulate the response in pDCs was not determined, the authors hypothesize that 
the immune suppression is occurring as a result of an extracellular interaction of a viral 
protein with a pDC cell surface receptor (Calzada-Nova et al., 2011). Results obtained by 
Zhang et al. demonstrated a lack of IFN-α production in MoDCs after Poly I:C 
stimulation, which could be attributed to pDCs not being present in MoDC populations. 
Later, Baumann et al. investigated the IFN-α response of pDCs upon challenge with 
various strains of PRRSV. They found that all PRRSV isolates, both type 1 and 2, were 
able to induce IFN-α, but the levels of IFN-α were considered negligible. Furthermore, 
there appeared to be a strain dependent variation as the Ch-HP strain (SY0608) 
suppressed 51% of IFN-α compared to VR2332’s 31% suppression upon stimulation with 
CpG (Baumann et al., 2013). During early stages of infection, IFN-α has been detected 
systemically in PRRSV infected animals (Guo et al., 2013). A group investigated the 
source of IFN-α in pigs infected with Lena virus and found that pDCs were responsible 
for the secretion of IFN-α. Their results indicate that pDCs detected PRRSV virions in 
association with infected macrophages, and PRRSV virion on its own was unable to 
induce IFN-α (Garcia-Nicolas et al., 2016). Overall, it doesn’t seem that pDCs are targets 
of PRRSV replication, but pDCs play a prominent role in the synthesis of IFN-α. 
Furthermore, past investigations would suggest that the induction levels of IFN-α appear 
to be dependent of the viral strain, which could provide some insight into the 
pathogenesis of PRRSV. 
  
1.5.3   Antigen processing and presentation 
The recognition of a peptide sequence in association with an MHC molecule by an αβ T 
cell receptor (TCR) is arguably the most important step towards stimulating a cell 
mediated immune response against the antigen from which the peptide sequence was 
derived. Although every nucleated cell in vivo is capable of presenting antigen on MHCI 
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molecules, antigen presentation is typically associated with those cell that express MHCII 
in addition to MHCI, which are MΦs, B cells, and DCs (and thymic epithelial cells). The 
pathways by which antigen is processed can be divided into the endogenous or the 
exogenous pathway (Klein et al., 2014; Vyas et al., 2008b). Antigens being processed and 
presented by APCs are not always foreign, as the majority are likely self-derived peptide 
sequences. Surveying self-derived peptide sequences aids in maintaining tolerance in 
addition to providing a means to survey for potentially oncolytic cells expressing 
abnormal proteins. As its name implies, the endogenous pathway involves the processing 
of antigen found within the cytoplasm of a cell. Essentially, this pathway provides a 
means by which cells are able to recycle amino acids from mis-folded proteins that have 
been polyubiquitinated and targeted for degradation into short peptide sequences (8-10 
amino acids in length) by the proteasome (Blum et al., 2013). In regards to pathogens, the 
endogenous pathway provides a means by which intracellular pathogen’s proteins can be 
presented on MHCI molecules for recognition by CD8β+ T cells. On the other hand, the 
exogenous pathway involves the processing of antigen that has been encountered 
extracellularly. Of note is the premise of cross-presentation, which is essentially antigen 
processed via the exogenous pathway that results in peptide sequences being loaded onto 
MHCI molecules in the endoplasmic reticulum. Cross-presentation explains how the 
stimulation of naïve CD8β+ T cells occurs when the APC is not susceptible to infection 
by an intracellular pathogen, therefore the pathogen’s antigens would need to be 
processed exogenously (Embgenbroich and Burgdorf, 2018). 
Antigens acquired from the external environment of an APC are processed through the 
exogenous pathway. In brief: antigen is phagocytosed and the phagosome eventually 
fuses with a lysosome (forming the phagolysosome), which results in the degradation of 
the antigen into short peptide sequences. After MHCII has undergone post-translational 
modification, it is transported to the phagolysosome where peptide sequences are loaded 
in the binding groove of MHCII so that it can be transported to the cell surface for 
antigen presentation to CD4α+ T cells (Vyas et al., 2008a). Unlike its MHCI counterpart, 
the length of peptide sequences bound the groove of MHCII can range from 10-51 amino 
acids in length. Furthermore, it has been shown that some of these longer peptide 
sequences may possess higher immunogenicity than some of the shorter peptides 
	 16	
(Niebling and Pierce, 1993). Variations in the length of peptide sequences bound to 
MHCII, in regards to immunogenicity, are likely antigen specific. Given that 10-12 
amino acids may be bound to the groove of MHCII at one time, any peptides longer than 
this would have interactions outside the groove of MHCII which would alter the 
interaction of the MHC molecule with a TCR. Before the MHCII molecule binds to a 
peptide sequence, it must go through a series of steps during its translation to ensure that 
it acquires a peptide sequence efficiently. Shortly after translation in the endoplasmic 
reticulum, the MHCII binding groove is occupied by the invariant chain (Iip31). The 
invariant chain serves to prevent self peptide sequences from occupying the binding 
groove before the MHCII molecule has been transported to a phagolysosome (Sercarz 
and Maverakis, 2003). Non-cysteine proteases are responsible for the initial trimming of 
the invariant chain before the MHCII-Iip31 complex is transported to the endosomal 
compartments. A crucial step in the maturation of the invariant chain is the processing of 
Iip31 into the class II-associated invariant chain peptide (CLIP). After being processed 
into CLIP, the accessory proteins HLA-DM/HLA-DO are able to exchange CLIP for a 
nascent peptide sequence within the endosome/phagolysosome. Cysteine proteases have 
been shown to be indispensible to the maturation of the invariant chain, particularly 
Cathepsin S. In mice, studies have demonstrated that Cathepsin S is responsible for the 
final processing of the Iip31 into CLIP. Furthermore, inhibition of Cathepsin S in DCs 
essentially eliminates their ability to present antigen to CD4α+ T cells and may even have 
an effect on germinal center development (Riese et al., 1998; Shi et al., 1999). Other 
cysteine proteases of interest, when considering the maturation of Iip31, are Cathepsin F 
and Cathepsin L. Considering there are multiple antigen-presenting cells, it doesn’t 
surprise that cysteine protease expression varies within specific cell types. Cathepsin F 
activity in MΦs has been shown to be higher than in B cells and DCs, and Cathepsin L 
activity seems to be indispensable for thymic epithelial cells antigen presentation during 
positive and negative selection process of thymocytes (Shi et al., 2000); (Turk et al., 
2012). Currently there is no information regarding the expression or role of cysteine 
proteases in pigs, nor has there been any research on the maturation of the invariant chain 
in pigs. Considering the variation in cysteine protease expression amongst APC 
populations in mice, it would seem plausible that this variation could have an effect on 
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the peptide sequences being presented within those specific APC populations. It has been 
demonstrated that PRRSV may be forming a replication complex in association with 
endoplasmic reticulum derived double membrane vesicles in infected cells (Kappes and 
Faaberg, 2015). If this is the case, PRRSV could be interfering with antigen processing.  
 
1.6  Humoral immunity 
1.6.1  Humoral immune response to PRRSV 
Humoral immunity involves antigen recognition by specific B cell receptors (BCRs) on 
the surface of B cells, which have been germline encoded. B cell activation can occur 
independently of T cell help, or with the aid of helper T cells. Upon antigen recognition, 
the BCR undergoes affinity maturation via isotype switching and somatic hypermutation 
within germinal centers. In the case of a viral infection, the primary mechanisms by 
which antibodies (ab) act would be through virus neutralization and opsonization 
(Hangartner et al., 2006). Regarding PRRSV, a robust ab response is detectable in serum 
7 days post infection, although they are non-neutralizing antibodies (non-NA) and do not 
aid in the subversion of the infection. Roughly 4 weeks post infection, the appearance of 
NA in serum and in mucosal secretions becomes apparent eventually leading to the 
resolution of viremia (Loving et al., 2015). Furthermore, the passive transfer of serum 
containing NA to naïve pigs protected them from infection when challenged with a 
homologous strain of PRRSV. Thus, it’s safe to conclude that NA provide sufficient 
protection from infection, although the role that cell mediated immunity plays in 
protection, in addition to influencing the humoral response, should not be dismissed 
(Osorio et al., 2002). In the past, research areas focused predominantly on identifying 
neutralizing epitopes within glycoprotein 5 (GP5) and the membrane (M) protein of 
PRRSV, but recently the GP2-GP3-GP4 trimer have gained increasing attention. The 
ideal vaccine candidate will stimulate a NA response within 2 weeks of immunization 
and have broad cross-protection across different strains of PRRSV. Difficulty in 
achieving NA induction stem mainly from the masking of neutralizing epitopes on the 
surface of virions by glycan shields, and the unusually high mutation rates seen in 
PRRSV make it difficult to identify conserved epitope motifs (Lopez and Osorio, 2004; 
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Loving et al., 2015; Lunney et al., 2016). Multiple questions arise when considering the 
humoral response to PRRSV, which include the following: What antibody isotypes 
correlate to the highest level of protection and how do they function? What is the role of 
non-NA and how do they influence disease progression? And lastly, why is there a delay 
in the appearance of NA?  
A kinetic of the ab response to PRRSV has indicated that immuglobulins are detectable in 
oral fluids of infected animals as early as 3 days post infection. Secreted IgM (sIgM) was 
detected from days 3-10, sIgG from days 7-10, and sIgA from days 8-14. 
Immunogloblins in serum are detected on similar days with (IgM>IgG>IgA 
concentrations), increasing until day 21 at the end of the trial (Kittawornrat et al., 2013). 
Classically, IgM is associated with a primary B cell response in humans and mice. 
However, the fetal pig does not rely on its mother for passive immunity in utero. Instead, 
the immune status of the pig begins to develop in utero. As such, it has been shown that 
isotype switching in pigs occurs during gestation. Additionally, it has been shown that 
isotype switching is able to occur in the absence of encountering antigen specific for its 
specific B cell receptor. This may be advantageous as it could speed up the process of 
developing an antibody repertoire conferring higher affinity for antigen by skipping the 
isotype switch process seen in humans and mice (Butler et al., 2001). But, somatic 
hypermutation will only occur in the presence of antigen, so the overall period of time of 
B cell affinity maturation may not be impacted that significantly (Butler et al., 2002). 
Regarding PRRSV, ab isotypes involved in protection include IgM, IgG, and IgA. Early 
during infection, B cells encounter their antigen inducing the secretion of IgM and 
proliferation of plasma cells. IgM is the first line of ab defense, in that is has a lower 
affinity for specific epitopes, but has 10 potential binding regions conferring a high 
avidity. Three main mechanisms by which IgM can function include: a) opsonization of 
antigen resulting in the recruitment of the C1 complex from complement; b) opsonization 
of antigen leading to increased uptake by APCs; and c) antigen neutralization. It is 
generally found in serum, but can also be detected in oral fluids (Burton, 2002), 
(Hangartner et al., 2006). IgG is found mainly in serum and tissues and possesses similar 
mechanisms to IgM. Primary mechanisms include virus neutralization and opsonization. 
Binding of IgG to viral antigen can prevent attachment of the virus to cells or inhibit viral 
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membrane fusion, preventing entry of the viral genome into the cell’s cytosol. 
Opsonization of the virus results in the recruitment of macrophages, dendritic cells, and 
neutrophils, mediating phagocytosis via an interaction with the Fc portion of the ab with 
the FcγR on the surface of the cells. Furthermore, a potential mechanism would be the 
binding of ab to viral antigen on the plasma membrane of an infected cell. This would in 
turn activate antibody-dependent cell-mediated cytotoxicity by NK cells, ultimately 
leading to the death of the cell (Hangartner et al., 2006). Although, this mechanism may 
not be as prevalent during PRRSV infection as viral proteins typically localize to the 
endoplasmic reticulum, and budding occurs at the golgi, not the plasma membrane. Viral 
particles are transported out of the cell via exocytosis, making it unlikely for PRRSV 
proteins to associate with the plasma membrane of cells (Veit et al., 2014). Lastly, IgA is 
commonly found as a secreted form in the mucosa, although it is also detectable in serum. 
The primary role of secreted IgA (sIgA) is neutralization of toxins or in the prevention of 
pathogen attachment to their target cells. Thus, an ideal vaccine candidate will elicit a 
strong IgA response in mucosal tissues in order to prevent the infection from breaching 
the mucosal epithelium, halting the establishment of a potential infection (Burton, 2002; 
Hangartner et al., 2006). The major hurdle that exists in the immune response to PRRSV 
is the robust non-NA response and the delay in NA induction, which is discussed below.  
 
1.6.2  Antibody mediated enhanced uptake 
As mentioned previously, NAs don’t appear until 4 weeks post infection. This could be 
attributable to immune evasion and the immune dysregulation in both the innate and 
adaptive branches of immunity. As such, the non-NAs have shown specificity for GP5, 
M, N, and multiple non-structural proteins (nsps). This begs the question as to what role 
non-NAs play during infection. It has been hypothesized that antibody dependent 
enhanced uptake (ADE) exists, which would result in a heightened rate of infection with 
potentially severe clinical outcomes if an animal were to be infected with a heterologous 
strain of PRRSV. But the evidence surrounding ADE has been sketchy, and likely is not 
occurring (Loving et al., 2015). Taking into consideration how quickly PRRSV 
disseminates to multiple organs throughout the body, it seems plausible that non-NA 
could be enhancing the rate of dissemination. The mechanism of dissemination would be 
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comparable to ADE, in that opsonization of viral particles with serum immunoglobulins 
(via interactions with FcRγ on the surface of APCs and the recruitment of C1 from 
complement) would result in increased uptake into APCs, particularly macrophages 
(MΦs). In addition to the early viremic state associated with PRRSV infection, enhanced 
uptake by APCs, and their subsequent infection, would provide a potential explanation 
for the rapid spread of virus throughout the body. The difficulty in demonstrating ADE 
upon challenging pigs with a heterologous strain of PRRSV could be attributed to ADE 
occurring in a primary challenge in naïve animals. Essentially, the mutation rates are so 
high within non-neutralizing epitopes of PRRSV that upon encountering a heterologous 
strain of PRRSV, the immune system would be unable to recognize it as being related to 
the primary strain. But this doesn’t mean that non-NA don’t enhance the rate of infection 
and dissemination. If anything it’s the opposite, in that a state of ADE occurs during 
every PRRSV infection, excluding challenges with homologous strains in the presence of 
NAs. Thus, a potential role for non-NA in PRRSV infection could be the enhancement of 
dissemination through the body via opsonization of viral particles, leading to enhanced 
uptake by APCs (the targets of viral replication). In terms of usefulness, non-NAs are not 
entirely useless as they can be utilized for diagnostic purposes. It is also possible that 
non-NA could play a role in virus neutralization, as discussed in the following paragraph.  
 
1.6.3  Targets for antibody intervention 
Antigenic epitopes associated with neutralization are buried beneath glycan shields and 
potentially within quartenary protein structures (the GP2-GP3-GP4 trimer) on the surface 
of the PRRSV virion. Furthermore, the principal neutralizing epitopes (NE) are flanked 
by non-neutralizing decoy epitopes (Loving et al., 2015; Lunney et al., 2016). It begs the 
question as to how NAs are able to circumvent the glycan shields (as glycan shields have 
been shown to be indispensable for PRRSV replication, they can’t be deleted or 
modified) to gain access to the NEs that are buried and hidden. It’s plausible that upon 
binding to their antigenic epitopes, non-NA could alter the conformation of adjacent viral 
proteins. Alterations in the conformation of proteins surrounding NEs could theoretically 
expose the NE. This could potentially explain how NAs are able to gain access to the 
hidden and buried NE, in addition to the NAs undergoing rigorous somatic hypermutation 
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(Burton, 2002; Hangartner et al., 2006). It’s clear that NAs are a necessary component in 
overcoming infection. Thus, the main issue that exists is the delay in the induction of NA 
and the preferential synthesis of non-NA during the viremic period of infection.  
 
1.6.4  Hypergammaglobulinemia 
The robust non-NA response seen early during infection with PRRSV may be attributable 
to hypergammaglobulinemia. Butler et al. were able to demonstrate that the amount of 
immunoglobulin present in bronchoalveolar lavages (BAL) during a PRRSV infection 
was increased more than 10 fold in comparison to pigs infected with swine-influenza 
virus (swIAV) and porcine circovirus-2 (PCV-2). They essentially showed that the 
majority of the B cells, during the viremic state of a PRRSV infection, express different 
isotypes (IgM, IgG, IgA) but nearly identical sequences in their 3rd complimentarity 
determining region (HCDR3) of the antibody heavy chain. In other words, the authors 
showed that the non-NA response to PRRSV originated from similar B cell clones that 
had not undergone somatic hypermutation. Furthermore they argued that the amino acids 
within the HCDR3 region (the central binding domain of the hypervariable region) were 
of hydrophobic nature, resembling a non-specific, polyvalent repertoire of antibodies 
characteristics of a naïve ab repertoire in infants (Schroeder et al., 1998). The authors 
hypothesized there is a PRRSV antigen that acts similar to a superantigen, stimulating the 
proliferation of a population of B cells derived from a nearly identical clone. There has 
been no evidence of a super antigen that PRRSV secretes. But it’s plausible that early 
during PRRSV infection B cells are activated independently of T cell help. In this case, 
ab-ag complexes could interact with B cells in peripheral lymphoid organs and stimulate 
a robust antibody response. Without the aid of T helper cells, somatic hypermutation 
would be delayed resulting in an ab repertoire with relatively low affinity for PRRSV 
antigens, and potentially even auto-reactive abs (Butler et al., 2008). Taking into 
consideration the timeline of the adaptive immune response to PRRSV, it seems that IFN-
γ cells appear in the periphery before NAs. Therefore, it is plausible that B cells 
proliferate independently of T cell help early during infection. Then once T cells have 
been activated, they interact with B cells driving somatic hypermutation, eventually 
resulting in NA synthesis. Overall, it seems likely that in order for B cells to undergo 
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somatic hypermutation, leading to the synthesis of NA, they must communicate with CD 
follicular T helper cells. Unfortunately, the cell-mediated immune response to PRRSV 
seems to be suppressed or dysregulated in some way. Knowledge surrounding the cell-
mediated immune response to PRRSV is lacking, and the information that does exist is 
relatively conflicting. Particularly whether regulatory T cells are being induced to 
suppress the progression to an effective T cell response must be addressed. In order to 
discover answers regarding the immune dysregulation that occurs during PRRSV 
infection, both cell-mediated immunity and humoral immunity warrant further attention.  
 
1.7  Cell-mediated immunity 
1.7.1  CD4+ T helper cells 
The initial stages of T lymphocyte development occur in the thymus, in which T cells 
undergo a process of positive and negative selection. During positive selection, 
CD4α/CD8β double positive thymocytes migrate to the thymic cortex and interact with 
thymic epithelial cells. If the double positive thymocytes interact more strongly with 
MHCII they become CD4α+ and if they interact more with MHCI they acquire a CD8β+ 
lineage. If the thymocyte has undergone a poor rearrangement of its T cell receptor 
(TCR) and does not interact with either MHCI or MHCII, that thymocyte undergoes 
apoptosis and is eliminated from the T cell repertoire. The negative selection of T cells 
eliminates those lymphocytes that have acquired a T cell receptor (TCR) that is reactive 
against self-MHC molecules in association with its peptide complex. Those T cells that 
are self reactive, for the most part, undergo apoptosis and are eliminated from the 
repertoire, in turn preventing self-reactivity and auto-immunity (Colf et al., 2007; Singer 
et al., 2008). Once a thymocyte has acquired markers towards a specific lineage (CD4α+, 
CD8β+, or γδ+) it then migrates to secondary lymphoid organs for further development 
(Klein et al., 2014). 
CD4+ T helper (Th) cells can be described as the directors of the adaptive immune 
response. As their name implies, the primary role of CD4+ Th cells is to aid in the 
development of both the cell-mediated and the humoral arms of immunity (Bevan, 2004; 
Crotty, 2015). A naïve CD4+ Th cell resides within peripheral lymphoid organs awaiting 
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its encounter with the antigen for which its αβ TCR has been rearranged to recognize. 
Upon acquiring antigen, APCs migrate towards the draining lymph node to stimulate T 
lymphocyte maturation. This step of T cell maturation is dependent on multiple factors 
during antigen presentation that include the following: First, the successful recognition 
and interaction of the TCR with the MHCII peptide bound molecule. Secondly, the 
induction of CD80/86 expression on the APC and its interaction with CD28 on the T cell. 
And lastly, the cytokines expressed by the APC to which the T cell is directed towards 
differentiating into a specific lineage (Pennock et al., 2013). In regards to PRRSV, the 
most effective lineage to combat the viral infection would be a Th1 type immune 
response. In order for this to occur, APCs presenting antigen to T cells would be 
expressing IL-12 and potentially IFN-α. The cytokines delivered by the APC stimulate 
the expression of different transcription factors that influence the type immune response 
the Th cell will be geared towards. In the case of a Th1 type immune response, the 
transcription factor T-bet would be activated in the lymphocyte (Luckheeram et al., 
2012a). Whether or not this is occurring during PRRSV infection is unknown. Multiple 
subsets of CD4+ Th cells exist and they will be discussed in the following paragraphs. For 
simplicity’s sake, this review will focus primarily on Th1 differentiated CD4+ Th cells as 
they are the major effectors when considering viral infections. CD4+ Th cells can thus be 
characterized as having an effector or a memory phenotype. 
Upon stimulation, a naïve CD4+ Th cell clone differentiates towards a specific lineage 
(eg: Th1) from which it undergoes cell division into effector T cells. The effector T cells 
acquire homing receptors that enable their migration towards sites of inflammation, 
resulting in their activity to clear the antigen to which they have been stimulated. Once 
antigen has been cleared, roughly 90% of the effector population dies leaving the residual 
population to undergo memory cell differentiation. T cells acquiring a memory phenotype 
can be categorized as central memory T cells (TCM) or effector memory T cells (TEM). 
The purpose of the memory cell population confers the ability to mount a secondary 
response to a previously encountered antigen. Although the mechanisms by which a 
CD4+ Th cell undergoes memory differentiation are not completely understood, marked 
differences between TCM and TEM cells are known. Central memory T cells reside within 
peripheral lymphoid organs, expressing the homing receptor CCR7 that permits their 
	 24	
migration between secondary lymphoid organs, surveying and sampling for their 
particular antigen. Furthermore, the TCM population seems to have a lower expression of 
the lineage committed transcription factors (eg T-bet) in comparison to their TEM 
counterparts. It’s likely that T effector clones arise from the TCM populations. The TEM 
population have higher expression of their lineage committed transcription factors and 
reside within specific organs or tissues, likely associated with their original homing 
destination (where the antigen was encountered at its highest concentration). Thus, the 
TEM population lends the ability to mount a quick and effective an immune response at 
the site of infection (Pepper and Jenkins, 2011a).  
As mentioned previously, the major role of CD4α T cells is to direct the immune 
response, given their “helper” T cell designation. Once stimulated, Th cells differentiate 
into different subsets. One important subset of CD4+ Th cells is the follicular T helper 
(TFH) cells. As their name implies, TFH are CD4+ Th cells that up-regulate the expression 
of CXCR5, which enables their migration to germinal centres. Within germinal centres 
TFH, in conjunction with follicular DCs, direct somatic hypermutation and isotype 
switching. They have been shown to be crucial in generating long lasting neutralizing 
antibody responses to certain viruses. In addition to aiding the activation of B cells, CD4+ 
Th cells also play a role in the stimulation of naïve CD8β+ CTLs. The activation of 
CD8β+ can be accomplished via stimulation and antigen presentation by APCs, but CD4+ 
Th cells seem to be crucial in forming a memory CD8β+ T cell response. An interaction 
of co-stimulatory molecules between CD4+ Th cells and CD8β T cells, particularly 
CD40-CD40L, results in a downregulation of TNF-related apoptosis inducing-ligand 
(TRAIL) within CD8β+ T cells, conferring long lived memory cells via inhibition of 
apoptosis (Swain et al., 2012b). In addition to helping, CD4+ T cells possess effector 
mechanisms that directly combat infection by influencing the cytokine environment at the 
sites of immune activation and infection.  
As mentioned previously, the activation of a CD4+ T cell clone results in its division into 
lymphoblast CD4+ effector T cells. These effector T cells migrate towards sights of 
inflammation in order to aid in clearing antigen to which they have been primed. 
Arguably, the major contribution of CD4+ effector T cells when combatting a viral 
infection is via the secretion of IFN-γ. The secretion of IFN-γ aids in the establishment of 
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an anti-viral response amongst cells surrounding the area in which the CD4+ effector T 
cell is located (eg: activation of MΦs to an M1 phenotype). Additionally, some CD4α+ 
effector T cells may possess some cytolytic activity, either through perforin secretion of 
FasL induced apoptosis of target cells (Swain et al., 2012a). After the resolution of an 
infection, T lymphocyte numbers return to base levels with the help of CD4+ regulatory T 
cells (TReg). Regarding a viral infection, it’s likely that regulatory T cells are induced in 
an antigen specific manner. A hallmark for regulatory T cell identification in pigs is the 
expression of Forkhead box P3 (FOXP3) and CD25, in addition to CD4α (Kaser et al., 
2015). Regulatory T cells possess potent anti-inflammatory mechanisms, mainly through 
secretion of IL-10 and tissue-growth factor β (TGF-β). These cytokines are also able to 
induce apoptosis in effector T lymphocytes that are no longer needed, in the case of 
antigen clearance. Regulatory T cells may also possess some cytolytic activity, through 
the secretion of granzyme A/B and perforin, which would also aid in the induction of 
apoptosis in lymphocytes that are no longer needed. Whether or not these inducible TRegs 
acquire a memory phenotype is unknown, but it’s possible that some of the natural TRegs 
that are more involved in self-tolerance and tissue homeostasis could be found to acquire 
a memory phenotype (Vignali et al., 2008). 
 
1.7.2  CD8β+ cytotoxic T cells 
The endogenous pathway of antigen presentation has been discussed previously. To 
recap, cytoplasmic antigen is processed via proteasomal degradation and presented as 
peptide sequences bound to MHCI molecules on the surface of cells. This provides the 
immune system with a mechanism to combat intracellular pathogens through the 
activation of CD8β+ CTLs. As such, an optimal Th1 type immune response mounted 
against a virus will involve the induction of CD8β CTLs (Rosendahl Huber et al., 2014). 
Similar to CD4+ Th cells, CTLs can acquire memory of effector phenotypes. The memory 
cell phenotype of CTLs follows similar principles to CD4+ induction, thus only effector 
mechanisms of CTLs will be discussed here. Viral infected cell recognition by CTLs 
results in their targeted apoptosis through multiple mechanisms. The main effector 
mechanism of CTLs would be through secretion of perforin, which punches holes in the 
membranes of cells, and the delivery of granzyme A/B to induce apoptosis. In addition to 
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perforin/granzyme secretion, CTLs can induce apoptosis via Fas-FasL interactions on cell 
surfaces. And lastly, similar to CD4+ effector T cells, CTLs are capable of influencing the 
immune environment through the secretion of inflammatory cytokines such as IFN-γ and 
TNFα (Barry and Bleackley, 2002).  
 
1.7.3  Porcine T lymphocytes 
Taking into consideration the porcine immune system, a study was performed to identify 
cell surface markers associated with T memory cell (TMem) differentiation and variation in 
T cell subsets over the first 6 months of a pig’s life. A portion of porcine CD4α+ Th cells 
are found to express CD8α, which seems to correlate with age. The authors went on to 
theorize that CD8α expression was associated with antigen-experienced memory Th cells. 
As a result, they noted an absence of CD4α+ CD8α+ T cells that were CD27-, early in life. 
Over time, as pigs would encounter antigen and begin to develop a memory Th cell pool, 
the CD4α+ Th cells began to express CD8α and were CD27+. Therefore, in pigs, it seems 
that CD4α+CD8α+CD27+ Th cells are an indicator of a memory cell phenotype and 
CD4α+CD8α-CD27- would account for the naïve CD4α+ Th cell population. The CD8β 
cytotoxic lymphocytes (CTL) seemed to follow a similar path of maturation as the CD4α 
Th cells. Essentially, the authors found that the expression of CD27 correlated with a 
naïve CTL phenotype. In the first week after birth, perforin expression was limited to NK 
cells. Perforin expressing CD8β T cells occurred in conjuction with the gradual loss of 
CD27 expression. The authors theorized that during the early stages of activation, 
effector CTLs begin to lose CD27 expression while up-regulating perforin. Therefore, the 
memory CTL pool can be described as CD3+CD8β+CD27+. Lastly, it should be 
mentioned that a major constituent to the T cell pool in pigs is the γδ T cell population 
(Talker et al., 2013).  
 
I.7.4  Gamma delta-T cells and natural killer cells 
Gamma delta-T cells (γδ T cells) are a CD3+ lymphocyte population that share properties 
characteristic of both the innate and adaptive arms of immunity. Found both in tissue and 
peripheral blood, multiple subsets possessing different qualities have been identified. 
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Their recognition of antigen occurs via interactions between the γδ TCR and CD1d 
molecule on APCs and T cells, which presents the antigen. Whether or not γδ Tcells can 
acquire a memory phenotype, being specific for a particular antigen, is still under 
investigation (Lalor and McLoughlin, 2016). It appears that this may be pathogen specific 
and it is also possible that different subsets of γδ T cells exist in which some may be more 
innate and others more adaptive. The innate aspect of γδ T cells has received more 
attention and the mechanisms of γδ antigen recognition have been identified. 
Phosphoantigens, which are host-derived and presented on CD1d molecules, have been 
shown to possess γδ T cell stimulatory capacity. Additionally, certain pathogen-
associated proteins can be recognized by γδ T cells to activate their anti-viral 
mechanisms. And lastly, γδ T cells have been shown to be sensitive to TLR stimulation, 
lending another method for activation in response to an infection (Vantourout and 
Hayday, 2013).  Regarding their mechanisms to combat pathogens, γδ T cells exhibit 
similar cytotoxic qualities to NK cells and CTLs. Being capable of perforin and 
granzyme B secretion, in addition to utilizing the Fas-FasL pathway, γδ T cells are potent 
inducers of apoptosis in target cells. Furthermore, γδ T cell secretion of pro-inflammatory 
cytokines play an important role early during infections to promote the recruitment of 
leukocytes and the activation of phagocytes, in addition to influencing APC maturation. 
Lastly, in mice it has been shown that γδ T cells may act in the stimulation of αβ T cells 
through antigen presentation, as studies have demonstrated their expression of MHCII in 
addition to CD80/86. Their function as APCs warrants further investigation. Overall, γδ T 
cells possess numerous functions to influence the outcome of an infection, resulting in 
their classification within the innate and adaptive branches of immunity (Zheng et al., 
2013). 
Natural killer cells (NK) are a branch of the innate immune system and were originally 
identified based on their anti-tumor properties. The recognition of stress or damage 
associated molecules on the surface of a cell is one mechanism that initiates NK cell 
cytotoxicity. In addition to this, tumor cells, and sometimes virally infected cells, often 
have down-regulated expression of MHCI molecules, which is also a primary mechanism 
utilized by NK cells for targeted apoptosis (Topham & Hewitt, 2009). Similar to CTLs, 
NK cells induce apoptosis via perforin/granzyme B secretion and the Fas-FasL pathway. 
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The expression of CD16 on NK cells confers the capability of inducing antibody 
dependent cell cytotoxicity (ADCC). Essentially, a virally infected cell could have viral 
proteins incorporated into its cell membrane that would be recognized by antibodies. The 
opsonization of the virally infected cell could then be recognized by CD16, through 
binding to the Fc portion of the antibody, which would in turn mediate the apoptosis of 
the infected cell. Lastly, NK cells are capable of secreting pro-inflammatory cytokines, 
such as IFN-γ and TNFα. Secretion of cytokines could lead to the activation of 
phagocytes, aid in the recruitment of leukocytes to the site of infection, and potentially 
influencing the adaptive arm of immunity. Their capabilities of cell cytotoxicity and their 
influence on the cytokine environment mirror those of CTLs, albeit in a primarily non-
antigen specific manner (Vivier et al., 2008). 
As mentioned previously, a large proportion of CD3+ T cells in the peripheral blood of 
pigs consist of γδ T cells. It was found that the amount of γδ T cells increased as a result 
of age, reaching upwards of 50% of the entire CD3+ T cell population. Furthermore, 
CD8α was expressed on the majority of the γδ T cell population, indicating their 
likelihood in thymic development. In addition to CD8α, the expression of CD27 on the 
surface of γδ T cells seems to decrease with age, potentially indicating antigen encounter. 
If this is the case, CD27 on γδ T cells could be utilized to address maturation stages for γδ 
T cells. In addition to γδ T cells, the study investigated proportions of NK cells. Of note, 
NK cells can be identified as CD8α+ and CD3- and the expression of perforin seems to be 
prominent immediately after birth, which is unlike other species. Proportions of NK cells 
seemed to vary and there was not a clear course in which their constitution to the T cell 
population could be identified (Talker et al., 2013). Further investigation into the roles of 
the γδ and the NK cell populations of pigs is warranted.  
 
1.7.5  Cell-mediated immunity to PRRSV 
It appears to be widely accepted that both cell-mediated and humoral immunity are 
necessary components in overcoming PRRSV infection. Yet, evidence regarding the type 
of immune response conferring resistance has not been clearly defined. The research 
surrounding cell-mediated immunity in particular has been quite confusing. Variability in 
results are attributable, but not limited, to the routes/dosage of inoculation, viral strains 
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utilized, controlled vs. field conditions, and the breed/age/sex of the pigs. Fortunately, 
there appears to be a trend near the end of the viremic stage in pigs when IFN-γ 
expression is highly up-regulated. Unfortunately, the period of viremia varies not only in 
a strain specific manner, but also according to breed, and SLA haplotype of individual 
pigs. Additionally, a subject of continuing debate is the role that regulatory T 
lymphocytes (Tregs) play in PRRSV pathogenesis, if they are induced at all. The 
following section hopes to resolve some of the conflicting research surrounding cell-
mediated immunity and PRRSV. 
A major hurdle for controlling PRRSV is identifying the stage of infection a herd is 
currently in, albeit acute or chronic. In 2008, Molina et al. inoculated pigs via the 
intramuscular route (IM) with the avirulent VR2332 strain and observed infected animals 
over the course of 193 days in a controlled environment. Overall, pigs became 
moderately ill showing non-specific symptoms. In order to assess cell-mediated 
immunity, IFN-γ was detected in serum over the course of the trial. At day 42 post 
infection (PI) the levels of IFN-γ spiked and slowly declined thereafter. It should be noted 
that the point at which IFN-γ was highest occurred in correlation with a decline in 
viremia, which led to half of the pigs resolving the infection (Molina et al., 2008). 
Overall, their results seemed to support that both cell-mediated immunity and humoral 
immunity were important for viral clearance. Similarly, Weesendorp et al. investigated 
the response of 5-week old pigs to Lelystad virus (LV) and found that IFN-γ also played 
an essential role in viral clearance. Furthermore, they observed an increase in NK cells 
and CTLs 26-33 days post infection (Weesendorp et al., 2013). Overall, it seems likely 
that CTLs and potentially NK cells are playing an important role in resolving the viremic 
state in response to avirulent strains of PRRSV. On the other hand, highly virulent strains 
have been able to suppress these activities, which could provide an explanation for 
increased virulence. However, these results were obtained is experimental trials and may 
need to be confirmed in trials mimicking field conditions. For example, Dotti et al. 
performed a trial under field conditions with a moderately virulent NA clinical isolate 
(BS/AL2011). Briefly, their results indicate that the levels of IFN-γ observed under 
controlled conditions did not occur in the field. The levels of IFN-γ they detected in the 
sera were comparable to the controls stimulated with PBS. This seems to indicate that 
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observing PRRSV immunopathogenesis in a controlled environment may not be 
applicable to what is occurring naturally (Dotti et al., 2013). 
As mentioned previously, confusion regarding PRRSV immunology could be due to 
strain specific virulence. Wang et al. was interested in the response of 1-month old 
piglets to NA highly pathogenic HuN4. In addition, they tested the efficacy of the 
currently available CH-1R vaccine. Piglets were inoculated intranasally (i.n.) with HuN4 
on day 28. The vaccinated group was immunized on day 0, boosted on day 14, and 
infected on day 28. Sera was collected over the 56 day trial for cytokine analysis. On day 
33 levels of IL-10 and IFN-γ increased significantly in the non-vaccinated group, peaked 
around day 38, and declined to normal levels by day 49. The vaccinated group had stable 
levels of IL-10 and IFN-γ in comparison to mock-infected pigs throughout the 
experiment. Of particular note, the vaccinated piglets had increased serum levels of IL-4 
at day 33 P.I., decreasing gradually by day 42. This occurred in conjunction with 
decreased levels, and eventual loss, of viremia. Unsurprisingly, IL-4 was not detected in 
the non-vaccinated group which remained viremic until day 56. Overall, it seems that 
high levels of IL-10 and low levels of IL-4 aided in the establishment of the persistence 
of the virus. The authors believed that the vaccine induction of IL-4 resulted in 
prevention of disease, although the virus was still detectable in peripheral lymphoid 
organs (Wang et al., 2011).  Yet, the levels of IFN-γ in the non-vaccinated group did not 
correlate with clearance of virus, which seems strange. In this case, it appears that 
humoral immunity could be playing a more important role than cell-mediated immunity. 
But, the delayed protection from infection could have occurred as a result of partial cell-
mediated immunity, exhibiting the inefficiency of the vaccine. It can therefore be 
assumed that the most effective and safe vaccine will evoke both cellular and humoral 
immune responses. 
Manickam et al. performed a thorough analysis of infection by NA highly virulent 
MN184. One month-old pigs were inoculated i.n. and the response in the blood, mucosal 
tissues, and lymphoid organs was assessed over 63 days. The cytokine profile showed an 
upregulation of IL-12 early during infection, a peak of IL-6 at day 42 until day 57, and 
high levels of IFN-γ at day 35, gradually decreasing by day 49. Resolution of infection 
appeared to coincide with increased expression of IL-6 and IFN-γ. Similar to Molina et 
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al., IFN-γ secreting cells were low in PBMCs, the lungs, and TBLN until day 30 at which 
point they increased significantly, but levels returned to normal at day 60. Levels of 
memory T cells and T helper (Th) cells increased in response to the infection in the lungs 
and lymphoid tissue. Levels of CD8β+ T cells only increased in the lungs. Interestingly, 
γδ T cells increased in lymphoid tissue and in the lungs throughout the infection. Two 
unique phenomena were observed during the trial. The first of which was the 
upregulation of of TGFβ but low levels of IL-10 (although slightly increased). As a 
result, Treg cell proliferation was detected in PBMCs, lung tissue, and peripheral 
lymphoid organs until day 60. The second occurrence was a decrease in the proportion of 
natural killer (NK) cells. Further analysis of the NK cell population indicated that their 
cytotoxic activity had decreased by 50% in the blood and the lungs. Overall the authors 
wanted to demonstrate that a new vaccine is needed. Viral titres were still high in the 
lungs at day 60 days PI but had decreased in lymph nodes, although PRRSV was still 
detectable (Manickam et al., 2013). In comparison to the Lena virus (Eu high virulent), 
the results are surprisingly different. Overall, Th cell levels decreased, there was a very 
weak IFN-γ response, γδ T cells didn’t increase, CD8β+ T cells remained the same, and 
the NK cell population increased (Weesendorp et al., 2013). The Lena virus is often 
compared to NA highly virulent strains, but it seems that their immunomodulatory 
capabilities are significantly different.  
More recently, a group developed an assay to measure cytotoxicity of PRRSV infected 
target cells from animals that had been exposed to PRRSV and subsequently recovered 
from the infection. Their results indicate that CD4α+ CD8α+ double positive T cells were 
capable of killing PRRSV infected macrophages 3-6 hours post infection. Furthermore, 
they found that CD4α+ CD8α- T cells possessed cytotoxic properties, killing infected 
macrophages 16-24 hours post infection. Interestingly, they noted that CD4α- CD8α+ T 
cells did not contribute to cytotoxicity. In addition, the authors noted that neutralizing 
antibodies were not detected in the infected animals. These results indicate the 
importance of cytotoxic T cells in the resolution of a PRRSV infection (Chung et al., 
2018). An investigation into the T cell response to a Type 1 PRRSV infection indicated 
that there is a delayed induction of memory T cells as CD4α+ CD8α+ and CD4α- CD8α+ 
CD8β+ detected roughly three weeks post infection in PBMCs. The kinetics of the T cell 
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response seem to indicate that regulatory T cells decrease upon infection in PBMCs as do 
CD21+ B cells, until roughly three weeks post infection at which point the levels of both 
regulatory T cells and CD21+ B cells begin to increase. Lastly, roughly one-week post 
infection there was a marked increase in the levels of natural killer T cells (NKT) and 
gamma delta (γδ) T cells (Ferrari et al., 2018). This may be an indication of the potential 
importance of γδ T cells and NKT early during a PRRSV infection. 
 
1.7.5.1  Natural killer cells and PRRSV 
Research surrounding the role of natural killer (NK) cells in PRRSV 
immunopathogenesis is in the early stages. Recently Cao et al. performed analysis 
utilizing the avirulent Lelystad virus to assess the immunomodulation of NK cells. 
Essentially, NK cells were enriched and cultured in the presence of IL-2 to spurn the 
population into an activated state. Using K652 cells (NK cell targets) and Pseudorabies 
virus (PrV) as positive controls to demonstrate NK cell lysis, the group infected PAMs 
with PRRSV and co-cultured them with the activated NK cells. Their results demonstrate 
that PRRSV infected PAMs were able to suppress the NK cell activity. Upon comparison 
to the mock-infected PAMs, NK cell activity in PRRSV infected PAMs was still lower. 
They hypothesized that PRRSV is able to modulate a receptor molecule on the surface of 
PAMs that is able to suppress the degranulation process in NK cells, which would inhibit 
perforin and granzyme secretion (Cao et al., 2013). Results obtained previously seemed 
to indicate that this was only occurring in highly virulent strains of PRRSV. Furthermore, 
the result obtained by Weesendorp are contradictory considering he saw a proliferation of 
NK cell activity. Further investigation into NK cell modulation by PRRSV is warranted. 
 
1.7.5.2  Regulatory T cells and PRRSV 
Shortly afterwards, Wongyanin et al. performed a similar analysis using an avirulent 
strain (01NP1) in vitro. They found that after 48 hours in co-culture with infected 
MoDCs, a similar Treg population had proliferated, which they characterized as being 
FoxP3+CD4α+CD25high which are similar to those in humans and mice. They continued to 
perform an in vivo analysis by which they infected pigs and harvested blood on day 0, 5, 
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and 10. Observations confirmed the in vitro results as a FoxP3+CD4α+CD25high 
population had proliferated. Lastly, they too agreed that TGFβ and not IL-10 was 
responsible for the proliferation, although it was mentioned that IL-10 could contribute to 
proliferation (Wongyanin et al., 2010). Regulatory T cell induction by PRRSV is under 
debate. Silva-Campa et al. (2009) was the first group to demonstrate Treg induction by 
PRRSV strains NVSL 97-7895 and CIAD008. Essentially, they infected MoDCs with the 
PRRSV strains and co-cultured them with PBMCs over a 5-day period. Their results 
indicate that Foxp3+CD25+ Tregs proliferated significantly in response to infection. 
Furthermore, upon treatment with IFN-α (either during MoDC infection or during co-
culture) Treg proliferation was inhibited. Upon closer analysis, they found that IL-10 
expression did not play a role as it was not up-regulated. They found that TGFβ was 
solely responsible for the differentiation. They defined the population as Th3 Tregs, and 
concluded that proliferation was occurring as a direct result of PRRSV infection (Silva-
Campa et al., 2009). More recently in 2012, Wongyanin published results that are 
conflicting to those obtained previously. Briefly, the N protein from PRRSV 01NP1 was 
transfected into PAMs, which resulted in the induction of IL-10. It should be noted, that 
Hou et al. had previously demonstrated that the GP5 protein was able to induce IL-10 
synthesis in transfected PAMs (Hou et al., 2012). Transfected PAMs were then co-
cultured with PBMCs, but no Treg induction occurred. Interestingly, when MoDCs were 
transfected and then co-cultured with PBMCs, Treg proliferation was prominent. Upon 
the addition of IL-10 antibody, the proliferation was suppressed. The authors concluded 
that IL-10 was responsible for Treg induction and failed to mention TGFβ (Wongyanin et 
al., 2012). Recently, a group demonstrated that Tregs were detected in the 
tracheobronchial lymph nodes and lung tissue of PRRSV infected animals. Furthermore, 
the authors demonstrated that mononuclear cells infected with PRRSV induced Treg 
differentiation from PRRSV negative animals, which is contradictory to what Rodriguez-
Gomez published previously (Rodriguez-Gomez et al., 2015). Lastly, the authors 
concluded that the induction of Tregs was likely attributable to the increased levels IL-10 
secretion (Nedumpun et al., 2018). The pathogen load of PRRSV, the breed and age of 
the animal, in addition to the strain of PRRSV are all potential contributors in the 
induction of Tregs and T cell immunity in general. The debate as to whether Tregs are 
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induced during a PRRSV infection and the potential role that Tregs have in the delayed 
induction of the cytotoxic T cell response, ultimately leading to the resolution of an 
infection, continues. 
 
1.8  Discussion 
 
Developing a vaccine for PRRSV has proven to be extremely difficult.  The major issues 
encountered thus far stem mainly from unusually high mutation rates, which has resulted 
in the divergence of PRRSV into countless variants between the Type 1 and Type 2 
PRRSV genotypes (Brar et al., 2015; Lu et al., 2017). Although multiple strategies have 
been employed, efforts have been met with limited success, as the induction of cross-
reactive neutralizing antibodies seems to be nearly impossible. Shedding light upon 
unknown aspects of PRRSV immunology and viral pathogenesis, particularly those 
surrounding the regulation of cell mediated immunity and humoral immunity, will aid in 
future vaccine development strategies.  
Based on current research, it is likely that both cytotoxic T cell mediated immunity and 
the induction of neutralizing antibodies are necessary components to provide protection 
and overcome a PRRSV infection. Currently distributed live attenuated vaccines for 
PRRSV are relatively efficacious, conferring cross protection and improving the overall 
health status of immunized animals in comparison to non-immunized animals (Canelli et 
al., 2018; Haiwick et al., 2018). A recent study demonstrates that MLV variants improve 
the health of challenged animals and provide differential protection, depending on the 
strain that animals were challenged with (Huang et al., 2019). A major challenge will be 
the development of a universal PRRSV vaccine for both Type 1 and Type 2 strains. 
Another recent study showed that immunization of gilts with a Type 2 MLV conferred 
increased overall health and a significant decrease in stillborn piglets when late-term 
pregnant gilts were challenged with a Type 1 PRRSV strain. The authors noted that T cell 
mediated immunity was the likely contributor to improved health status and decreased 
viremia in the challenged gilts, as neutralizing antibody titres were low (Jeong et al., 
2018). In contrast, a recent study demonstrated that pigs infected with a Type 2 PRRSV 
strain possessed cross-reactive IFN-γ secreting T cells to other Type 2 strains, but not 
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with a Type 1 PRRSV strain. Additionally, the authors noted that neutralizing antibodies 
were not cross-reactive amongst any of the challenge strains (Correas et al., 2017). The 
discrepancy between the studies could be attributable to methods utilized in the assay. It 
would be surprising if a Type 2 PRRSV immunization offered cross-protection against a 
Type 1 PRRSV strain. Although the currently available MLVs are beneficial towards 
improving health status amongst PRRSV challenged animals, immunization with a live 
virus is not without risk. Major issues associated with the currently available MLVs 
include the risk of reversion to virulence and the immunosuppressive attributes associated 
with PRRSV itself, resulting in animal susceptibility to opportunistic pathogens (Liu et 
al., 2018; Niederwerder et al., 2015). Therefore, given the high mutation rates observed 
amongst strains of PRRSV, the ideal vaccine candidate would not be attenuated. Utilizing 
inactivated, vector delivered, DNA, or conjugate vaccine platforms are potential options 
for future vaccine formulations. In order for one of the previously listed strategies to be 
effective, viral epitopes leading to the induction of both cytotoxic T cells and neutralizing 
antibodies must be determined. Based on previous studies, it seems that T cell epitopes 
are relatively well conserved, as demonstrated by cross-reactive IFN-γ secreting T cells 
within the Type 2 genus (Correas et al., 2017). Theoretically, supplementing a peptide 
vaccine with an appropriate adjuvant platform will elicit a T cell mediated response. 
Therefore, shedding light upon the delayed induction of neutralizing antibodies to 
PRRSV, and identifying epitopes associated with PRRSV neutralization, will be crucial 
for future vaccine development efforts. 
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Chapter 2  HYPOTHESIS AND OBJECTIVES 
2.1 Rationale  
 
The tropism of PRRSV has been shown to be restricted to cells that express CD163. The 
majority of these cells are of myeloid origin and are responsible for the stimulation of 
both naïve and memory T cell responses. There is a delayed adaptive immune response to 
PRRSV and the cause(s) surrounding the delay are unknown. Thus, we chose to 
investigate the influence that PRRSV infection has on specific antigen-presenting cell 
(APC) subsets. Furthermore, we chose to investigate the stimulatory capacity of PRRSV 
infected APCs when co-cultured with T cells, in order to assay the progression to T cell 
immunity over the course of a PRRSV infection. We hypothesize that a specific subset of 
DCs is critical for the induction of T cell mediated immunity. The delayed induction of T 
cell immunity could be attributable to the relative rarity of this specific DC population 
and the dysregulated humoral immune response can be attributable to a lack of follicular 
T helper cell directing somatic hypermutation. 
 
2.2 Objectives and hypotheses  
2.2.1 Objective 1: Characterization of Flt3L derived bone marrow dendritic cells 
Dendritic cells are the professional APCs of the immune system, directly linking the 
innate and adaptive immune response. They are responsible for antigen presentation to 
naïve T cells and the cytokines that DCs secrete play a significant role in directing T cell 
lineage (Th1, Th2, Th17, Th22, Treg). Multiple DC subsets exist in vivo, but their rarity 
makes it difficult to obtain the different subsets for in vitro assays. As such, we chose to 
differentiate DCs from bone marrow hematopoietic stem cells in order to obtain a 
population of DCs consisting of multiple subsets. We characterized the successful 
differentiation of our bone marrow DC populations using flow cytometry. 
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2.2.2 Objective 2: Comparison of antigen-presenting cell susceptibility to PRRSV 
infection 
Antigen presentation to naïve T cells is not restricted to DCs, as macrophages (MΦs) and 
potentially B cells are also capable of presenting antigen to stimulate a naïve T cell. 
Because PRRSV infects MΦs and DCs, we were interested in susceptibility of different 
APCs to infection and how they responded to the infection. We hypothesized that 
PRRSV replicates more efficiently in MΦs than in DCs, making DCs more properly 
equipped to stimulate naïve T cell activation. 
 
2.2.3 Objective 3: Investigate the maturation of the invariant chain 
The maturation of the invariant chain is a critical step during antigen processing that 
ensures an antigen-derived peptide sequence is loaded into the binding groove of an 
MHCII molecule. This process of maturation occurs within endosomes.  Coincidentally, 
it has been demonstrated that PRRSV forms a double membrane vesicle replication 
complex, reminiscent of endosomes. Given the importance that invariant chain 
maturation has during antigen processing and presentation, we hypothesized that PRRSV 
infection interferes with the maturation of the invariant chain. By immunoprecipitating 
MHCII from infected and non-infected APCs, we aimed to demonstrate that PRRSV 
infection prevents maturation of the invariant chain. This could provide a potential 
explanation for the delayed induction of cell-mediated immunity to PRRSV. 
 
2.2.4 Objective 4: Investigate the T cell response to PRRSV infection 
Studying the susceptibility of APCs to PRRSV infection, and their subsequent response, 
does not provide information regarding the effect that infection has on the interaction of 
APCs with T cells. In order to study the interaction of APCs with T cells, we established 
an APC-T cell co-culture assay using a mixed leukocyte reaction (MLR). The MLR 
confirmed our hypothesis that specific APC populations possess differential 
immunostimulatory capacities to promote T cell proliferation. This allowed us to perform 
an animal trial analyzing the progression of the T cell response over the course of a 
PRRSV infection, comparing the antigen-presenting capability of either monocyte-
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derived MΦs or monocyte-derived DCs. We hypothesized that DCs were more potent 
stimulators of CD4+ T helper cells, contributing directly to the initiation of the T cell 
immune response, whereas MΦs, still possessing the capability to stimulate T cells, are 
more involved during the recall of cytotoxic lymphocyte responses during the resolution 
of an infection.  
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Chapter 3   ANTIGEN-PRESENTING CELL 
SUSCEPTIBILITY TO PORCINE REPRODUCTIVE AND 
RESPIRATORY SYNDROME VIRUS INFECTION 
Joseph Darbellay, Jill Van Kessel, Volker Gerdts 
 
3.1 Abstract 
Porcine reproductive and respiratory syndrome virus (PRRSV) has a worldwide 
distribution and is the most economically devastating virus in the swine industry today.  
The tropism of PRRSV has been shown to be restricted to antigen-presenting cells (APC) 
that express CD163. Furthermore, a characteristic of PRRSV disease is the delayed 
induction of T cell immunity. Given their roles in the stimulation of both naïve and 
memory T cell responses, we chose to investigate the rates of viral replication within 
APC populations using flow cytometry (FCM) and rt-qPCR. The susceptibility of 
monocyte-derived macrophages (MoMϕs), monocyte-derived DCs (MoDCs), and Flt3L-
derived bone-marrow DCs (BMDCs) to PRRSV infection were compared in vitro. 
Intracellular detection of PRRSV was comparable and prominent 24 hours post infection 
in MoDCs and Mϕs. Furthermore, using rt-qPCR we found that viral copies in the 
supernatants of Mϕs increased at a higher rate than the DC populations. In comparison to 
the Mϕs, the rate of PRRSV replication in CD163+ BMDCs was much lower. 
Additionally, we investigated the expression of cell surface molecules associated with 
antigen presentation in PRRSV infected APCs with FCM. The levels of MHCI and 
MHCII expression on the surface of infected non-stimulated Mϕs were both down-
regulated. Although it is difficult to conclude why DCs are less susceptible to infection, 
our study allows for speculation on the potential role that DCs may have in the induction 
of T cell immunity. 
 
3.2 Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a positive sense, single-
stranded, enveloped RNA virus that causes disease in swine worldwide. The virus was 
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first identified in the early 1990s and is thought to have emerged during the early-mid 
1980s (Shi et al., 2010). Today, PRRSV is the most significant pathogen in the swine 
industry causing losses upwards of $650 million dollars in the United States alone 
(Holtkamp, 2012). Outcomes of disease include respiratory difficulty, spontaneous 
abortions and fetus mummification in sows, weight loss, and death under certain 
circumstances (Reeth, 1997; Tong et al., 2007). The demand for an efficacious vaccine 
and the development of strategies for disease control are top priorities (Kimman et al., 
2009). 
Two main species of PRRSV exist, the North American (Type 1) and the European (Type 
2) in which a roughly 40% nucleotide identity is shared (Shi et al., 2010). It is classed 
under the order Nidovirales from the Arteriviridae family. The tropism of PRRSV is 
restricted to cells that express the hemoglobin/haptoglobin scavenger molecule CD163, 
which was identified as the main cellular receptor for viral entry into the cytoplasm 
(Calvert et al., 2007). Although it has been widely accepted that porcine alveolar 
macrophages (PAMs) are the main target cells for PRRSV infection and replication, it 
has been proposed that dendritic cell (DC) are also targets of infection (Calzada-Nova et 
al., 2010; Calzada-Nova et al., 2011; Chang et al., 2008; Chaung et al., 2010; Peng et al., 
2009; Rodriguez-Gomez et al., 2012; Silva-Campa et al., 2009). Because DCs are the 
professional antigen-presenting cell (APC) of the immune system, the modulation of their 
antigen-presenting ability, or their being targets of PRRSV replication, would have major 
implications on the transition from innate to adaptive immunity (Randolph et al., 2005).  
A major interest in the field of PRRSV virology and immunology is the transition to 
adaptive immunity. PRRSV specific antibodies can be detected in animals within days of 
being exposed to the virus, although the antibodies are non-neutralizing. The virus 
continues to spread unchecked, as non-neutralizing antibody titres increase steadily, until 
4+ weeks post infection when neutralizing antibodies become apparent in serum (Loving 
et al., 2015). Although numerous investigations have been undertaken to understand why 
there is a delayed induction of neutralizing antibodies, there has not yet been a concrete 
explanation.  On the other side of adaptive immunity, very little is known about the T cell 
response to PRRSV. It seems that there is a similar delay in the induction of T cell 
immunity as is seen with the neutralizing antibodies. The majority of what is known 
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about T cell immunity has been collected through analyses using IFN-γ ELISpots, which 
have essentially indicated that IFN-γ secreting cells in PBMCs of infected animals 
become apparent around the same time as neutralizing antibodies (Loving et al., 2015). 
Future investigations into the induction of T cell immunity by PRRSV may contain long 
sought after answers. In this study, we focus on antigen-presenting cell susceptibility to 
PRRSV in order to obtain information regarding the first step towards inducing T cell 
immunity. 
 
We feel the confusion surrounding DC susceptibility to PRRSV has arisen as a result of 
utilizing DC models subject to monocyte/macrophage contamination. Studies carried out 
thus far have been performed with GM-CSF bone marrow-derived DC (BMDC) or 
monocyte-derived DC (MoDC) populations. These populations are often subject to 
macrophage contamination, making them inaccurate for elucidating the DC response to 
PRRSV. We have thus chosen to utilize FMS-like tyrosine kinase 3 ligand (Flt3L) 
BMDCs to study PRRSV infection of DCs in vitro. We hypothesize that specific subsets 
of DCs, and not the entire population, are susceptible to PRRSV. Furthermore, we hope 
to demonstrate that immune modulation in this DC subset occurs in a strain specific 
manner according to pathogenicity of the particular strain being investigated. Overall, we 
aim to shed light upon the immunopathogenesis of PRRSV and the evasion strategies it 
possesses. Understanding its mechanisms of immune evasion will be crucial for 
developing new methods of control in addition to establishing strategies for 
immunization.  
 
3.3 Materials and methods 
 
Animals: 
Six-eight week old Dutch Landrace pigs were purchased from the pathogen free herd at 
the Prairie Swine Centre (Saskatchewan). A group of 8 pigs was immunized with the 
Fostera® PRRS modified live virus (MLV) intramuscularly to measure T lymphocyte 
proliferation in a co-culture assay. All experiments were conducted in accordance with 
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the ethical guidelines of the University of Saskatchewan and Canadian Council of Animal 
Care. 
 
Cells and viruses: 
Flt3L bone marrow-derived dendritic cells (BMDCs) were prepared as described 
previously (Guzylack-Piriou et al., 2010). Briefly, the sternums were removed from 6-8 
week old Dutch Landrace pigs. Bone marrow was flushed from the sternum with PBS 
(supplemented with 0.7% EDTA, 1% Antibiotic/antimycotic (Gibco®-BRL), and 0.5% 
Gentamycin (Gibco®-BRL)) using an 18-gauge syringe. Hematopoietic stem cells 
(HSCs) were removed from a buffy coat, using a FICOLL-PAQUE® Plus gradient (GE 
Healthcare, Uppsala Sweden) centrifuging at 1000 x g, 40 minutes. Cells were cultured in 
6 well, non-tissue culture treated plates, at a concentration of 5.0x105 cells/mL in RPMI-
1640 complete (Gibco®-BRL) (1% Antibiotic/antimycotic, 0.5 mM β-mercaptoethanol, 
1% MEM non-essential amino acids (Gibco®-BRL), 1% HEPES (Gibco®-BRL), and 
10% FBS) supplemented with 20 ng/mL huFlt3L (R&D Systems). Every third day, 1.0 
mL of media was removed and replaced with fresh media. Cells were harvested on day 7 
for analysis. Monocytes were isolated from whole blood as previously described (Auray 
et al., 2013). Briefly, PBMCs were isolated on a FICOLL-PAQUE® Plus gradient (GE 
Healthcare, Uppsala Sweden). Monocytes were labeled with anti-human CD14 beads and 
selected for on LS columns using a magnetic isolated cell sorter (Miltenyi Biotec, 
Auburn, CA). To obtain MoMΦs, monocytes were plated at 1.0x10^6 cells/mL in RPMI 
complete supplemented with rpGM-CSF (20 ng/ml - Biosource, Camarillo, CA) for 3 
days at 37 °C with 5% carbon dioxide. To obtain MoDCs, monocytes were plated at 
1.0x10^6 cells/mL in RPMI complete with recombinant porcine (rp) IL-4 (100 ng/mL – 
R&D 654-P4) and rpGM-CSF (20 ng/mL – R&D 711-PG) for 6 days at 37 °C with 5% 
carbon dioxide, and media was changed every 3rd day as shown previously (Facci et al., 
2010).  PRRSV strains VR2332 and VR2385 (ATCC, Manassas, VA, USA) were used in 
the study. Virus was grown up on MARC-145 cells and titers were calculated as the 
TCID50/mL (Reed and Muench, 1938).  
 
 
	 43	
BMDC Characterization: 
BMDCs were harvested on day 6 and resuspended in cold 1 x PBS (pH 7.2, 0.2% gelatin, 
0.03% Na Azide at 1.0x10^6 cells/mL). BMDCs were characterized by staining with 
each antibody for 20 min at 4° C, washed three times (1 x PBS), and fixed with 2% 
paraformaldehyde. Cells (>10,000 events) were analyzed using FACScalibur™, Becton 
Dickinson, BD Biosciences and CELLQUEST™ software. The following antibodies 
were used for BMDC characterization: CD172a (BL1H7, Bio-Rad), CD90 (F15-42-1, 
Bio-Rad), CD3 (PPT3, Southern Biotech), CD14 (MIL-2, Bio-Rad), CD163 (2A10/11, 
Bio-Rad), CD16 (G7, Bio-Rad), CD21 (BB6-11C9.6, Southern Biotech), Swc9 (PM18-7, 
Bio-Rad), MHC II (K274.3G8, Bio-Rad), and MHC I (JM1E3, Bio-Rad). FITC anti-
mouse immunoglobulins IgG1 (1072-07) and IgG2b (1092-02, Southern Biotech) were 
used as secondary antibodies.  
 
Microscopy: 
Cells were fixed, permeabilized and stained with the FITC-SR30 ab as indicated 
previously at 1.0x106 cells/mL. Cells were pipetted (10 µL) onto glass slides, air dried, 
and 1 drop of ProLong® Gold antifade reagent with DAPI (Life Technologies) was 
applied to sample according to the manufacturer’s instructions. Immunofluorescence was 
visualized with the Zeiss Axiovert 200m Inverted microscope (Carl Zeiss Light 
Microscopy, Germany) under 20x magnification. Images were captured with the 
Axiocam (Zeiss, 1069-414) and analyzed using AxioVision Rel. 4.6 (Carl Zeiss Light 
Microscopy). 
 
Antigen presenting cell infections: 
Antigen presenting cells were infected with PRRSV strain VR-2385 at a 0.1 MOI for 3 
hours at 37°, 5% CO2. Cells were centrifuged at 350 g, resuspended in fresh media, and 
seeded on 12 well plates. Cells and supernatant were harvested at 8, 24, 48, and 72 hours 
post infection for flow cytometry analysis and rt-qPCR. Monocyte-derived macrophages 
were either non-stimulated (M0), or stimulated with IL-4 (100 ng/mL) or with 
recombinant porcine IFN-γ (20 ng/mL, R&D 985-PI) for 24 hours to mimic an M2 or M1 
phenotype, respectively before being infected with the PRRSV as previously. 
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Flow cytometry: 
At 24 or 48 hours post infection, DCs and MoMΦs were harvested and resuspended in 1× 
phosphate buffered saline (PBS) pH 7.3 containing sodium azide (0.03%) and gelatin 
(0.02%) (staining media) and stained to assess cell surface marker expression by flow 
cytometry. Briefly, cells were incubated 20 min at 4°C with primary antibodies, then 
washed twice before incubation with their respective secondary antibody. The primary 
antibodies utilized are as follows: CD163 (2A10/11, Bio-Rad), MHC II (K274.3G8, Bio-
Rad), and MHC I (JM1E3, Bio-Rad). Cells were incubated for 20 min at 4°C with a goat-
anti mouse IgG1-APC secondary antibody (Southern Biotech 1070-11s). For PRRSV 
nucleocapsid staining, cells were fixed and permeabilized with the 
Fixation/Permeabilization Kit (eBioscience) according to the manufacturer’s instructions. 
At least 10000 events were collected on a FACSCALIBUR™ (BD Biosciences, 
Mountain View, CA) using the CELLQUEST™ software. Changes in mean fluorescence 
intensity (MFI) were calculated by subtracting the MFI from the infected cells by the 
MFI of the non-infected cells.  
 
Reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR): 
To measure PRRSV replication, 180 µl of supernatant was collected from infected cell 
cultures and stored at -80. RNA was extracted using a QIAmp Viral RNA Mini Kit 
(Qiagen) according to the manufacturer’s instructions. A 2-step reverse transcription PCR 
was performed to determine levels of PRRSV in the supernatant. Complementary DNA 
was synthesized (High Capacity cDNA Reverse Transcription Kit, Invitrogen) and then 
quantitative-PCR was performed using 2 µL of each cDNA reaction with the KAPA 
SYBR® Fast qPCR kit according to the manufacturer’s instructions (Kapa Biosystems). 
Analysis was performed using a Bio-Rad iCycler iQ 5 (Bio-Rad, Hercules, CA). Primers 
were selected based on previous publication ( S-GGCCAGCCAGTCAATC; AS-
CACACGGTCGCCCTAATTG) (Calzada-Nova et al., 2011).  
 
Interferon-gamma ELISpots: 
A group of 8 animals was immunized with the Fostera® PRRS modified live virus 
(MLV). Peripheral blood mononuclear cells (PBMCs) were isolated on day 0 and day 16 
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for IFN-γ ELISpots. ELISpots were performed as demonstrated previously (Dar et al., 
2012). Briefly, nitrocellulose microtiter plates (UNIFILTER® 350, Whatmann, Florham 
Park, NJ, USA) were coated with 0.5 µg/100 µl of anti-porcine IFN-γ monoclonal 
antibodies solution (Thermo Fisher Scientific, Inc., Nepean, ON, Canada). 
5.0x10^5 PBMC were added to each well and cells were stimulated with PRRSV or 
inactivated PRRSV (VR-2385, MOI 1.0). After 24 hr incubation at 37 °C, rabbit anti-
porcine IFN-γ antibody solution (0.2 µg/100 µl in phosphate buffer saline with 0.05% 
tween® 20) was added and plates were incubated for 4 hours at room temperature. Biotin-
conjugated goat ant-rabbit IgG (Invitrogen-Zymed, Burlington, ON, Canada) was added 
(1/5000 dilution) for 2 hours at room temp before the addition of 1/5000 diluted 
streptavidin alkaline phosphatase solution for 1.5 hours at room temp. Lastly, spots were 
developed with NBT/BCIP (Sigma-Aldrich, St. Louis, MO, USA). Spots were counted 
with an AID ELISpot Reader Classic.  
 
Monocyte-derived macrophage – T cell co-cultures and lymphocyte proliferation assay: 
Monocyte-derived macrophages and T cells were co-cultured to investigate the 
stimulatory capacity of PRRSV infected M0 MoMΦs, to promote T lymphocyte 
proliferation. Animals were immunized with the MLV and 14 days post immunization, 
monocytes were isolated from PBMCs of MLV immunized animals. After 3 days in 
culture monocytes had differentiated into MoMΦs. On the same day, T cells were 
isolated from PBMCs of the MLV immunized animals. To isolate T cells, PBMCs were 
stained with anti-CD172a and anti-CD21 for 15 minutes at 4o C, then washed twice. Cells 
were then incubated with IgG1 MACS beads for 15 minutes at 4o C before passing the 
cells through LS columns (Miltenyi Biotec). The enriched T cell population was stained 
with CFSE according to the manufacturer’s protocol (Cell Trace CFSE, Thermo Fisher) 
to monitor proliferation, before being plated at 3.0x10^5 cells/well on a 96 well U bottom 
plate. The M0 MoMΦs were infected with PRRSV VR-2385 for 3 hours, or mock-
infected, before being washed and plated with T cells at a ratio of 1:10. After the addition 
of M0 MoMΦs, the MoMΦ-T cell co-culture was incubated at 37o C, 5% CO2 for 4 days 
before assessing proliferation with FCM. 
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Statistical Analysis: 
All data points on graphs are representative of genetically unrelated individual animals. 
All the data were statistically analysed using GRAPHPAD PRISM™ 7 software 
(GraphPad Software, Inc., La Jolla, CA). Differences between groups were assessed 
using the Mann-Whitney U test for non-paired, non-Gaussian data. When P≤0.05, 
differences were considered significant. 
 
3.4 Results 
 
Characterization of bone marrow-derived dendritic cells: 
Flow cytometry (FCM) was carried out on day 7 of culture to demonstrate successful 
differentiation of HSC precursors into BMDCs. The relative purity of DCs in the culture 
can be seen by the lack of macrophages (Swc9), lymphocytes (CD3/CD21), and 
fibroblasts (CD90). Furthermore, the BMDCs were consistently CD172ahigh and 
MHCIImid/high (Supplementary Figure 3-10 and 3-11). Supplementary Figure 3-12 
demonstrates the clustered arrangement of DCs in culture after they have differentiated. 
Cells were non-adherent, further indicating purity of DCs in the cultures. Based on 
previously published data, we are confident in confirming successful differentiation of 
the BMDC populations (Guzylack-Piriou et al., 2010), (Facci et al., 2010). 
 
Susceptibility of BMDCs to PRRSV: 
A preliminary investigation was launched in order to determine the susceptibility of 
BMDCs to PRRSV infection using VR-2385. Figure 3-1 demonstrates that over a 72-
hour period of time, cells became gradually infected with PRRSV, as the level of staining 
against the viral nucleocapsid protein increased (FCM schematic shown in supplementary 
Figure 3-13). Lastly, RT-qPCR for PRRSV transcripts in the supernatant indicated a 
roughly 400-fold increase after 72 hours (Supplementary Figure 3-14). 	
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Figure 3-1: BMDC infection with VR-2385 over 72 hours. BMDCs were infected at an 
moi of 0.1 and harvested at the indicated time points. Cells were subsequently fixed, 
permeabilized, and stained with the SR30-FITC to detect the PRRSV N protein. Data 
points are representative of genetically unrelated animals, performed as single samples. 
The figure demonstrates flow cytometry (FCM) data showing individual pigs (dots) and 
the percentage of infected cells (bars); Cx = non-infected cells. P<0.05 = *; P<0.005 = 
**; P<0.0005 = ***. 
 
CD163+ and CD163- BMDC susceptibility to PRRSV: 
BMDCs were sorted using a fluorescence activated cell sorter (MoFlo XDP Cell Sorter, 
Beckman Coulter) according to CD163 expression (Supplementary Figure 3-15). The 
BMDC populations were exposed to the PRRSV and stained intracellularly for the viral 
N protein (Supplementary Figure 3-16). Based on the FCM results, CD163+ BMDCs are 
susceptible to infection and CD163- BMDCs are not susceptible to infection (Figure 3-2). 
 
 
 
 
 
 
Cx
 8h
rs
Vir
us
 8h
rs
Cx
 24
hr
s
Vir
us
 24
hr
s
Cx
 48
hr
s
Vir
us
 48
hr
s
Cx
 72
hr
s
Vir
us
 72
hr
s
0
5
10
15
20
25
30
Treatment
%
 In
fe
ct
ed
PRRSV (SR30) positive BMDCs
** ** ***
	 48	
 
 
 
 
 
 
Figure 3-2: Sorted BMDC (CD163+ and CD163-) susceptibility to PRRSV. BMDCs were 
sorted into two populations (A - CD163+ or B - CD163-). Cells were infected with two 
strains of PRRSV and stained as previously indicated against the PRRSV N protein at the 
indicated time points. Data points were collected from unrelated animals, performed as 
single replicates.  
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Antigen presenting cell susceptibility to PRRSV: 
MoMΦs were stimulated with IL-4 or IFN-γ for 24 hours to mimic and M2 or M1 
phenotype respectively. M1 and M2 MoMΦs and MoDCs were infected with two strains 
of PRRSV (VR-2385 and VR-2332). The susceptibility of the MoMΦs and MoDCs was 
compared to that of the BMDCs (Figure 3-3). There was no difference amongst the 
susceptibility of MoMΦs, regardless of stimulation and the MoDCs seem share a 
similarity in susceptibility to MoMΦs. The CD163+ BMDCs were not as susceptible to 
infection in comparison to the other APC populations. 
As shown in Figure 3-4, upon comparing forward scatter (FSC) / Side scatter profiles 
(SSC) of the infected APCs, it became apparent that MoDCs (Supplementary Figure 3-
17) and MoMΦs were no longer viable 48 hours post infection, in comparison to the 
BMDCs which still appear to be healthy. The assessment of cell viability is based on the 
relative diameter of the cell (FSC). As cells begin to die they appear lower on the FSC 
axis where debris is normally located on FSC/SSC dot plots. 
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Figure 3-3: APC cell susceptibility to PRRSV infection. MoMΦs, MoDCs, and BMDCs 
were infected with two different strains of PRRSV (3a: VR-2332; 3b: VR-2385). Cells 
were fixed, permeabilized, and stained with SR30-FITC at 24 hours post infection. Data 
points were collected from unrelated animals, performed as single replicates. Statistical 
significance was determined comparing the groups to the BMDC infected population. 
P<0.05 = *; P<0.005 = **. 
 
APC viability of PRRSV infected cells 
 
 
Figure 3-4: Antigen-presenting cell viability post infection. Forward scatter (FSC), side 
scatter (SSC) dot plots demonstrating cell viability of infected MoMΦs and infected 
BMDCs 24 hr and 48 hr post infection. Non-infected control (Crl) cells are on the left and 
the VR-2332 infected cells are shown on the right (PI-post infection). 
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Real time quantitative-PCR of PRRSV copies in supernatant of infected APCs: 
Viral RNA was isolated from the supernatants of APC cell cultures infected with PRRSV 
VR-2385 at 8 hours, 24 hours, and 48 hours post infection (PI). In order to quantify viral 
copies, a PRRSV stock of known TCID50 was used to develop a standard curve 
(Supplementary figure 3-18). The results indicate that viral copies are detected earlier and 
at a higher concentration in the infected MoMΦs, and potentially MoDCs, in comparison 
to infected BMDCs (Figure 3-5).  
 
 
Figure 3-5: Real time quantitative PCR of PRRSV copies in the supernatant of infected 
cells. MoMΦs, MoDCs, and CD163+ BMDCs were infected with PRRSV VR-2385 
(MOI 0.1) and supernatants were collected 8hr, 24hr, and 48hr post infection (PI). Data 
points were collected from unrelated animals, performed as single replicates. Reverse 
transcription reactions were performed in duplicate. A standard curve developed using 
known TCID50 viral stock in order to quantify viral copies present in the supernatant of 
the infected cell cultures. P = 0.0159. 
 
Expression of cell surface markers associated with antigen presentation: 
The cell surface marker expression of MHCII (Figure 3-6) and MHCI (Figure 3-7) were 
analyzed in APCs infected with PRRSV using FCM. Change in expression was 
determined by calculating the difference between the mean fluorescence intensity (MFI) 
of the infected cells and their respective controls. There may be a trend in which M1 
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MΦs and both DC populations have increased MHCI and MHCII expression when 
exposed to PRRSV, but there was no statistical difference amongst the treatments. (FCM 
staining example in Supplementary Figure 3-19. Additional time points for the CD163- 
BMDCs and CD163+ BMDCs can be seen in supplementary Figures 3-20 and 3-21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6: MHCII Cell surface expression on APCs infected with PRRSV. APCs were 
infected with VR-2332 (A) or VR-2385 (B). Change in cell surface expression of MHCII 
were determined by calculating the difference between the mean fluorescent intensity of 
the infected cells and their respective controls. The data was collected from non-related 
animals, performed as single replicates, and was determined to show no statistical 
significance. 
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Figure 3-7: MHCI Cell surface expression on APCs infected with PRRSV. APCs were 
infected with VR-2332 (A) or VR-2385 (B). Changes in cell surface MHCI expression 
were determined by calculating the difference between the mean fluorescent intensity of 
the infected cells and their respective controls. The data was collected from non-related 
animals, performed as single replicates, and was determined to show no statistical 
significance. 
 
Non-stimulated macrophage (M0) cell surface marker expression: 
The MHCI and MHCII cell surface markers on non-stimulated MoMΦs infected with 
PRRSV VR-2385 and VR-2332 were assessed as previously performed in the other APC 
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populations. As Figure 3-8 indicates, there is a clear downregulation in the expression of 
both MHCI and MHCII on the surface of M0 MoMΦs infected with PRRSV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8: Cell surface expression of MHCII (A) and MHCI (B) on M0 MoMΦs infected 
with PRRSV VR-2332 and VR-2385. Changes in cell surface expression of MHC were 
determined by calculating the difference between the mean fluorescent intensity of the 
infected cells and their respective controls. Data points represent non-related animals, 
performed as single replicates, with VR-2332 and VR-2385 infections from non-related 
animals. P < 0.05 = *; P< 0.005 = ** 
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T cell recall response from immunized animals in a macrophage-T cell co-culture: 
We were interested in how the expression of MHC molecules might influence T cell 
proliferation. Therefore, M0 MoMΦs were either: infected, treated with inactivated 
PRRSV, or mock-infected with media for 3 hours before being washed, and then cultured 
with T cells. The T cells were isolated from animals immunized with the PRRSV MLV 
and cultured with macrophages from syngeneic animals. As the results indicate in Figure 
3-9, although there was a downregulation of MHC expression in MoMΦs infected with 
PRRSV (Figure 3.8), it did not abrogate their stimulatory capacity to promote 
lymphocyte proliferation. Lastly, inactivated PRRSV treatment of PBMCs promoted 
IFN-γ secretion in ELISpots. Which unlike the MoMΦ-T cell co-culture in which the 
inactivated virus treatment was applied, there was no lymphocyte proliferation potentially 
indicating a lack of stimulation (Supplementary Figure 3-23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9: T cell recall-response from immunized animals via macrophage- T cell co-
culture. Non-stimulated MoMΦs (M0) from immunized animals were infected with 
PRRSV VR-2385, and subsequently co-cultured with CFSE stained T cells from 
autologous animals to assay for lymphocyte proliferation. After 4 days in culture, 
proliferation was assessed with flow cytometry. Statistical significance was determined 
by comparing the treatments to the media alone treatment. P < 0.05 = *; P< 0.005 = **. 
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3.5 Discussion 
 
The tropism of PRRSV is restricted to cells that express the hemoglobin/haptoglobin 
scavenger molecule CD163, which was identified as a necessary cellular receptor for 
viral entry into the cytoplasm (Calvert et al., 2007). In addition to CD163, sioladhesin 1 
(CD169) and heparin-sulfate residues have been identified as attachment factors for 
PRRSV (Van Breedam et al., 2010; Van Gorp et al., 2008). Although it has been widely 
accepted that porcine alveolar macrophages (PAMs) are the primary target for PRRSV 
infection, dendritic cell (DC) susceptibility has been a subject of continuing debate. We 
feel that confusion surrounding DC permissibility to PRRSV exists as a result of utilizing 
inappropriate DC cultures to study the virus. The majority of DC research has been 
carried out in monocyte-derived DC (MoDC) cultures or granulocyte macrophage 
colony-stimulating factor (GM-CSF) bone marrow-derived DC (BMDC) cultures, which 
are both subject to MΦ and/or monocyte contaminants (Calzada-Nova et al., 2011; Chang 
et al., 2008; Flores-Mendoza et al., 2008; Peng et al., 2009; Silva-Campa et al., 2009; 
Subramaniam et al., 2011; Wang et al., 2007; Wongyanin et al., 2012; Wongyanin et al., 
2010; Zhang et al., 2012). Because PRRSV is able to infect MΦs, the analysis of the DC 
innate response in these models may not be entirely accurate.  
The in vivo differentiation of DCs from hematopoetic progenitor cells has been 
demonstrated to occur in response to FMS-related tyrosine kinase 3 ligand (Flt3L). 
Although GM-CSF and M-CSF have also been shown to play a role in DC 
differentiation, Flt3L knock out mice have shown markedly reduced levels of DCs. 
Furthermore, DCs obtained through in vitro differentiation utilizing Flt3L have been 
shown to contain multiple DC subsets, one of which is the plasmacytoid DCs (pDCs) 
(Belz and Nutt, 2012). Unfortunately, one of the major issues that exist in studying 
porcine DC immunology is obtaining cell surface markers that are specific for DCs. 
Unlike in mice and humans, porcine DCs cannot be identified based on the expression of 
CD11c. Furthermore, GM-CSF and MoDC cultures contain a specific subset of DCs, 
which is not representative of in vivo populations. As is demonstrated in supplementary 
Figure 3-11, the staining pattern of our BMDC populations appeared to correlate to those 
obtained in previous studies as being MHCIImid/high, CD172ahigh, and consisting of a 
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mixed population of CD163- or CD163+ cells (Guzylack-Piriou et al., 2010). We feel 
confident in assuming the successful differentiation of our HSC precursors into DCs.  
The results obtained from the preliminary investigation with the highly virulent strain of 
PRRSV (VR-2385) indicate that BMDCs are infected by PRRSV (Figure 3-1). 
Furthermore, it was apparent that not every cell in the culture was infected, as the 
majority of the population (>80%) was negative for PRRSV 72 hours post-infection. It 
seemed logical to assume that the population being infected consisted of DCs expressing 
CD163. Additionally, we were interested in determining whether an avirulent strain (VR-
2332) was also able to infect the CD163+ DCs. A major strategy that viruses have 
developed for immune evasion has been an interference with antigen presentation and 
maturation in DCs (Kruse et al., 2000; Mahanty et al., 2003; Wang et al., 2007). Thus, we 
isolated our BMDC population based on CD163 expression (Supplementary Figure 3-15). 
As expected, the CD163+ BMDCs were susceptible to infection and the CD163- BMDCs 
were not susceptible (Figure 3-2). Considering there are multiple APC populations in 
pigs, we continued our investigation by comparing the susceptibility of CD163+ BMDCs 
to MoMΦs and MoDCs infected with PRRSV. Our results, as indicated in Figure 3-3 and 
Figure 3-5, show that PRRSV seems to infect MΦs more efficiently than the CD163+ 
BMDCs and potentially MoDCs. As mentioned previously, MoDC cultures are subject to 
MoMΦ contamination, which could explain the non-statistically significant difference in 
PRRSV transcripts between MoDCs and BMDCs or MoMΦs. At this time, it is difficult 
to conclude why there is a difference in APC susceptibility to PRRSV. Lastly, when 
comparing the forward scatter/side scatter profiles of the PRRSV infected APCS (Figure 
3-4), it could be assumed that the CD163+ BMDCs remained healthy 48 hours post 
infection, whereas the MoDCs and MoMΦs were essentially dead after 48 hours. This 
difference in APC viability may be attributable to a less severe rate of infection, but it 
could also be an indication of a defense mechanism the CD163+ BMDCs possess not seen 
in the MoMΦs or MoDCs. An aspect of major interest in our lab is the progression to T 
cell immunity during PRRSV infection. Thus, we investigated the expression of cell 
surface markers associated with antigen presentation in the APC populations after 
PRRSV infection. 
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Antigen presenting cells utilize MHCI and MHCII to present peptide sequences derived 
from antigen to CD8β+ and CD4α+ T cells respectively. When comparing the levels of 
MHCI and MHCII expression on the APC populations (Figure 3-6 and Figure 3-7) there 
was no significant change in the expression of the molecules in PRRSV infected APCs. 
Furthermore, we were unable to detect any changes in CD80/86 expression (results not 
shown). On the other hand, non-stimulated MoMΦs (M0) showed clear downregulations 
in both MHCI and MHCII cell surface expression when PRRSV infected (Figures 3-8). 
Ultimately, these results tell us little of what effect the changes in MHC expression have 
during antigen presentation to T cells. Thus, we chose to utilize M0 MoMΦs to 
investigate whether PRRSV induced downregulation of MHC molecules had an effect of 
their capacity to stimulate T cell proliferation. Our results demonstrated that even though 
there is a downregulation of MHC molecules on the surface of MoMΦs infected with 
PRRSV, it did not abrogate their stimulatory capacity, as the M0 MoMΦs clearly retained 
their capacity to stimulate a recall response in T cells from immunized animals (Figure 3-
9). Interestingly, the inactivated virus treatment in our IFN-γ ELISpot assay was able to 
stimulate IFN-γ secretion (Supplementary Figure 3-23) but we did not observe T cell 
proliferation in the M0 MoMΦs treated with inactivated PRRSV in the T cell co-cultures. 
We speculate that this could be attributable to DCs not being present in our co-culture 
when they are present in the PBMC ELISpot assays. Overall, we can conclude that 
alteration of MHC expression on APCs does not necessarily correlate to their antigen-
presenting ability, nor their T cell stimulatory capacity. This did not come as a surprise, 
as the MHC expression on the MoMΦs was only down-regulated and not completely 
abrogated. 
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3.6 Supplementary figures 
 
Figure 3-10: Bone marrow dendritic cell (BMDC) characterization. Flow cytometry 
demonstrating the cell surface markers of the stained BMDC population. 
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Figure 3-11: Summary of flow cytometry staining to characterize BMDC derived 
population. Each dot is representative of a different pig and the bars are representative of 
the mean staining for each marker. The mean % gated for each marker are as follows: 
MHCI (93.57% ), MHCII (61.28%), CD172a (73.37%), CD163 (23.24%), and CD14 
(47.89%). The cell population was devoid of macrophages (Swc9), T cells (CD3), B cells 
(CD21), and fibroblasts (CD90). Data points are from non-related animals. 
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Figure 3-12: Light microscopy of BMDCs from 1 pig on day 7 of culture (6 well plates, 
5.0x10^5 cells/mL). 
 
 
Figure 3-13: BMDC infection with VR-2385 over 72 hours. BMDCs were infected at an 
moi of 0.1 and harvested at the indicated time points. Flow cytometry of cells stained 
with the SR30-FITC ab against the PRRSV N protein. Yellow represents control cells 
stained with the SR30 ab; purple overlay represent infected cells stained with the SR30 
ab 
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Figure 3-14: PRRSV replication in the supernatant. A 1 step reverse transcription was 
used to determine levels of PRRSV in the supernatant using the SuperScript® III 
Platinum® One-Step qRT-PCR Kit (Invitrogen) according to the manufacturer’s 
instructions. Fold expression was determined by comparing Ct values at indicated time 
points to their respective controls (non-infected cell supernatants). (Cx = non-infected, 
control cells). Data points are representative of BMDCs from non-related animals. 
 
 
Figure 3-15: Fluorescence activated cell-sorting images to show gating strategy for the 
CD163+ sort of the BMDC population. 
 
 
 
 
 
 
 
 
 
Cx
 8h
rs
Vir
us
 8h
rs
Cx
 24
hr
s
Vir
us
 24
hr
s
Cx
 48
hr
s
Vir
us
 48
hr
s
Cx
 72
hr
s
Vir
us
 72
hr
s
0
50
100
200
400
600
800
Treatment
Fo
ld
 E
xp
re
ss
io
n 
 
PRRSV in supernatant of BMDCs
0.0360 0.0084
	 62	
 
Figure 3-16: BMDCs sorted for CD163 expression were infected with PRRSV and 
stained intracellularly for PRRSV N protein. (Infected cells-Green; Non-infected cells-
purple). Both populations were stained with SR30-FITC. 
 
 
Figure 3-17: MoDC forward scatter/side scatter plots demonstrating cell viability 24 and 
hours post infection with PRRSV VR-2332. Non-infected cells are on the left side and the 
infected cells are on the right side. 
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Figure 3-18: Standard curve utilized to demonstrate primer efficiency and quantification 
of PRRSV transcripts. Y  = -2.704ln(x) + 62.863. R² = 0.99971 
 
 
 
Figure 3-19: Representation of the flow cytometry staining of antigen-presenting cells for 
cell surface marker expression. Above, macrophages infected with PRRSV VR-2385 or 
VR-2332 were stained with anti-MHCI or anti-MHCII antibodies. Numbers a 
representative of the mean fluorescence intensity. 
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Figure 3-20: Flow cytometry demonstrating MFI of MHCI and MHCII expression on 
CD163- BMDCs treated with PRRSV. (Cx= non-infected control). Changes in the MFI of 
MHCI and MHCII cell surface expression was determined as previously indicated. The 
data was collected from non-related animals, performed as single replicates, and was 
determined to show no statistical significance. 
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Figure 3-21: Flow cytometry data demonstrating MHCI and MHCII expression from the 
48 hour time points of PRRSV infected CD163+ BMDCs. The data was collected from 
non-related animals, performed as single replicates, and was determined to show no 
statistical significance. (Cx= non-infected control) 
 
 
Figure 3-22: Interferon-gamma ELISpots from PRRSV immunized animals on day 0. 
Peripheral blood mononuclear cells (PBMCs) were plated at 5.0x10^5 cells per well and 
stimulated with either live or inactivated PRRSV VR-2385 for 24 hours before IFN-γ 
ELISpot plates were developed.  
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Figure 3-23: Interferon-gamma ELISpots from PRRSV immunized animals on day 16 
post immunization. Peripheral blood mononuclear cells (PBMCs) were plated at 5.0x10^5 
cells per well and stimulated with either live or inactivated PRRSV VR-2385 for 24 hours 
before IFN-γ ELISpot plates were developed. 
 
Contributions: JD and JVK isolated PBMCs and monocytes. JD isolated hematopoietic 
stem cells. JD performed cell macrophage and MoDC cell differentiation cultures. JD 
performed the flow cytometry. JD isolated viral RNA and performed rt-qPCR. JD 
performed microscopy. JD did statistical analysis. JD and VG designed experiments. 
 
 
 
 
3.7 Conclusion 
Bone marrow-derived DCs were successfully differentiated and characterized using 
Flt3L. Antigen presenting cell susceptibility to PRRSV is restricted to cells that express 
CD163. The PRRSV replicates more efficiently in MoMΦs than in CD163+ BMDCs, and 
potentially MoDCs. Lastly, the downregulation of surface MHCII in PRRSV infected M0 
MoMΦs did not abrogate their immunostimulatory capacity to induce CD4α+ Th cell 
proliferation, when co-cultured with T cells from MLV immunized animals. To further 
investigate PRRSV’s influence on antigen presentation, in Chapter 4 we investigated the 
maturation of the invariant chain in MoDCs and PAMs infected with PRRSV. 
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Chapter 4  PRRSV INFECTION ALTERS THE 
ASSOCIATION OF GAMMA ACTIN 1 WITH MHCII IN 
MONOCYTE-DERIVED DENDRITIC CELLS 
 
4.1 Abstract 
 
Trafficking of peptide loaded MHCII molecules to the plasma membrane is an integral 
step during antigen presentation, driving the progression to CD4+ Th cell mediated 
immunity. The mechanism by which peptide loaded MHCII molecules are trafficked to 
the plasma membrane is unresolved, although the utilization of the actin cytoskeleton is 
likely. Additionally, it is relatively common for enveloped RNA viruses to hijack the 
actin cytoskeleton to mediate their entry, replication, and assembly within susceptible 
cells. Very little is known regarding the role of the actin cytoskeleton during infection 
with the porcine reproductive and respiratory syndrome virus (PRRSV) and an 
explanation for the delayed induction of T cell immunity to PRRSV is unknown. Porcine 
alveolar macrophages (PAMs) and monocyte-derived dendritic cells (MoDCs) were 
infected with PRRSV and MHCII was immunoprecipitated to determine whether PRRSV 
had an effect on antigen processing/presentation. Shotgun mass spectrophotometry 
indicated that the infection of porcine MoDCs by PRRSV alters the association of gamma 
actin 1 with MHCII. Furthermore, PRRSV did not alter the expression of gamma actin 1 
in PAMs. PRRSV interference of antigen processing and presentation in MoDCs could 
influence the progression to T cell immunity. 
 
4.2 Introduction 
 
The eukaryotic cytoskeleton has both structural and functional roles. Structurally, within 
antigen-presenting cells (APCs), the actin cytoskeleton localizes just below the plasma 
membrane and is a major factor in podosome formation (Skruber et al., 2018). 
Podosomes, a characteristic of immature dendritic cells (DCs), play a crucial role in 
cellular attachment, motility, and in sampling the external environment. Upon maturation, 
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the actin cytoskeleton is rearranged and DC podosomes are no longer apparent. 
Additional hallmarks of DC maturation include loss of phagocytic capacity, upregulation 
of co-stimulatory molecules, increased MHCII expression on the surfaces of cells, and 
halting the synthesis of new MHCII molecules, as the DCs prepare for antigen 
presentation (Kleijmeer et al., 2001; West et al., 2004). Functionally within eukaryotic 
cells, the actin cytoskeleton is utilized to traffic proteins and molecules throughout the 
cytoplasm. Concerning APCs, it has been shown that inhibition of the actin cytoskeleton 
prevented the maturation of the invariant chain in B cells, but this may not be the case 
with DCs (Barois et al., 1998). An additional role of the actin cytoskeleton in APC is 
during the formation of the immunological synapse between DCs and T cells, by 
sequestering co-stimulatory molecules and adhesion molecules to the site of antigen 
presentation (Comrie et al., 2015; Girard et al., 2012). 
Viral infections are often associated with rearrangements of the actin cytoskeleton. It has 
been demonstrated that viruses, like respiratory syncytial virus (RSV), adenoviruses, 
reoviruses, and picornaviruses, utilize the actin cytoskeleton for entry, migration, 
replication, and egress. In particular, it has been shown that viral entry via clathrin-coated 
pits utilizes the actin cytoskeleton for trafficking (Jans et al., 2016; Wang et al., 2018). 
The role of the actin cytoskeleton during a PRRSV infection has gone largely unstudied. 
Manipulation of the rearrangement of the actin cytoskeleton in APCs by the PRRSV 
could influence multiple factors, including the following: cellular locomotion (migration 
of APCs to the draining lymph node); antigen processing (influencing the peptide 
repertoire being presented); antigen presentation (interfering with peptide loaded MHCII 
(pMHCII) trafficking to the plasma membrane). Although multiple theories have been 
postulated for the delayed induction of T cell immunity to PRRSV, like the necrosis and 
apoptosis in the thymus and lymph nodes leading to an overall lymphocyte depletion or 
the potential suppression of immunity by regulatory T cells early during infection, there 
has not yet been a definitive explanation (Manickam et al., 2013; Silva-Campa et al., 
2009; Weesendorp et al., 2013; Wongyanin et al., 2010). Given that PRRSV is able to 
infect APCs, it may be plausible that the virus could be interfering with the processing 
and/or presentation of antigenic peptide sequences to T cells. Interrupting antigen 
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presentation in APCs could potentially offer an explanation for the delayed induction of T 
cell mediated immunity to the PRRSV. 
Here, we sought to investigate the maturation of the invariant chain in response to 
PRRSV infection. MoDCs and porcine alveolar macrophages (PAMS) were infected with 
PRRSV (VR-2385) and cells were lysed 24 hours post infection. MHCII was 
immunoprecipitated from whole cell lysates and separated on a polyacrylamide gel. 
Bands on the gel were identified using shotgun mass spectrometry. Our results indicate 
that PRRSV does not have an influence on the maturation of the invariant chain. Mass 
spectrometry analysis indicated that PRRSV infection influences the association of 
gamma actin 1 with MHCII in MoDCs. Lastly, we show that the expression levels of 
proteins associated with MHCII in PAMs and MoDCs are different, potentially 
highlighting the professional antigen-presenting capability associated with DCs.   
 
4.3 Materials and methods 
 
Animals: 
Six to eight-week old Dutch Landrace pigs were purchased from the pathogen free herd 
at the Prairie Swine Centre (Saskatchewan). All experiments were conducted in 
accordance with the ethical guidelines of the University of Saskatchewan and Canadian 
Council of Animal Care.  
 
Cells and viruses: 
Monocytes were isolated from whole blood as previously described (Auray et al., 2013). 
Briefly, PBMCs were isolated on a FICOLL-PAQUE® Plus gradient (GE Healthcare, 
Uppsala Sweden). Monocytes were labeled with anti-human CD14 beads and selected for 
on LS columns using a magnetic isolated cell sorter (Miltenyi Biotec, Auburn, CA). To 
obtain MoDCs, monocytes were plated at 1.0x10^6 cells/mL in RPMI complete with 
recombinant porcine (rp) IL-4 (100 ng/mL – R&D 654-P4) and rpGM-CSF (20 ng/mL – 
R&D 711-PG) for 6 days at 37 °C with 5% carbon dioxide, and media was changed every 
3rd day as performed previously (Facci et al., 2010). Dendritic cells are susceptible to 
PRRSV infection and are often referred to as the professional APCs of the immune 
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system, thus we chose to investigate PRRSV effect on antigen presentation in MoDCs. 
Porcine alveolar macrophages (PAMs) are easily accessible and readily infected by 
PRRSV. PAMs were isolated via bronchoalveolar lavage, as described previously (Zhang 
et al., 2009). Briefly, lungs were removed from animals and 500 ml of PBS, at 4°C 
supplemented with 10% fetal bovine serum + gentamycin (100 µg/ml, Gibco) and 2x 
Antibiotic/Antimycotic (Sigma Aldrich), was poured into the lung using an endotracheal 
tube. The lung was massaged and cells were poured into a collection vessel. The effluent 
from the lung collection was filtered through 40 µm filters (Falcon) to remove debris. 
Cells were then pelleted (400xg) and washed twice before culturing in Dulbecco’s 
Modified Eagle’s Medium (Sigma Aldrich) + 2% FBS, 14 mM HEPES (Gibco), 0.1 mM 
non-essential amino acids (Gibco), 100 µg/ml Gentamycin (Gibco), 1x 
Antibiotic/Antimycotic (Gibco).  PRRSV strain VR2385 (ATCC, Manassas, VA, USA) 
was used in the study.  
 
Antigen presenting cell infections and sample preparation: 
Briefly, ten million antigen-presenting cells were infected with PRRSV (MOI 0.1), or 
cells were non-infected for 3 hours at 37°, 5% CO2 . Cells were pelleted at 350 g, 
resuspended in fresh media, and seeded on 12 well plates. Cells were harvested 24 hours 
post infection, cells were then pelleted and washed before lysing in RIPA lysis buffer + 
0.1mM PMSF protease inhibitor. Cells were incubated for 20 minutes at 4oC with 
shaking and sonicated for 2 minutes. Cellular debris was removed by centrifuging 
samples at 10,000xg for 5 minutes (twice) and the supernatant was placed into a new 
microcentrifuge tube. Protein concentration was determined using a Pierce BCA Protein 
Assay Kit (Thermo Fisher) and concentrations were normalized across samples.  
 
MHCII Immunoprecipitation: 
Dynabeads Magnetic Beads, Protein A, were utilized to immunoprecipitate MHCII 
according to the manufacturer’s instructions. We identified an appropriate antibody to 
immunoprecipitate MHCII and silver stained a polyacrylamide gel. Briefly, fifty 
microliters of Dynabeads Protein A were incubated with 20.0 µg of MHCII (MSA3, King 
Fisher) for 20 minutes at room temperature with rotation. The dynabead-MHCII complex 
	 71	
was washed utilizing the magnet and washing buffer supplied by the manufacturer, before 
combining MHCII-dynabeads with the cellular lysates prepared previously. The lysates 
were left to immunoprecipitate overnight at 4oC with shaking, before following the 
manufacturer’s instructions in completing the immunoprecipitation.  
 
Polyacrylamide Gel Electrophoresis: 
Samples were loaded into wells of a 12.5% polyacrylamide gel with a stack. The 
ProteoSilverTM Silver Stain Kit (SIGMA) was used according to the manufacturer’s 
instructions. A band appeared at 40-45 kDa in the non-infected control cell sample but 
not in the PRRSV infected MoDC sample lane. The band was extracted with a razor 
blade, stored in ultra distilled water, and sent for shotgun mass spectrometry sequencing 
at the Proteomics Platform of the CHU de Québec Research Center (Quebec, Qc, 
Canada). 
 
Tryptic digest: 
Bands of interest were extracted from gels and placed in 96-well plates and then washed 
with water. Tryptic digestion was performed on a liquid handling robot (MultiProbe, 
Perkin Elmer) according to the manufacturer’s specifications. Briefly, proteins were 
reduced with 10mM DTT and alkylated with 55mM iodoacetamide. Trypsin digestion 
was performed using 126nM of modified porcine trypsin (Sequencing grade, Promega, 
Madison, WI) at 37°C for 18h. Digestion products were extracted using 1% formic acid, 
2% acetonitrile followed by 1% formic acid, 50% acetonitrile. The recovered extracts 
were pooled, vacuum centrifuge dried and then resuspended into 12 µl of 0.1% formic 
acid and 5 µl were analyzed by mass spectrometry.  
 
Mass spectrometry: 
Peptide samples were injected and separated by online reversed-phase (RP) nanoscale 
capillary liquid chromatography (nanoLC) and analyzed by electrospray mass 
spectrometry (ESI MS/MS). The experiments were performed with a Dionex UltiMate 
3000 nanoRSLC chromatography system (Thermo Fisher Scientific / Dionex Softron 
GmbH, Germering, Germany) connected to an Orbitrap Fusion mass spectrometer 
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(Thermo Fisher Scientific, San Jose, CA,USA) driving with Orbitrap Fusion Tune 
Application 2.0 and equipped with a nanoelectrospray ion source. Peptides were trapped 
at 20 µl/min in loading solvent (2% acetonitrile, 0.05% TFA) on a 5mm x 300 µm C18 
pepmap cartridge pre-column (Thermo Fisher Scientific / Dionex Softron GmbH, 
Germering, Germany) during 5 minutes. Then, the pre-column was switched online with 
a self-made 50 cm x 75µm internal diameter separation column packed with ReproSil-
Pur C18-AQ 3-µm resin (Dr. Maisch HPLC GmbH, Ammerbuch-Entringen, Germany) 
and the peptides were eluted with a linear gradient from 5-40% solvent B (A: 0,1% 
formic acid, B: 80% acetonitrile, 0.1% formic acid) in 30 minutes at 300 nL/min. Mass 
spectra were acquired using a data dependent acquisition mode using Thermo XCalibur 
software version 3.0.63. Full scan mass spectra (350 to 1800m/z) were acquired in the 
orbitrap using an AGC target of 4e5, a maximum injection time of 50 ms and a resolution 
of 120 000. Internal calibration using lock mass on the m/z 445.12003 siloxane ion was 
used. Each MS scan was followed by acquisition of fragmentation MSMS spectra of the 
most intense ions for a total cycle time of 3 seconds (top speed mode). The selected ions 
were isolated using the quadrupole analyzer in a window of 1.6 m/z and fragmented by 
Higher energy Collision-induced Dissociation (HCD) with 35% of collision energy. The 
resulting fragments were detected by the linear ion trap in rapid scan rate with an AGC 
target of 1e4 and a maximum injection time of 50ms.  Dynamic exclusion of previously 
fragmented peptides was set for a period of 20 sec and a tolerance of 10 ppm. 
Database searching: 
 All MS/MS peak lists (MGF files) were generated using Thermo Proteome Discoverer 
software (Thermo Fisher Scientific Inc., version 2.1.0). MGF sample files were then 
analyzed using Mascot (Matrix Science, London, UK; version 2.5.1). Mascot was set up 
to search the contaminants_thegpm_20170713.fasta; 
AX_Desulfovibrio_CI_194924_20160714 database (unknown version, 104802 entries) 
assuming the digestion enzyme trypsin. Mascot was searched with a fragment ion mass 
tolerance of 0,60 Da and a parent ion tolerance of 10,0 PPM. Carbamidomethyl of 
cysteine was specified in Mascot as a fixed modification. Deamidated of asparagine and 
glutamine and oxidation of methionine were specified in Mascot as variable 
modifications. Two missed cleavages were allowed. 
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Criteria for protein identification: 
Scaffold (version Scaffold_4.7.5, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 95.0% probability by the Peptide 
Prophet algorithm (Keller et al., 2002) with Scaffold delta-mass correction. Protein 
identifications were accepted if they could be established at greater than 95.0% 
probability and contained at least 2 identified peptides. Protein probabilities were 
assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins that contain 
similar peptides and could not be differentiated based on MS/MS analysis alone were 
grouped to satisfy the principles of parsimony.        
 
4.4 Results 
 
PRRSV infection alters protein association with immunoprecipitated MHCII: 
Twenty-four hours post infection with PRRSV, PAMs and MoDCs were lysed and whole 
cell fractions were analyzed by immunoprecipitation of MHCII. Protein concentrations 
were normalized and equal amounts of protein were loaded into separate wells on a 
PAGE-gel before silver staining. Non-infected MoDCs had a band of 40-50 kDa in size 
that was prominent in comparison to PRRSV infected MoDCs (Band “A”). The band was 
faint in PAMs, and PRRSV infection did not alter the prominence of the band. The 
indicated bands (A- 42-45 kDa; B- 30-35 kDa; C – 28-30 kDa; Figure 4-1) were 
extracted for identification via mass spectrometry sequencing. 
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Figure 4-1: Silver stained SDS-PAGE-Gel of immunoprecipitated MHCII samples from 
PRRSV infected and non-infected APCs. MoDCs and PAMs were either infected or non-
infected for 24 hours before immunoprecipitating MHCII. Protein concentrations were 
normalized before samples were loaded into their respective wells. Lane 2: Non-infected 
MoDCs; Lane 3: VR-2385 infected MoDCs; Lane 4: Non-infected PAMS; Lane 5: VR-
2385 infected PAMs. Bands A, B, and C were extracted from Lane 2 and sent for mass 
spec sequencing. The experiment was repeated three times from non-related animals. The 
immunoprecipitation of MHCII from PAMs and MoDCs in the above image (isolated 
from the same animal) was performed simultaneously. 
 
 
PRRSV infection alters the association of gamma actin 1 with MHCII: 
The mass spectrometry data indicated that the missing band in the PRRSV infected 
MoDCs was gamma actin 1. Beyond gamma actin 1, there wasn’t as remarkable of a 
difference in the expression pattern of the other protein bands amongst the other APC 
populations that were infected with PRRSV versus those that were not infected. The 
identification of the bands sent for mass spec sequencing were as follows: Band A - Actin 
gamma 1; Band B – SLA-DRA1; Band C – SLA-DRB1. 
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Table 4.1: Mass spectrometry identified proteins from the MHCII immunoprecipitation. 
 
 
Extracted bands from the silver stained SDS-PAGE-Gel were identified using shotgun 
mass spectrophotometry as explained previously. Ten proteins, of 115, were identified as 
being relevant to the immunoprecipitation of MHCII using Scaffold 4 software. 
Quantitative value, total spectrum count, exclusive unique spectrum count, and protein 
identification probability indicate that the missing band is gamma actin 1. Bands B and C 
were identified as HLA-DRA1 and SLA-DRB1 respectively, confirming the successful 
immunoprecipitation of MHCII. A, B, C letter designations correspond to the extracted 
bands. 
 
4.5 Discussion 
 
Dendritic cells (DCs) are often referred to as the professional APCs of the immune 
system. This being attributable to their capability of processing antigens into peptide 
sequences for presentation on MHC molecules to stimulate naïve T cells, driving the 
adaptive immune response in a particular direction. Although macrophages are capable of 
stimulating T cell responses, the repertoire of peptide sequences being presented by DCs 
is likely more diverse. Studies have shown macrophages have higher proteolytic activity 
and a lower pH within late endosomes than DCs, theoretically resulting in increased 
Identified	Proteins Accession	Number MW	(kDa) A B C A B C
Actin	gamma	1 I3LVD5_PIG 42 119 10 5 107 6 6
Sus	scrofa	SLA-DRB1 A0A287ARX3_PIG 30 2 15 23 2 9 26
Sus	scrofa	HLA-DRA1 A0A287AYL4_PIG 25 0 41 6 0 24 7
Cathepsin	B A0A287F94_PIG 41 0 0 7 0 0 8
Cathepsin	Z A5GFX7_PIG 34 0 0 7 0 0 8
Sus	scrofa	SLA-3 A0A287AJS8_PIG 40 8 0 0 7 0 0
SLA	class	II,	DQ	
haplotype	C	beta	chain HB2C_PIG 30 0 0 5 0 6
Actin,	beta	like	2 A0A287A4R1_PIG 42 40 0 0 36 0 0
Sus	scrofa	CD74 A0A287B7S0_PIG 31 0 0 3 0 0 3
SLA	class	II,	DQ	
haplotype	C	alpha	chain HA2C_PIG 28 0 5 0 0 3 0
Identified	Proteins Accession	Number A B C A B C
Actin	gamma	1 I3LVD5_PIG 49 6 6 100% 100% 100%
Sus	scrofa	SLA-DRB1 A0A287ARX3_PIG 2 7 10 100% 100% 100%
Sus	scrofa	SLA-DRA1 A0A287AYL4_PIG 0 9 5 0% 100% 100%
Cathepsin	B A0A287F94_PIG 0 0 8 0% 0% 100%
Cathepsin	Z A5GFX7_PIG 0 0 7 0% 0% 100%
Sus	scrofa	SLA-3 A0A287AJ58_PIG 7 0 0 100% 0% 0%
SLA	class	II,	DQ	
haplotype	C	beta	chain HB2C_PIG 0 0 5 0% 0% 100%
Actin,	beta	like	2 A0A287A4R1_PIG 2 0 0 100% 0% 0%
Sus	scrofa	CD74 A0A287B750_PIG 0 0 3 0% 0% 100%
SLA	class	II,	DQ	
haplotype	C	alpha	chain HA2C_PIG 0 3 0 0% 100% 0%
Quantitative	Value	(Normalized	Spectra) Total	Spectrum	Count
Exclusive	Unique	Spectrum	Count Protein	Identification	Probability
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levels of proteolysis, which would in turn deplete the peptide repertoire for presentation 
(Delamarre et al., 2005]. When considering the immune response to a pathogen, a high 
degree of peptide diversity is favorable. The pathway in which MHCII is synthesized and 
loaded with peptide has been largely deduced, but the trafficking of peptide loaded 
MHCII to the plasma membrane in APCs has not been completely resolved (Blum et al., 
2013; ten Broeke et al., 2013).  
Originally we sought to investigate whether PRRSV has an influence on the maturation 
of the invariant chain. Referring to Figure 4.2 on the following page, shortly after 
translation, MHCII is trafficked to the endoplasmic reticulum (ER) for further 
modification. Within the ER, an invariant chain trimer acts as a scaffold to which three 
MHCII alpha chains and three MHCII beta chains bind. The MHCII nonamer is then 
trafficked through the trans-golgi network or to the plasma membrane, after which the 
MHCII-Invariant chain (I chain) complex can be found within early and late endosomes. 
Internalization of MHCII at the plasma membrane has been hypothesized to occur in 
response to poly-ubiquitination of a lysine residue on the cytoplasmic tail of the MHCII 
beta chain. This ubiqutination process has been showed to occur more readily in 
immature DCs than mature DCs, and may even be utilized as a differentiation marker of 
maturation. Within these endosomes, acidic conditions, in addition to cysteine proteases 
(Cathepsins S, F, and L), lead to the processing of the invariant chain into CLIP. CLIP 
occupies the binding groove of MHCII to prevent autonomic peptides from occupying the 
groove. An MHCII homologue, HLA-DM, is responsible for removing CLIP from the 
binding groove, thus facilitating the loading of a peptide sequence for antigen 
presentation. The peptide loaded MHCII heterodimer is then ready to be trafficked to the 
plasma membrane, where it localizes to lipid rafts for peptide presentation to CD4+ Th 
cells (Blum et al., 2013; Mellins and Stern, 2014). To determine whether PRRSV 
influences maturation of the invariant chain, we infected cells and immunoprecipitated 
MHCII. 
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Figure 4-2: Schematic summarizing the replication and assembly of PRRSV, and the 
potential association of PRRSV with the maturation of the invariant chain and MHCII 
antigen processing and presentation. The schematic demonstrates the potential that 
PRRSV may interfere with the maturation of the invariant chain and/or with MHCII 
associated antigen processing/presentation. Arrows and numbers in green indicate the 
pathway of PRRSV replication and assembly. Arrows and numbers in red indicate the 
pathway of invariant chain maturation and MHCII peptide presentation; pMHCII = 
peptide loaded MHCII; CatS = Cathepsin S; CatF = Cathepsin F; CatL = Cathepsin L. 
Triangles = PRRSV proteins. 
 
Our results coincide with what has been shown in the literature, as the alpha chain (HLA-
DRA1) we identified was 33-35 kDa and the beta chain (SLA-DRB1) was 28-30 kDa 
(Schafer et al., 1998). Ultimately we observed one major discernable difference in the 
levels of MHCII associated molecules amongst the infected and non-infected cell 
populations. The size of the band did not correspond to that of the processed invariant 
chain (CD74 = 10 kDa) on the silver stained gel (Pierre and Mellman, 1998). At this time 
it is difficult to conclude whether PRRSV influences the maturation of the invariant 
chain, as there is no antibody available to detect the invariant chain in pigs. Considering 
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we have demonstrated that PRRSV infected macrophages and MoDCs were capable of 
stimulating antigen specific T cell proliferation (Chapter 6), we believe that PRRSV may 
not be suppressing invariant chain maturation. Interestingly a band within the PRRSV 
infected MoDCs was practically diminished, which was identified to be gamma actin 1. 
Upon maturation, DCs undergo several changes including but not limited to the 
following: a) increased MHCII on the plasma membrane; b) upregulation of co-
stimulatory molecules; c) diminished phagocytic capacity; d) abrogation of new MHCII 
molecule synthesis; e) loss of podosomes as a result of cytoskeletal rearrangement 
(Kleijmeer et al., 2001; ten Broeke et al., 2013; West et al., 2004). As mentioned 
previously, little is known as to how pMHCII is trafficked to the plasma membrane, it has 
been shown that microtubules are utilized in transport, but it’s also plausible that 
transport utilizes the cytoskeleton (Rocha and Neefjes, 2008).  
Filamentous actin can be found underneath the plasma membranes of cells, providing a 
structural base in addition to aiding in cellular motility (Wang et al., 2018). Actin 
filaments accumulate at podosomes in APCs, enabling movement and sampling of the 
environment, and potentially playing a role in cellular migration. Upon activation, the 
actin filaments at podosomes are rearranged to favour endocytosis and phagocytosis of 
antigen, ultimately leading to the loss of podosomes in activated APCs (Burns et al., 
2001). Gamma actin 1 and beta actin (twice as prominent in cells) are the predominant 
forms of actin that contribute to the actin cytoskeleton. Characterizing the roles of beta 
actin and gamma actin has proven to be challenging, owing to difficulty in purifying the 
actin filaments separately. It has been shown that beta-actin knockout mice do not survive 
embryogenesis, whereas gamma-actin knockouts survived into adulthood, although they 
struggled with morbidity throughout, suggesting gamma-actin’s potential role in 
immunity (Skruber et al., 2018). Additionally it has been shown that the inhibition of the 
actin cytoskeleton prevents IFN-γ secretion in RSV infected cells (Jans et al., 2016). 
Furthermore, considering the localization of gamma actin has been to the cytoplasm it’s 
plausible gamma actin could play a role in trafficking molecules to the plasma 
membrane, whereas beta actin filaments accumulate more so at lamellipodia, making beta 
actin more likely to serve as a structural component for cells. 
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Transport of MHCII to the plasma membrane potentially relies on the reorganization of 
the cytoskeleton. Late MHCII compartments (MIICs) have been shown to fuse together, 
by way of microtubules. It’s plausible that vesicular bodies, budding from the MIICs, are 
responsible for carrying the peptide loaded MHCII molecules to the plasma membranes, 
by way of microtubules and cytoskeletal filaments. Microtubules extend from the MIICs, 
which have released vesicular bodies containing the peptide loaded MHCII molecules, to 
the plasma membrane (Chow et al., 2002; Kleijmeer et al., 2001; van Nispen tot 
Pannerden et al., 2010). It has been shown that microtubule formation can occur 
independently of antigen exposure, as a stimulus is the only necessary component. That 
being the case, stimulation of DCs by a TLR agonist into a mature phenotype will 
theoretically induce microtubule formation. Although, it seems that these microtubules 
appear to utilize kinesins and dyneins for movement, there was no association with actin 
filaments (Vyas et al., 2007). On the other hand, it has been shown that transport of 
MHCII in B cells occurs in association with the actin cytoskeleton. Trafficking of 
lysosomal vesicles containing either antigen or MHCII molecules within B cells appeared 
to be dependent on the activity of Myosin II in association with actin microfilaments 
(Vascotto et al., 2007). But these authors did not investigate the transport of MHCII to 
the plasma membrane. It’s possible that MHCII transport to the plasma membrane could 
differ within APC populations and potentially differ between species. Overall, it seems 
that the rearrangement of the cytoskeleton is a characteristic of APC maturation and 
likely plays a role in trafficking of pMHCII to the plasma membrane. Trafficking of 
molecules within cells is highly dependent on utilizing the actin cytoskeleton, thus it 
comes as no surprise that viruses often rearrange the actin cytoskeleton for their own 
benefit. 
Viral infections are often associated with rearrangements of the actin cytoskeleton. It has 
been demonstrated that viruses utilize the actin cytoskeleton for entry, migration, 
replication, and egress (Wang et al., 2018). Similar to actin cytoskeleton rearrangements, 
certain viruses utilize microtubules for entry or egress. It has been shown that successful 
entry, via endocytosis at clathrin-coated pits, of the respiratory syncytial virus in human 
monocytes is dependent on the actin cytoskeleton (Jans et al., 2016). Referring again to 
Figure 4.2, considering PRRSV entry via clathrin-coated pits, it’s likely that PRRSV is 
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utilizing the actin cytoskeleton during viral entry. In the context of a PRRSV infection, 
the virus would be internalized via clathrin-coated pits into endosomes. Early endosomes 
mature into late endosomes, through acidification, eventually forming an MHCII class 
compartment (MIIC). The environment, specifically the low pH, within these late 
endosomes is relatively harsh, resulting in the proteolysis of antigen to generate peptide 
sequences, which are then loaded into the binding groove of MHCII, being under the 
regulation of HLA-DM. The pH of the late endosomes in DCs is much higher than that of 
macrophages, which theoretically would result in a more diverse repertoire of peptide 
sequences given the lower activity of proteolysis associated with a less harsh endocytic 
environment (Blum et al., 2013; Delamarre et al., 2005). 
The role of the cytoskeleton during a PRRSV infection has gone largely unstudied. Our 
results seem to indicate that the association of gamma actin 1 with MHCII is present in 
MoDCs but not alveolar macrophages. Furthermore, the gamma actin 1 association with 
MHCII was largely diminished when MoDCs were infected with the PRRSV. We are 
thus left questioning why gamma actin 1 was immunoprecipitated with MHCII, and why 
gamma actin 1 was not as pronounced in the PRRSV infected MoDCs. Additionally, we 
are left questioning why the alveolar macrophages did not have gamma actin 1 in similar 
levels as the MoDCs. Our results seem to indicate that gamma actin 1 could play a 
prominent role during antigen presentation, although this is based on speculation. 
Overall, there are a few potential explanations for the association of gamma actin 1 with 
MHCII in response to a PRRSV infection. They include but are not limited to the 
following: a) PRRSV induces rearrangement of the actin cytoskeleton to favor its 
replication, assembly, and/or egress; b) maturation of MoDCs induces rearrangement of 
the actin cytoskeleton for cellular locomotion (migration of APCs to the draining lymph 
node); c) trafficking of pMHCII to the plasma membrane is dependent on gamma actin 
filament reorganization; d) PRRSV influences the rearrangement of gamma actin 1 in 
MoDCs, potentially interfering with antigen presentation. If PRRSV does interfere with 
antigen processing and presentation, it could have drastic implications on the stimulation 
of naïve T helper cells and the progression to T cell immunity. In conclusion, the role of 
the actin cytoskeleton during a PRRSV infection and the potential role of gamma actin 1 
during antigen presentation warrant further attention. 
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Contribution: JD isolated PBMCs and monocytes. JD performed MoDC differentiation 
cultures. JD isolated PAMs. JD performed MHCII immunoprecipitation. JD ran SDS-
PAGE gels. The Proteomics Platform of the CHU de Québec Research Center (Quebec, 
Qc, Canada) ran the mass spec. JD and VG designed experiments. 
 
 
 
4.6 Conclusion 
Gamma actin 1 association with MHCII is more pronounced in MoDCs than in PAMs. 
Furthermore, PRRSV infection of MoDCs alters the association of actin gamma 1 with 
MHCII. The role of the actin cytoskeleton during a PRRSV infection, in addition to the 
role of the actin cytoskeleton in the trafficking of peptide loaded MHCII to the plasma 
membrane, should be investigated further. To investigate the interaction of APCs with T 
cells, in Chapter 5 we established an assay using a mixed leukocyte reaction (MLR) so 
that the MLR could be modified to assess antigen specific T cell responses to the 
PRRSV. 
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Chapter 5   PORCINE M1 MACROPHAGES ARE MORE 
POTENT INDUCERS OF LYMPHOCYTE 
PROLIFERATION THAN M2 OR M0 MACROPHAGES 
 
5.1 Abstract 
 
Antigen presenting cells (APCs) are responsible for the activation of naïve T 
lymphocytes in addition to playing a significant role in stimulating the proliferation of 
central memory and effector memory T cells. Dendritic cells are the professional APCs of 
the immune system, but monocytes, macrophages and B cells also possess the capacity to 
process and present antigen to T lymphocytes.  It is not uncommon for macrophages to be 
characterized into an M1 (inflammatory) or M2 (non-inflammatory) phenotype. Thus, we 
were interested in the differential stimulatory capacity of phenotypically distinct 
macrophages in a mixed leukocyte reaction. Here we show a method to measure the 
differentiation of porcine macrophages into an M1 or M2 phenotype, and their 
differential ability to stimulate T cells in a mixed leukocyte reaction (MLR).  
 
5.2  Introduction: 
 
The mixed leukocyte reaction (MLR) is an immunological assay representative of a graft 
versus host disease response. Essentially, the MLR is exemplary in demonstrating 
alloreactivity of T lymphocytes. During the development of the T cell repertoire in the 
thymus, T cells undergo a process of positive and negative selection. During positive 
selection, CD4α/CD8β double-positive thymocytes migrate to the thymic cortex and 
interact with thymic epithelial cells. If the double positive thymocytes interact more 
strongly with MHCII they become CD4α+ and if they interact more with MHCI they 
acquire a CD8 lineage. If the thymocyte has undergone a poor rearrangement of its T cell 
receptor (TCR) and does not interact with either MHCI or MHCII, that thymocyte 
undergoes apoptosis and is eliminated from the T cell repertoire. The negative selection 
of T cells eliminates those lymphocytes that have acquired a T cell receptor (TCR) that is 
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reactive against self-MHC molecules in association with a self-peptide sequence. Those T 
cells that are self reactive, for the most part, undergo apoptosis and are eliminated from 
the repertoire, in turn preventing self-reactivity and auto-immunity. Alloreactivity can 
therefore be defined as T cells that recognize foreign MHC molecules, as they are non-
self. This phenomenon becomes highly relevant when considering host rejection of graft 
tissue transplants (Colf et al., 2007; Nagy, 2012).  
MLRs are typically performed using entire leukocyte populations from whole blood 
mixed with the leukocytes from the whole blood of another individual. Here, we have 
modified the traditional MLR to evaluate the capacity of macrophages to stimulate 
lymphocyte proliferation by culturing APCs with a T lymphocyte enriched population, 
with the intent of promoting increased levels of lymphocyte proliferation. Pigs are 
becoming an increasingly popular animal model to study human diseases, due to the 
similarity in anatomy, physiology, and genetics with humans (Bassols et al., 2014; 
Meurens et al., 2012; Summerfield et al., 2015). Additionally, pork is a primary protein 
source globally and limiting disease in pigs enhances food security. Taking this into 
consideration, investigating APC function and APC interactions with T cells will provide 
insight towards the induction of T cell immunity to pathogens.  
Several different macrophage populations exist in vivo (Varol et al., 2015). For the most 
part, a resting macrophage can be characterized as having an M2 phenotype 
(homeostatic). When an M2 macrophage becomes activated, usually via cytokine 
stimulation or pattern recognition receptor activation, it acquires an M1 phenotype. The 
M1 macrophages have a lower endosomal pH, are more sensitive to stimulation via 
pattern recognition receptors, and respond with higher levels of inflammatory cytokine 
secretion in comparison to their M2 counterparts (Martinez and Gordon, 2014; Mills and 
Ley, 2014). Given the activation status of M1 macrophages, we hypothesized that M1 
macrophages would possess a higher capacity to stimulate T cell proliferation in 
comparison to M2 macrophages. We were interested in determining whether the 
metabolic state of MΦs correlates to an APC’s capability to stimulate lymphocyte 
proliferation in a MLR. 
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5.3 Materials and methods 
 
Animals: 
Six to eight week old Dutch Landrace pigs were purchased from the pathogen free herd at 
the Prairie Swine Centre (Saskatchewan). All experiments were conducted in accordance 
with the ethical guidelines of the University of Saskatchewan and Canadian Council of 
Animal Care.  
 
Cell isolation and differentiation: 
Monocytes were isolated from whole blood as previously described (Auray et al., 2013). 
Briefly, PBMCs were isolated on a FICOLL-PAQUE® Plus gradient (GE Healthcare, 
Uppsala Sweden). Monocytes were labeled with anti-human CD14 (TUK4) directly 
conjugated to magnetic beads, and selected using LS columns with magnetic activated  
cell sorter (MACS; Miltenyi Biotec, Auburn, CA). To derive macrophages, monocytes 
were plated at 1.0x10^6 cells/mL, in 3 ml per well, of RPMI-1640 complete (Gibco®-
BRL) (1% Antibiotic/antimycotic, 0.5 mM β-mercaptoethanol, 1% MEM non-essential 
amino acids (Gibco®-BRL), 1% HEPES (Gibco®-BRL), and 10% FBS) supplemented 
with rpGM-CSF (20 ng/ml - Biosource, Camarillo, CA) for 3 days at 37 °C with 5% CO2. 
After the 3rd day in culture with rpGM-CSF, to derive an M1 phenotype, macrophages were 
cultured in RPMI supplemented with 20 ng/mL of rpIFN-γ (Ceiba Geigy) for 24 hours. To 
derive an M2 phenotype, macrophages were cultured in RPMI supplemented with 100 
ng/mL of rpIL-4 (GibcoTM ThermoFisher) for 24 hours. The M0 macrophages were 
cultured without the addition of any cytokines. Macrophages were chosen to perform the 
MLRs because the differentiation time is only 3 days as opposed to 6 days with MoDCs. 
T-lymphocytes were enriched from PBMCs using a MACS sorter. Briefly, 3.0x10^7 
PBMCs were incubated with 300 µg of anti-CD172a antibody (BL1H7, BioRad) and 300 
µg of anti-CD21 antibody (BB6-11C9.6, Southern Biotech) in 300 µl of PBS+2% FBS 
for 15 minutes at 4o C with shaking. Cells were washed twice, and anti-IgG1 bead 
conjugated antibody (Miltenyi Biotec) was added to the CD172a/CD21 labeled PBMCs 
according to manufacturer’s recommendations. Cells were washed and resuspended in 1 
ml of MACS buffer (Miltenyi Biotec), before capturing non-T cells on a MACS LS 
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column to obtain a T-lymphocyte enriched population. The enriched T cells were labeled 
with carboxyfluorescein succinimidyl ester (CFSE) according to the manufacturer’s 
protocol (CFSE, Thermo Fisher), enumerated, and seeded at 3.0x10^5 cells/well on a 96 
well U-bottom plate. 
 
Macrophage – T cell mixed leukocyte reaction: 
Monocyte-derived macrophages (MoMΦ) and T cells were co-cultured to investigate the 
stimulatory capacity of M1 and M2 MoMΦs, to promote T lymphocyte proliferation. 
After 3 days in culture and 24 hours after the addition of IL-4 or IFN-γ, 3.0x10^4 
macrophages were co-cultured with 3.0x10^5 T cells from the same or from genetically 
non-related pigs. The macrophage-T cell co-cultures were incubated at 37o C, 5% CO2 for 
4 days before assessing proliferation with flow cytometry as described below. Concavalin 
A (5 µg/mL) stimulated lymphocytes served as a positive control. 
 
Figure 5-1: Figure demonstrating the plating schematic utilized in co-culturing APCs 
with an enriched T cell population for the MLRs.  
 
Flow cytometry: 
Briefly, recovered cells were incubated 20 min at 4°C with primary antibodies, then 
washed twice before incubation with their respective secondary antibody. The primary 
and secondary antibodies utilized were as follows: mouse anti-pig CD4α (MIL17, 
BioRad); mouse anti-pig CD8β  (PG164a, Kingfisher Biotech); mouse anti-pig γδ  
(PGBL31A, Kingfisher Biotech); Goat anti-mouse IgG1-PE (Southern Biotech, 1072-
09); Goat anti-mouse IgG2a-Al647 (Southern Biotech, 1080-31); Goat anti-mouse 
	 86	
IgG2b-biotin (Southern Biotech, 1091-08); Streptavidin-PerCP-Cyanine 5.5 
(eBioscience, 45-4317-80) 
At least 50,000 events were collected on a FACSCALIBUR™ (BD Biosciences, 
Mountain View, CA) using the CELLQUEST™ software. Data were analyzed using 
FlowJo X (treestar) software. Populations were defined as follows: a) CTL: γδ- CD4α- 
CD8β+; b) CD4α+ Th cells: γδ- CD4α+ CD8β-; c) gamma delta: γδ+ CD4α- CD8β-. 
 
Statistical Analysis: 
All data points on graphs are representative of genetically unrelated individual animals. 
All the data were statistically analysed using GRAPHPAD PRISM™ 7 software 
(GraphPad Software, Inc., La Jolla, CA). Multiple comparisons between >2 groups were 
assessed using the Kruskal-Wallis test for non-paired, non-Gaussian data. For 
comparissons between 2 groups, the Mann-Whitney test for non-paired, non-Gaussian 
data was used. When P≤0.05, differences were considered significant. 
 
5.4 Results 
 
An enriched population of T lymphocytes (Supplementary Figure 5-7) was stained with 
CFSE in order to monitor proliferation in a mixed leukocyte reaction (MLR). After 
deriving macrophages from blood monocytes, cells were either non-stimulated (M0) with 
RPMI complete, IFN-γ stimulated (M1), or IL-4 stimulated (M2) for 24 hours before 
were culturing with T cells at a ratio of 1:10, either from the same animal (autologous) or 
from different animals (allogenic). 
Our results indicate that the M1 MoMΦs possess the highest capacity to stimulate T 
lymphocyte proliferation in a MLR. As shown in Figure 5-5, the CD4α T cell population 
co-cultured with the M1 MoMΦs had a mean proliferation of 46.2% in comparison to the 
M0 MoMΦs which had 14.2% or M2 MoMΦs which had 18.4% CD4α mean 
proliferation. Similarly, as demonstrated in Figure 5-6, the CD8β population in the M1 
MLR had 34.1% mean proliferation while the M0 and M2 MLRs had 9.8% and 10.2% 
mean proliferation levels respectively. We did not record any significant difference in the 
proliferation levels of the gamma delta T cell populations. 
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Figure 5-2: M0 mixed leukocyte reaction T cell proliferation. Non-stimulated MoMΦs 
(M0) were cultured with CFSE-labeled T lymphocytes, either autologous or allogenic, 
and stained for specific T lymphocyte subsets to monitor proliferation after 4 days in 
culture. Statistical analysis performed using Mann-Whitney test comparing the 
autologous versus allogenic T cell proliferations within each T cell subset. Data points 
are single replicates, from non-related animals (N=4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3: M2 mixed leukocyte reaction T cell proliferation. Interleukin-4 stimulated 
MoMΦs (M2) were cultured with CFSE-labeled T lymphocytes, either autologous or 
allogenic, and stained for specific T lymphocyte subsets to monitor proliferation after 4 
days in culture. Statistical analysis performed using Mann-Whitney test comparing the 
autologous versus allogenic T cell proliferations within each T cell subset. Data points 
are from non-related animals performed as single replicates (N=3). 
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Figure 5-4: M1 mixed leukocyte reaction T cell proliferation. Interferon-gamma 
stimulated MoMΦs (M1) were cultured with CFSE-labeled T lymphocytes, either 
autologous or allogenic and stained for specific T lymphocyte subsets to monitor 
proliferation after 4 days in culture. Statistical analysis performed using Mann-Whitney 
test comparing the autologous versus allogenic T cell proliferations within each T cell 
subset. Data points are from non-related animals performed as single replicates (N=3). 
 
Figure 5-5: CD4α T cell proliferation. Comparison of the level of CD4α T cell 
proliferation amongst the M0, M2, and M1 MoMΦ mixed leukocyte reactions. Statistical 
analysis performed using Kruskal-Wallis test of multiple comparisons. P<0.05=*; 
P<0.005=**; P<0.0005=***. Data points are from non-related animals performed as 
single replicates (N=3), with M1 and M2 MoMΦs from the same animals. 
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Figure 5-6: CD8β T cell proliferation. Comparison of the level of CD8β T cell 
proliferation amongst the M0, M2, and M1 MoMΦ mixed leukocyte reactions. Statistical 
analysis performed using Kruskal-Wallis test of multiple comparisons. P<0.05=*; 
P<0.005=**; P<0.0005=***. Data points are from non-related animals performed as 
single replicates (N=3), with M1 and M2 MoMΦs from the same animals. 
 
5.5 Discussion 
 
Macrophages have an indispensable role during tissue development, in the regulation of 
homeostasis, and in providing a first line of defense against invading pathogens (Varol et 
al., 2015). Multiple organs have tissue resident macrophages that are seeded during 
gestation. The origin of tissue resident macrophages has been traced to progenitor cells 
arising mainly from the fetal liver or yolk sac (Perdiguero and Geissmann, 2016). 
Interestingly, resident macrophage populations, such as Kupfer cells in the liver, are self-
replenishing throughout adulthood and do not arise from blood monocytes (Krenkel and 
Tacke, 2017). The complexity associated with different stimuli and the diverse 
microenvironments that macrophages may encounter within specific tissues makes it 
difficult to characterize the numerous subsets that exist, particularly when considering the 
phenotypic state of the macrophage (Hoeffel and Ginhoux, 2015). Furthermore, 
mimicking diverse tissue microenvironments in vitro is nearly impossible. During an 
infection, blood monocytes are recruited to sites of inflammation where they differentiate 
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into MoDCs or MoMΦs (Epelman et al., 2014; Lutz et al., 2017). Thus, deriving 
macrophages from blood monocytes in vitro provides insight as to how MoMΦs may be 
functioning in vivo. In addition, discrepancies exist when comparing in vitro mouse 
studies of macrophages to humans, making pig monocyte/macrophages potentially more 
comparable in studying human APC population dynamics (Murray et al., 2014). Thus, for 
the purpose of simplicity, in this study we have chosen to analyze macrophages derived 
from blood monocytes in two classical states, those being the M1 or M2 phenotype.  
As mentioned in the introduction, M2 macrophages exhibit a steady-state phenotype, 
being most prominent in the absence of a pathogen or inflammatory state. They are non-
inflammatory, have high phagocytic capacity, and play a role in tissue regeneration and 
tissue maintenance. Macrophages display plasticity, switching from an M2 to M1 
phenotype, and vice versa (Mantovani et al., 2013). Immune stimulation, such as IFN-γ 
or lipopolysaccharide, can drive an M2 macrophage into an M1 phenotype. The M1 
macrophages are inflammatory, more sensitive to pattern recognition receptor 
stimulation, and have lower pH in their endosomes making M1 macrophages ideal to kill 
invading pathogens. Once an infection has been resolved, M1 macrophages are fully 
capable of returning to their original resting state (M2) via cytokine stimulation (IL-4, IL-
13, or IL-10) (Martinez and Gordon, 2014). We utilized non-stimulated MoMΦs as a 
comparison to the M1 and M2 phenotypes to determine whether non-stimulated MoMΦs 
were more similar to resting M2 MΦs or to the inflammatory M1 MΦs. Given the 
phenotypic differences between M1 and M2 macrophages, we hypothesized that IFN-γ 
stimulated (M1) MoMΦs would stimulate increased T lymphocyte proliferation when 
compared non-stimulated (M0) or IL-4 stimulated (M2) MoMΦs. Using an MLR, our 
results confirmed that M1 MoMΦs were more proficient in promoting T lymphocyte 
proliferation in both CD4α and CD8β T cell populations. The macrophages and T cells 
being from pigs becomes relevant when considering the increased utilization of pigs to 
study human pathologies and human infectious diseases, as responses in pigs are more 
similar to humans than what has been seen in mice (Fairbairn et al., 2011; Meurens et al., 
2012). We did not see any difference in the proliferation of gamma delta (γδ) T cells in 
the MLRs, but γδ T cells proliferated in response to ConA stimulation (Supplementary 
Figure 5-9). The role of γδ T cells during graft rejection has not been entirely elucidated. 
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It has been hypothesized that γδ T cells play a secondary role during tissue rejection, 
being dependent on the alloreactivity of CD4α+ Th cells (Tsuji et al., 1996). Furthermore, 
it has been hypothesized that γδ T cells have immunosuppressive qualities during host vs 
graft tissue rejection, benefiting the host (Nagai et al., 1998). Another possible 
explanation for the lack of γδ T cell proliferation may be attributable to a secreted 
inhibitory molecule by monocytes, or potentially through the proliferative suppression 
exhibited by IL-2 on γδ T cells (Okragly et al., 1995). We feel that because alloreactivity 
seems to be dependent on αβ TCR recognition, and γδ T cells do not interact directly with 
MHCI or MHCII, it could explain why we did not observe proliferation in the γδ T cell 
population. 
In conclusion, we have demonstrated that M1 macrophages possess a greater capacity to 
promote T lymphocyte proliferation than M0 or M2 macrophages derived from blood 
monocytes. Furthermore, we have demonstrated that γδ T cells do not directly participate 
in the mixed leukocyte reaction. Lastly, we conclude that the stimulation of APCs 
towards specific phenotypes has clear implications on both the magnitude of T cell 
proliferation and type of T cell effectors induced to proliferate. 
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5.6 Supplementary Figures 
 
Figure 5-7: FlowJo schematic demonstrating the purity of the enriched T cell population. 
CD21+ B cells and CD172a+ APCs were depleted from the PBMC population to obtain 
an enriched CD3+ T cell population for the APC-T cell co-culture assays.  
 
 
 
 
Figure 5-8: Schematic representing the gating strategy for analysis of T cell proliferation 
in the MLR co-culture assay. 
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Figure 5-9: Schematic demonstrating T cell proliferation in response to ConA 
stimulation in the MLR. All three of the T cell subsets (CD4α+, CTL, gamma delta T 
cells) proliferated in response to the ConA positive control. 
 
 
 
Contributions: JD and JVK isolated PBMCs and monocytes. JD performed macrophage 
and MoDC cell differentiation cultures. JD performed the flow cytometry and analysis. 
JD established the MLR. JD did statistical analysis. JD and VG designed experiments. 
 
 
 
 
5.7 Conclusion 
Interferon-gamma stimulated (M1) monocyte-derived macrophages (MoMΦs) possess a 
higher capacity to stimulate lymphocyte proliferation than non-stimulated (M0) or IL-4 
stimulated (M2) MoMΦs, as evidence in the increased proliferation of CTLs and CD4α+ 
T cells. Gamma-delta T cells (γδ) do not proliferate in the MLR, likely being attributable 
to a lack of γδ T cell receptor interaction with MHCI or MHCII molecules. To investigate 
the antigen-specific T cell response to PRRSV, in Chapter 6 we modified the MLR and 
co-cultured MoDCs and MoMΦs over the course of a PRRSV infection with T cells from 
PRRSV infected animals.  
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Chapter 6  T-CELL IMMUNE RESPONSE TO PRRSV 
INFECTION 
 
6.1 Abstract 
The T cell adaptive immune response to the porcine reproductive and respiratory 
syndrome virus (PRRSV) is delayed. Previous studies indicate that IFN-γ secreting cells 
in peripheral blood, detected 2 weeks post infection, and neutralizing antibodies, detected 
4 weeks post infection, are correlates of protection. Research surrounding immune 
regulation by the PRRSV has generally focused on identifying viral mechanisms of 
innate immune regulation. Little is known regarding the T cell immune response to 
PRRSV and the delayed induction of T cell immunity. Considering the tropism of 
PRRSV is restricted to antigen-presenting cells (APCs) of the porcine immune, it’s 
plausible that PRRSV could be regulating antigen processing/presentation in APCs. Thus, 
we chose to investigate the T cell immune response to PRRSV in animals over the course 
of an infection, utilizing a commercial, swine-influenza A virus vaccine (FluSure XP) as 
a comparison. Here, we show that the infection of monocyte-derived dendritic cells 
(MoDCs) and monocyte-derived macrophages (MoMΦ) by PRRSV does not abrogate 
their immunostimulatory capacity to induce T cell proliferation, the T cell immune 
response to PRRSV is geared towards Th1 type immunity, PRRSV infection may 
increase the T cell immune response to the FluSure XP vaccine, and lastly we highlight 
potential differences in the T cell immunostimulatory capacity of MoMΦs and MoDCs, 
specifically showing that MoDCs may be more potent inducers of central memory T 
helper cell proliferation. 
 
6.2  Introduction: 
 
The porcine reproductive and respiratory syndrome virus (PRRSV) is a positive sense, 
single-stranded, enveloped RNA virus that causes disease in swine worldwide. The virus 
is classed under the order Nidovirales from the Arteriviridae family and was first 
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identified in the early 1990s (Shi et al., 2010). Today, the PRRSV is the most significant 
pathogen in the swine industry causing losses upwards of $650 million dollars in the 
United States alone (Holtkamp, 2012). Outcomes of disease include respiratory difficulty, 
spontaneous abortions and fetus mummification in sows, weight loss, and death under 
certain circumstances (Reeth, 1997; Tong et al., 2007). The demand for an efficacious 
vaccine and the development of strategies for disease control are top priorities for 
producers and consumers alike. 
PRRSV infects both MΦs and DCs, with its viral tropism being restricted to cells that 
express the hemoglobin/haptoglobin scavenger molecule CD163 (Calvert et al., 2007). 
The PRRSV spreads rapidly after an infection, being detectable in peripheral lymphoid 
organs within the first few days of infection. Hallmarks of a PRRSV infection include a 
general immune suppression of innate cytokine secretion (Type 1 IFNs and pro-
inflammatory cytokines), although this appears to be strain specific as some of the highly 
pathogenic Chinese strains seem to induce a cytokine storm, resulting in increased rates 
of mortality in herds (Yoo et al., 2010) (Guo et al., 2013). The adaptive immune response 
to PRRSV can be characterized by an early appearance of non-neutralizing antibodies 
(within 9 days) and a delayed induction of IFN-γ secreting cells (2 weeks post infection) 
in peripheral blood mononuclear cells (PBMCs). Shortly after the appearance of IFN-γ 
secreting cells in PBMCs, neutralizing antibodies become prominent, correlating with the 
resolution of the infection, although PRRSV persists in the tonsils of pigs for up to year 
(Loving et al., 2015). There has not yet been an explanation for the delayed appearance of 
neutralizing antibodies, and even less is known regarding the delayed induction of T cell 
immunity. A subject of continuing debate is whether the delayed induction of immunity 
is attributable to PRRSV specific regulatory T cells (Tregs) (Nedumpun et al., 2018; 
Rodriguez-Gomez et al., 2015; Silva-Campa et al., 2009; Wongyanin et al., 2012; 
Wongyanin et al., 2010). Another potential explanation for the delayed induction of 
immunity could be attributable to the atrophy and apoptosis of lymphocytes in the thymus 
and peripheral lymphoid organs of infected animals (Gomez-Laguna et al., 2013a; He et 
al., 2012). Considering PRRSV infects APCs, we believe this could also have a 
detrimental impact on the progression to T cell immunity, potentially having an effect on 
the skewed humoral immune response. 
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Our previous investigation indicated that the susceptibility of MoDCs and MoMΦs are 
comparable. Furthermore, results indicated that the cell surface expression of MHCI and 
MHCII on non-stimulated MoMΦs is downregulated in response to a PRRSV infection, 
while a potential slight upregulation on the surface of MoDCs was observed. Here, we 
chose to compare the immunostimulatory capacity of MoDCs and MoMΦs to induce T 
cell proliferation in response to a PRRSV infection in animals. A previous study 
investigating the pathogenesis of swIAV in the pig lung found that there was a marked 
increase in the migration of MoDCs into the parenchyma surrounding the lungs after pigs 
were infected with swIAV. Additionally, the authors demonstrated that MoDCs 
possessed a high capacity to induce the proliferation of CD4α+ and CD4α- CD8α+ T cells 
(Maisonnasse et al., 2016). Thus we chose to immunize animals with a swIAV, and 
induce a T cell recall response with live-swIAV (H1N1) as a positive control in our 
study. In total 24 animals were separated into three groups of 8 and were either infected 
with PRRSV, immunized with FluSure XP and infected with PRRSV, or housed 
separately and immunized with the FluSure XP vaccine as a control. Over the course of a 
month we utilized an APC-T cell co-culture assay to monitor PRRSV-antigen specific 
and swIAV-antigen specific T cell recall responses. We accomplished this by isolating 
monocytes from animals using a Multi-MACS sorter and, after differentiating monocytes 
into MoMΦ or MoDCs, on the appropriate days T cells were isolated from the same 
animals and the differentiated APCs were co-cultured with T cells from autologous 
animals. This allowed us to monitor the progression to T cell immunity over the course of 
an infection to PRRSV while comparing the immune response to animals that were either 
immunized with FluSure XP or animals that received the FluSure XP vaccine in addition 
to being infected with PRRSV. Lastly, using 6-colour flow cyomtery we compared the 
immunostimulatory capacity of MoMΦs and MoDCs to induce specific T cell subsets in 
response to either PRRSV or swIAV. 
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6.3 Materials and methods 
 
Animals: 
Twenty-four, 3-week old Dutch Landrace pigs were purchased from the high health herd 
at the Last Mountain Lake (Saskatchewan). Animals were confirmed to be free of Swine 
Influenza and PRRSV via serum samples (IDEXX Influenza A ab; IDEXX PRRS X3 ab 
Test). All experiments were conducted in accordance with the ethical guidelines of the 
University of Saskatchewan and Canadian Council of Animal Care.  
 
Trial Design: 
Animals were separated into three groups and acclimatized for a week. Immunizations 
were delivered intramuscularly (2.0 ml). Group A received the FluSure XP vaccine 
(Zoetis) and was housed separately from Group B and Group C. Group B received the 
FluSure vaccine, and Group C received a PBS mock immunization. Animals received a 
boost immunization two weeks later. The FluSure XP vaccine was prepared according to 
the manufacturer’s instructions and adjuvanted with Emulsigen D (20:80 ratio of ED to 
total volume). On the same day as the boost (animals at 6 weeks of age), Groups B and C 
were infected with PRRSV VR-2385 intranasally (1 ml in each nostril, 5.0x10^5 
TCID50/mL) and Group A received a PBS mock infection intranasally. Three weeks after the 
PRRSV infection, Groups A and B received an additional FluSure XP booster 
immunization. Antigen presenting cells and T cells were co-cultured to investigate the 
stimulatory capacity of PRRSV infected MoMΦs and MoDCs, to promote T lymphocyte 
proliferation. As a comparison, PBMCs from each animal were treated in the same 
manner as the APC-T cell co-cultures. Monocytes were isolated from animals and 
cultured into MoMΦs or MoDCs. The enriched T cell population was isolated either 3 
days later (MoMΦ co-culture) or 6 days later (MoDC co-culture).  
 
Serum ELISAs: 
Serum was collected from animals to confirm seroconversion in response to the influenza 
immunization and the PRRSV infection. The IDEXX Porcine Reproductive and 
Respiratory Syndrome Virus Antibody X3 Test Kit (IDEXX Laboratories) was utilized to 
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assess serconversion to PRRSV infection and the IDEXX Swine Influenza Antibody Test 
Kit (IDEXX Laboratories) was utilized to assess seroconversion to swIAV. Briefly, 
serum from animals of each group were collected and diluted according to 
manufacturer’s protocol. Serum ELISAs were performed in triplicate according to the 
manufacturer’s instructions. The absorption spectrums were measured at A650, and after 
fulfilling the validity criteria, the average of the triplicate samples were interpreted as 
positive or negative according to the manufacturer’s instructions. To further interpret the 
data, test samples were compared to the negative control, as the baseline of 1.0, in order 
to obtain a “titre” index. 
 
Cells and viruses: 
Peripheral blood mononuclear cells (PBMCs) were isolated from 50 ml of fresh pig blood 
using SepmateTM tubes and LymphoprepTM according to the manufacturer’s instructions 
(StemCell Technologies). Prior to monocyte isolation, 1.5x10^7 PBMCs were removed 
for the PBMC proliferation assay and for the IFN-γ ELISpots. PBMCs intended for the 
cell proliferation assay were labeled with Cell Trace Violet (Cell Trace Violet, Thermo 
Fisher) according to the manufacturer’s protocol prior to infection with PRRSV or 
swIAV. The remaining PBMCs were labeled with anti-human CD14 beads (Miltenyi 
Biotec) and selected for on LS columns using a Multi-MACS (Miltenyi Biotec, Auburn, 
CA). To obtain MoMΦs, monocytes were plated at 1.0x10^6 cells/mL in RPMI complete 
supplemented with rpGM-CSF (20 ng/ml - Invitrogen) for 3 days at 37 °C with 5% 
carbon dioxide. To obtain MoDCs, monocytes were plated at 1.0x10^6 cells/mL in RPMI 
complete with recombinant porcine (rp) IL-4 (100 ng/mL – GibcoTM ThermoFisher) and 
rpGM-CSF (20 ng/mL – R&D 711-PG) for 6 days at 37 °C with 5% carbon dioxide, and 
media was changed every 3rd day as shown previously (Facci et al., 2010). Enriched 
populations of CD3+ T cells were isolated from PBMCs using a Multi-MACS sorter. 
Briefly, 3.0x10^7 PBMCs were isolated as previously from 20 ml of fresh blood. PBMCs 
incubated with 300 µg of anti-CD172a antibody (BL1H7, BioRad) and 300 µg of anti-
CD21 antibody (BB6-11C9.6, Southern Biotech) in 300 µl of PBS+2% FBS for 15 
minutes at 4o C with shaking. Cells were washed twice, and anti-IgG1 MACS beads 
(Miltenyi Biotec) were added to the CD172a/CD21 labeled PBMCs according to the 
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manufacturer’s protocol. Cells were washed and resuspended in 1.0 ml of MACS buffer 
(Miltenyi Biotec), before sorting on a Multi-MACS block to obtain a T-lymphocyte 
enriched population. The enriched T cell population was stained with Cell Trace Violet 
according to the manufacturer’s protocol (Cell Trace Violet, Thermo Fisher) before being 
plated at 2.0x10^5 cells/well on a 96 well U bottom plate. After the addition of APCs 
(1:10 ratio to T cells), the APC-T cell co-culture was incubated at 37o C, 5% CO2 for 4 
days before assessing proliferation with FCM. 
PRRSV strain VR2385 (ATCC, Manassas, VA, USA) was used in the study. Virus was 
grown up on MARC-145 cells and titers were calculated as the TCID50/mL (Reed and 
Muench, 1938). Swine influenza, strain A/SW/SK 02 H1N1, was propagated on MDCK 
cells and titres were calculated as plaque forming units/mL (Dulbecco et al 1953).  
 
PBMC, APC infection, and T cell proliferation assay: 
Cell Trace Violet labeled PBMCs were infected with PRRSV strain VR-2385 at a 1.0 
MOI for 3 hours at 37°, 5% CO2. Similarly, cells were treated with swIAV (H1N1) at an 
MOI of 10.0. PBMCs were left in culture to proliferate for 4 days and Concavalin A (5 
µg/mL) was administered to cell cultures as a positive control. MoMΦs, and MoDCs 
were infected with PRRSV strain VR-2385 at a 1.0 MOI for 3 hours at 37°, 5% CO2. 
Similarly, cells were treated with swIAV (H1N1) at an MOI of 10.0. After 3 hours, APCs 
were washed and pelleted at 350 g, resuspended in fresh media, and plated with their 
respective autologous population of enriched T cells at a ratio of 1-APC: 10-T cells. Prior 
to culture, T cells were labeled with Cell Trace Violet according to the manufacturer’s 
protocol as indicated previously. Cells were left to proliferate in culture for 4 days 
(PBMCs), (MoDCs and MoMΦs with T cells). Cell proliferation was measured as the 
percent of Cell Trace Violet labeled cells that proliferated in response to each treatment. 
Comparisons of percent proliferation were performed within groups, according to each 
treatment relative to the control (media alone treated cells). Supernatants were removed 
from cell cultures on the 4th day for cytokine ELISAs and the cells were pooled for flow 
cytometry staining. 
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Flow cytometry: 
After 4 days in culture, the PBMC cell cultures and APC-T cell co-cultures were pooled 
from 8 wells into one well and stained to assess cell surface marker expression by flow 
cytometry. Briefly, cells were stained with the LIVE/DEADTM Fixable Near-IR Dead 
Cell Stain Kit (Thermo Fisher) according to the manufacturer’s instructions. After 
live/dead staining, cells were incubated for 8 minutes at room temperature with primary 
antibodies, then washed twice (PBS + 2% FBS) before incubation with their respective 
secondary antibody. At least 100,000 events within the gated population (lymphocytes) 
were collected on a CyanADP (BD Biosciences, Mountain View, CA) and data was 
analyzed using FlowJo X software. To normalize the data, the percentage of cells within 
the proliferating cell subset was cross-multiplied with the total percentage of proliferating 
CD3+ cells. Thus, the frequencies of cell subsets presented in the results below are 
representative of the total amount of cells that proliferated in within the entire CD3+ T 
cell population. 
 
Table 6.1: Table indicating the primary and secondary antibodies, including their clone 
numbers and suppliers, utilized for the multicolour flow cytometry staining. 
Antibody Clone/Cat # Working dilution Fluorochrome Manufacturer 
Anti-pig CD27 (g1) B307 1/33 APC BD 
Anti-pig CD3  PPT3 1/10 FITC Abcam 
Anti-pig CD4a 74-12-04 1/20 PerCP-Cy5.5 BD 
Anti-pig CD8a 76-2-11 1/80 PE Southern Biotech 
Anti-g1 APC 1070-11s 1/400 Anti-g1 APC Southern Biotech 
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Figure 6-1: Schematic demonstrating the gating strategy applied for the analysis of 
CD4α+ CD8α+ T cells (red), CD4α+ CD8α- T cells (blue), and CD4α- CD8α+ T cells 
(orange) (6-1A) from a PBMC cell culture treated with PRRSV. The gating schematic 
shown was from PBMCs of pig 343 (Group B) that were stimulated with PRRSV. 
Briefly, a gate was established around singlets before drawing a gate surrounding 
lymphocytes. A gate was then drawn on live cells, before gating on CD3+ T cells and 
then gates were established for the T cell subsets (Figure 6-1A). After establishing 
appropriate gates for the subsets, we then drew a gate surrounding the proliferating cell 
population and the previously established gates for T cell subsets were used to assess 
proliferation of the specific T cell subsets (Fig 6-1B). Gating strategies for CD4α+ CD8α+ 
CD27+/CD27- T cells can be found in the supplemental figures. The percentage of cells 
within the proliferating cell subset is representative of the total percentage of proliferating 
CD3+ T cells, within the entire CD3+ T cell population. 
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Interferon-gamma ELISpots: 
Peripheral blood mononuclear cells (PBMCs) were isolated using Sepmate tubes and 
lymphoprep according to the manufacturer’s instructions. ELISpots were performed as 
demonstrated previously (Dar et al., 2012). Briefly, nitrocellulose microtiter plates 
(UNIFILTER® 350, Whatmann, Florham Park, NJ, USA) were coated with 0.5 µg/100 µl 
of anti-porcine IFN-γ monoclonal antibodies solution (Thermo Fisher Scientific, Inc., 
Nepean, ON, Canada). 5.0x10^5 PBMC were added to each well and cells were 
stimulated with PRRSV (VR-2385, MOI 1.0) or H1N1 influenza virus (MOI 1.0). After 
24 hr incubation at 37 °C, rabbit anti-porcine IFN-γ antibody solution (0.2 µg/100 µl in 
phosphate buffer saline with 0.05% tween® 20) was added and plates were incubated for 
4 hours at room temperature. Biotin-conjugated goat ant-rabbit IgG (Invitrogen-Zymed, 
Burlington, ON, Canada) was added (1/5000 dilution) for 2 hours at room temp before 
the addition of 1/5000 diluted streptavidin alkaline phosphatase solution for 1.5 hours at 
room temp. Lastly, spots were developed with NBT/BCIP (Sigma-Aldrich, St. Louis, 
MO, USA). Spots were counted with an AID ELISpot Reader Classic.  
 
Multiplex fluorescent microsphere immunoassay (FMIA): 
To measure cytokine secretion, supernatant samples were collected on the 4th day of the 
lymphocyte proliferation cell culture assays. A six-plex assay was developed as 
previously described (Laidnig 2014). Briefly, capture antibodies (Table 2) were coupled 
to magnetic beads (Biorad, Mississauga ON, Canada). All reactions took palce at room 
temperature. Beads (1200 beads/µl) were diluted 1:50 in PBSA + 1% New Zealand Pig 
Serum (Sigma P3484) + 0.05% Na Azide and 50 µl of diluted beads was added to each 
well on a Grenier Bio-One Fluotrac 200 96F black plate (VWR catalogue #82050-754). 
Beads were washed with PBST in BioPlex plate washer before adding samples and 
standards. Fifty microliters of standard and cell supernatants (diluted 1:2) were added to 
their respective wells and incubated in the dark for 1 hour, shaking at 800 rpm. The plates 
were washed 3x as previously before adding 50 µL of the appropriately diluted secondary 
antibodies coupled to biotin. Plates were incubated for 40 minutes with shaking before 
washing as previously. Fifty µL of prozyme Streptavidin RPE (Cedarlane cat # PJRS20), 
diluted to 5 µg/mL in PBS-NZ, was added to each well and incubated for 30 minutes with 
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shaking. Plates were washed as previously in PBST and 100 µl of TE buffer was added to 
each well and placed on a shaker for 5 minutes before reading. Cytokine samples were 
analyzed on a Bio-Plex® 200 system and subsequently analyzed with the Bio-Plex 
Manager software version 6.1 (Biorad, Mississauga, ON, Canada). 
 
Table 6.2: Table indicating the primary and secondary antibodies, including their 
concentrations and suppliers, utilized in the FMIA. 
Protein Supplier Concentration Biotin Supplier Concentration 
rPorc IFN- 
alpha 
GeneTex 
GTX11408 
200 pg/mL Porc IFN- 
alpha 
PBL 1/5000 
rPorc IFN- 
gamma 
Fisher 
PIMP700 
2000 pg/mL Porc IFN- 
gamma 
Fisher 
(Endogen) 
1/400 
rPorc IL-10 Invitrogen 
ASC0104 
5000 pg/mL Porc IL-10 Invitrogen 0.5 µg/ml 
rPorc IL-12 Kingfisher 
MA0413S 
5000 pg/mL Porc IL-12 R&D 0.5 µg/ml 
rPorc IL-13 Kingfisher 
PB0094S-100 
5000 pg/mL Porc IL-13 Kingfisher 0.5 µg/ml 
rPorc IL-
17A 
Kingfisher 
KP0498S-100 
500 pg/mL Porc IL-
17A 
Kingfisher 0.1 µg/ml 
 
 
Table 6.3: Table indicating the standards utilized in the FMIA along with the suppliers. 
Standard Supplier Standard Supplier 
rPorc IFN-alpha Genetech 
 
rPorc IL-12 R&D 912PL025  
rPorc IFN-gamma Ceiba Geigy 
 
rPorc IL-13 Kingfisher RP0007S-005  
rPorc IL-10 Invitrogen PSC0104  
 
rPorc IL-17A Kingfisher RP0128S-005  
 
Statistical Analysis: 
All data points on graphs are representative of genetically unrelated individual animals. 
All the data were statistically analysed using GRAPHPAD PRISM™ 7 software 
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(GraphPad Software, Inc., La Jolla, CA). Differences between groups were assessed 
using the Mann-Whitney U test for non-paired, non-Gaussian data unless otherwise 
indicated. When P≤0.05, differences were considered significant 
6.4 Results: 
 
Animal trial design: 
The animals in all three of the groups did not exhibit any clinical symptoms to the 
PRRSV infection. There was no remarkable difference in recorded body temperatures or 
behavior. Additionally, there was no adverse reaction to the FluSure-XP immunization. 
Animals from Group A were housed separately from animals of Groups B and C, which 
were housed together, to prevent passive exposure to PRRSV. The trial design is 
demonstrated in the table below: 
 
Table 6.4: Table indicating the groups and their immunization with the FluSure-XP 
vaccine of exposure to PRRSV strain VR-2385 
Group FluSure XP immunization VR-2385 PRRSV 
Group A Three doses PBS inoculation (1x) 
Group B Three doses 5.0x10^5 TCID50 per nostril (1x) 
Group C PBS inoculation (3x) 5.0x10^5 TCID50 per nostril (1x) 
Animals from Groups A and B received 2 ml immunizations according to the 
manufacturer’s instructions of the FluSure-XP vaccine (Zoetis). Animals from Groups B 
and C were infected with PRRSV VR-2385 via nasal inoculation with 5.0x10^5 TCID50 in 
1 ml per nostril for a total of 1.0x10^6 TCID50. 
 
Sero-conversion in response to swIAV immunization and PRRSV infection: 
Serum ELISAs were utilized to demonstrate that the animals underwent seroconversion 
in response to the swIAV immunization and the PRRSV infection. Serum was collected 
on days 9, 18, and 32 post PRRSV challenge. Figure 6-2a demonstrates that antibodies to 
PRRSV were present 9 days post challenge and continued to increase over the course of 
the trial. The antibody response to the influenza immunizations followed a similar trend, 
increasing as the trial progressed. Of note, on day 32 post-PRRSV infection the swIAV 
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titres increased in response to the booster immunization (Figure 6-2b). The increase could 
be attributable to animals receiving a double dosage of the vaccine (2 ml in each side of 
the neck) with the intention of increasing the T cell response in the lymphocyte 
proliferation cell culture assays.  
 
 
 
Figure 6-2: Serum ELISAs measured utilizing the commercial IDEXX ELISA kits for 
PRRSV (Fig 2a) or swIAV (Fig 2b) to demonstrate seroconversion and compare the 
humoral immune response amongst the treatments. The IDEXX ELISA kits for both 
PRRSV and swIAV give a read out of seroconversion as positive or negative. Serum 
indice calculations are described previously. Statistical significance was determined in 
the PRRSV ELISAs by comparing Groups B and C to Group A. And similarly in the 
swIAV ELISAs, Groups A and B were compared to Group C. Group A – swIAV 
immunized & non-PRRSV infected. Group B – swIAV immunized & PRRSV infected. 
Group C – non-swIAV immunized & PRRSV infected. ELISAs were performed in 
duplicate and the average was used to calculate the absorbance value. Values were 
reported with statistical significance if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = ***.  
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Interferon-gamma secreting cells in PBMCs: 
The IFN-γ secreting cells were measured in PBMCs on the days indicated below (Figure 
6-3).  Briefly, 5.0x10^5 PBMCs were plated per well and swIAV (MOI 10) or PRRSV 
(MOI 1.0) was subsequently added. After 20 hours in culture, the ELISPOTs were 
developed to assay for IFN-γ secretion. As shown in the graphs below, IFN-γ secretion to 
PRRSV became apparent in Group B and Group C 14 days post challenge and increased 
as the trial progressed. This indicates a successful conversion to T cell immunity. We 
detected IFN-γ secreting cells in response to the swIAV treatment on Day 0 PRRSV 
challenge in Groups A and B, and IFN-γ secreting cells to swIAV remained detectable 
throughout the trial, although it was much less prominent than the IFN-γ response to 
PRRSV (Figure 6-3). 
 
 
Figure 6-3: Peripheral blood mononuclear cell (PBMC) interferon-gamma ELISPOTs 
from the different treatment groups over the course of the trial. Briefly, 5.0x10^5 PBMCs 
were isolated on the respective dates listed. Cells were treated with PRRSV (MOI 1.0) or 
swIAV (MOI 10.0) and the IFN-γ ELISpot plates were developed 20 hours post 
treatment. ELISpots were performed in triplicate, from which the average number of 
spots was calculated. Statistical significance was determined by comparing the swIAV or 
PRRSV treated samples to the negative control (non-stimulated cells). Values were 
reported with statistical significance if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = ***.  
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Total lymphocyte proliferation: 
We were interested in comparing the immunostimulatory capacity of MoMΦs and 
MoDCs to determine whether a difference existed in their ability to induce T cell 
proliferation. In order to perform this comparison, monocytes were isolated from the 
PBMCs of the animals and subsequently derived into MoMΦs or MoDCs (as described in 
the materials and methods section), after which they were co-cultured with an enriched T 
cell population from autologous animals. The co-culture assays were compared to the T 
cell proliferation in PBMCs.  
First, we measured the overall level of lymphocyte proliferation in the PBMC and the 
antigen-presenting cell–T cell (APC-T cell) co-culture assays. On day 0 of the PRRSV 
challenge, there was no proliferation in PBMCs in response to any treatments. Therefore, 
we increased the MOI of swIAV to 10.0. Similarly, we did not detect proliferation in the 
APC-T cell co-culture assays during the first week of PRRSV infection. During the 
second week of infection, lymphocyte proliferation was prominent in response to both the 
PRRSV and swIAV treatments. The highest level of lymphocyte proliferation to PRRSV 
was seen in the PBMC cultures (Group C – 27.44%) while the highest level of 
proliferation to the swIAV treatment was observed in the MoMΦ-T cell co-culture 
(Group B – 16.83%) (Figure 6-5a, and Supplementary Table 6.6).  These results were 
reflected at a later time point with the highest level of lymphocyte proliferation to 
PRRSV in the PBMCs of Group C (44.30%) and the highest level of lymphocyte 
proliferation to swIAV in Group B of the MoMΦ-T cell co-culture (16.60%) (Figure 6-
5b, and Supplementary Table 6.6). Lastly, lymphocyte proliferation was detected in the 
media alone treatments in the MoMΦ and MoDC-T cell co-culture assays during the 
second week of infection (Figure 6-5a) of Groups B and C, but not Group A. During the 
third week of infection, we did not detect lymphocyte proliferation in the media alone 
treatments within Groups A, B, or C (Figure 6-5b). Data showing the proliferation of 
lymphocytes in response to swIAV or PRRSV, within respective Groups and different 
cell culture proliferation assays, can be found in Supplementary Table 6.6 . 
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Figure 6-4: The level of total lymphocyte proliferation in PBMC cell culture assays in 
response to PRRSV (MOI 1.0), swIAV (MOI 1.0), or co-infected treatments on day 0 from 
their respective animal groups. PBMCs were stained with Cell Trace Violet prior to 
treatment. After treatment, PBMCs were left in culture for 4 days before measuring cell 
proliferation using flow cytometry. Proliferation of lymphocytes was based on the entire 
population of Cell Trace Violet labeled cells, acquired as single replicates (n=6-8). 
(gating previously on singlets and dead cell exclusion).  
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Figure 6-5: The percentages of total lymphocyte proliferation from PBMC, MoMΦ-T cell 
co-cultures, and MoDC-T cell co-cultures in response to PRRSV (MOI 1.0), swIAV (MOI 
10.0), or co-infected treatments from their respective groups on the indicated days post 
PRRSV challenge. After treatment, lymphocytes were left in culture for 4 days before 
measuring proliferation using flow cytometry. Proliferation of lymphocytes was based on 
the entire population of Cell Trace Violet labeled cells (gating previously on singlets and 
dead cell exclusion), acquired as single replicates (n=6-8). Statistical significance was 
determined by comparing the co-infected, swIAV, or PRRSV treated samples to the 
negative control (non-stimulated cells). Values were reported with statistical significance 
if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = ***. *MoMΦs were added at a 1:5 ratio to 
T cells on day 17. 
 
CD3+ T cell proliferation: 
The proliferation of CD3+ T cells was measured in response to the treatments. Figure 6-
6a demonstrates that we detected T cell proliferation in response to the swIAV 
immunization in Groups A (PBMCs – 5.51%; MoMΦ – 10.72 %; MoDC – 3.33%) and 
Groups B (PBMCs – 4.83%; MoMΦs – 10.88%; MoDCs – 10.69%) during the second 
week post PRRSV infection. The percent of CD3+ T cell proliferation data reflects those 
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results observed in the lymphocyte proliferation assay with the highest level of 
proliferation to PRRSV being in the PBMC culture in Group C  (20.16%, 14 DPI and 
27.23%, 24 DPI) and to swIAV in the MoMΦ-T cell co-cultures in Group B (10.88%, 17 
DPI and 13.76%, 27 DPI). The mean proliferation percent between the MoDC and 
MoMΦ-T cell co-cultures were comparable (Supplementary Table 6.7). 
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Figure 6-6: The percentages of CD3+ T cell proliferation from PBMC, MoMΦ-T cell co-
cultures, and MoDC-T cell co-cultures in response to PRRSV (MOI 1.0), swIAV (MOI 
10.0), or co-infected treatments from their respective groups on the indicated days post 
PRRSV challenge. After treatment, lymphocytes were left in culture for 4 days before 
measuring proliferation using flow cytometry, acquired as single replicates (n=6-8). 
Statistical significance was determined by comparing the co-infected, swIAV, or PRRSV 
treated samples to the negative control (non-stimulated cells) within each group. Values 
were reported with statistical significance if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = 
***. *MoMΦs were added at a 1:5 ratio to T cells on day 17. 
 
Naïve T cell proliferation: 
The indicated percentage of proliferation in the T cell subsets was determined by cross-
multiplying the level of proliferation of the entire CD3+ T cell population with the 
percentage of proliferation from the specific subset. Thus, the percentages indicated in 
the following figures are an indication of the percent of T cell subset proliferation within 
the entire CD3+ T cell population. We were interested in comparing the 
immunostimulatory capacity of MoMΦs and MoDCs to induce the proliferation of 
different T cell populations. Here we show the proliferation of naïve T cells (defined as 
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CD4α+ CD8α-) in response to different treatments (Figure 6-7). There was no comparable 
difference in the level of proliferation between the APC-T cell co-culture assays. A slight 
proliferation of naïve T cells was observed in the PBMC cultures over the course of the 
trial (Figure 6-7a and 6-7b; Supplementary Table 6.8). It’s plausible that the proliferating 
naïve T cells are CD8α low/dim T cells trending towards becoming activated, as it would 
be unexpected to see antigen specific recall proliferation in a naïve T cell.  
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Figure 6-7: The percentages of total CD4α+ CD8α- T cell (naïve) proliferation from 
PBMC, MoMΦ-T cell co-cultures, and MoDC-T cell co-cultures in response to PRRSV 
(MOI 1.0), swIAV (MOI 10.0), or co-infected treatments from their respective groups on 
the indicated days post PRRSV challenge. After treatment, cell cultures were left to 
proliferate for 4 days before measuring proliferation using flow cytometry, acquired as 
single replicates (n=6-8). Statistical significance was determined by comparing the co-
infected, swIAV, or PRRSV treated samples to the negative control (non-stimulated cells) 
within each group. Values were reported with statistical significance if P < 0.05 = *; P < 
0.005 = **; P < 0.0005 = ***. *MoMΦs were added at a 1:5 ratio to T cells on day 17. 
 
Activated T helper cell proliferation: 
To measure the levels of activated, antigen specific, T helper cell (Th cell) proliferation, 
cells were gated on CD4α+ CD8α+ expression (Figure 6-1). There was in increase in Th 
cell proliferation as the trial progressed in all of the cell culture assays (Figure 6-8a vs 6-
8b). At 24 days post PRRSV challenge, the highest mean proliferation of actiavted Th 
cells in response to PRRSV treatment was detected in the PBMC cultures in Group C 
(6.720%). The mean proliferation of activated Th cells in the APC-T cell co-cultures to 
PRRSV treatment was higher in MoDCs (Group C – 4.947%) than in MoMΦs (3.116%) 
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as indicated in Supplementary Table 6.9. Lastly, the mean percent of activated Th cell 
proliferation in response to swIAV treatment was higher in Groups B than in Groups A in 
the PBMC cell cultures (Group A – 1.746%; Group B – 1.948%) and in the APC-T cell 
co-cultures (MoMΦs: Group A-1.14%; Group B - 2.36%. MoDCs: Group A – 2.27%; 
Group B – 3.60%,) as indicated in Supplementary Table 6.9. The mean proliferation of 
activated Th cells was highest in the MoDC-T cell co-culture assay. 
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Figure 6-8: The percentages of total CD4α+ CD8α+ T cell (activated) proliferation from 
PBMC, MoMΦ-T cell co-cultures, and MoDC-T cell co-cultures in response to PRRSV 
(MOI 1.0), swIAV (MOI 10.0), or co-infected treatments from their respective groups on 
the indicated days post PRRSV challenge. After treatment, lymphocytes were left in 
culture for 4 days before measuring proliferation using flow cytometry, acquired as single 
replicates (n=6-8). Statistical significance was determined by comparing the co-infected, 
swIAV, or PRRSV treated samples to the negative control (non-stimulated cells) within 
each group. Values were reported with statistical significance if P < 0.05 = *; P < 0.005 = 
**; P < 0.0005 = ***. *MoMΦs were added at a 1:5 ratio to T cells on day 17. 
 
Cytotoxic lymphocyte proliferation: 
To measure the proliferation of cyototoxic lymphocytes (CTLs), cells were gated as 
CD3+ CD4α- CD8α+ (Figure 6-1). Proliferation of CTLs in response to PRRSV was 
evident in the media alone treatment in Groups B and C, from the APC-T cell co-culture 
assays, during the second week post PRRSV challenge (Figure 6-9a). At the later time 
point during the trial, CTL proliferation was not detected in the media alone treatments of 
the APC-T cell co-culture assays (Figure 6-9b). The highest level of CTL proliferation 
was observed in response to PRRSV treatment, 24 days post-PRRSV infection, in the 
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PBMC culture in Group C (11.59%). The mean percent of CTL proliferation to PRRSV 
treatment in the APC-T cell co-cultures was highest in Group C as well. The level of CTL 
proliferation was higher in the MoMΦ-T cell co-culture (6.44%) than in the MoDC-T cell 
co-culture (4.89%) as indicated in Supplementary Table 6.10. The mean proliferation of 
CTLs in response to swIAV treatment was comparable amongst the PBMC and APC-T 
cell co-culture assays. The highest level of CTL proliferation in response to swIAV 
treatment during the later time point of the trial was observed in the MoMΦ-T cell co-
culture, in Group B (5.72%), followed by the PBMCs in Group A (4.46%), and lastly the 
MoDC-T cell co-culture in Group A (3.391%). The overall highest level of CTL 
proliferation amongst the cultures was observed in the MoMΦs 17 days post infection 
(6.82% in response to PRRSV treatment in Group C) as indicated in Supplementary 
Table 6.10.  
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Figure 6-9: The percentages of total CD3+ CD4α- CD8α+ T cell (CTL) proliferation from 
PBMC, MoMΦ-T cell co-cultures, and MoDC-T cell co-cultures in response to PRRSV 
(MOI 1.0), swIAV (MOI 10.0), or co-infected treatments from their respective Groups, on 
the indicated days post-PRRSV infection. After treatment, lymphocytes were left to 
proliferate in cell cultures for 4 days before measuring proliferation using flow 
cytometry, performed as single replicates (n=6-8). Statistical significance was determined 
by comparing the co-infected, swIAV, or PRRSV treated samples to the negative control 
(non-stimulated cells) within each group. Values were reported with statistical 
significance if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = ***. *MoMΦs were added at a 
1:5 ratio to T cells on day 17. 
 
 
Central memory T helper (Th) cell proliferation: 
Central memory Th cells were defined as being CD3+ CD4α+ CD8α+ and CD27+. Central 
memory Th cells were detectable as early as 14 days post infection in the PBMC and 
APC-T cell co-culture assays in response to the PRRSV treatment (Figure 11a). The 
highest level of central memory Th cell proliferation over the course of the animal trial, 
in response to PRRSV treatment, was detected in Groups C. During the earlier time point 
of the trial, the highest levels of central memory Th cell proliferation were observed in 
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the MoMΦ-T cell co-cultures (2.26%), then the MoDC-T cell co-cultures (1.30%), 
followed by the PBMC cultures (0.79%) as indicated in Supplementary Table 6.12.  
During the later time point, the highest level of central memory Th cell proliferation to 
PRRSV was recorded in the PBMC cultures (3.60%) compared to the MoDC-T cell co-
culture (2.96%) or to the MoMΦ T-cell co-culture (1.60%) as shown in Supplementary 
Table 6.12. In response to the swIAV treatment, the highest mean proliferation of central 
memory Th cells was observed in the MoDC-T cell co-cultures, at both the early and later 
time points during the animal trial, although the difference was more pronounced in the 
later time point (Figure 6-11). The mean percent proliferation of Group B (MoDCs – 
1.06%; MoMΦs – 0.738%) in response to swIAV in the APC-T cell co-cultures was 
higher than that of Group A (MoDCs - 0.86%; MoMΦs - 0.36%. The percent 
proliferation of central memory Th cells in the PBMCs was similar to the MoMΦ–T cell 
co-culture (Group A – 0.425%; Group B – 0.502%) as indicated in Supplementary Table 
6.12.  
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Figure 6-10: The percentages of CD4α+ CD8α+ CD27+ Th cell (central memory T helper 
cell) proliferation from PBMC, MoMΦ-T cell co-cultures, and MoDC-T cell co-cultures 
in response to PRRSV (MOI 1.0), swIAV (MOI 10.0), or co-infected treatments from their 
respective groups at the indicated time points post-PRRSV infection. After treatment, 
lymphocytes were left to proliferate in culture for 4 days before measuring proliferation 
using flow cytometry, performed as single replicates (n=6-8). Statistical significance was 
determined by comparing the co-infected, swIAV, or PRRSV treated samples to the 
negative control (non-stimulated cells) within each group. Values were reported with 
statistical significance if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = ***. *MoMΦs were 
added at a 1:5 ratio to T cells on day 17. 
 
Effector T helper cell proliferation: 
Effector Th cells were defined as being CD3+ CD4α+ CD8α+ CD27-. The results are 
similar to the other T cell proliferation profiles measured previously. Effector Th cells 
were detected as early as 14 days post infection in the PBMC cultures and APC-T cell co-
cultures. During the earlier time point of the animal trial, the highest mean percentages of 
effector Th cell proliferation was recorded in the MoMΦ-T cell co-culture to both 
PRRSV and swIAV (Figure 6-12a and Supplementary Table 6.13). During the later time 
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point, the highest level of effector Th cell proliferation in response to PRRSV treatment 
was observed in Group C for the PBMC culture (3.12%), followed by the MoDC-T cell 
co-culture (1.99%), and the least in the MoMΦ-T cell co-culture (1.410%) as indicated in 
Supplementary Table 6.13 and show in Figure 12b. In response to the swIAV treatment, 
during the early time point of the trial, the mean percent proliferation reflects those 
recorded for the PRRSV treatment with the highest level of proliferation being recorded 
in the MoMΦ-T cell co-culture (1.16%), followed by the MoDC-T cell co-culture 
(0.67%), and finally the PBMC culture (0.06%). During the later time point of the trial, 
higher levels of effector Th cell proliferation to swIAV were seen in Groups B (MoDC – 
2.54%; MoMΦ – 1.67%; PBMC – 1.45%) than in Groups A (MoDC – 1.41%; MoMΦ – 
0.77%; PBMC – 1.32 %) as shown in Supplementary Table 6.13, and the highest level of 
proliferation were recorded in the MoDC-T cell co-cultures.  
 
 
 
PBMC	14	DPI	
Macros	17	DPI	
MoDCs	20	DPI	
A	
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group A Effector Th cells
*** *** ***
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group B Effector Th cells
*** *** ***
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group C Effector Th cells
*** ***
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group A Effector Th cells
* *
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group B Effector Th cells
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group C Effector Th cells
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group A Effector Th Cells
***
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group B Effector Th Cells
*
Me
dia
Co
-in
fec
ted
PR
RS
V SIV
0
2
4
6
8
10
Treatment
Pe
rc
en
t T
ot
al
 P
ro
lif
er
at
io
n
Group C Effector Th Cells
	 123	
 
 
Figure 6-11: The percentages of CD4α+ CD8α+ CD27- T cell (effector memory T helper 
cell) proliferation from PBMC, MoMΦ-T cell co-cultures, and MoDC-T cell co-cultures 
in response to PRRSV (MOI 1.0), swIAV (MOI 10.0), or co-infected treatments from their 
respective groups at the indicated time points post PRRSV-challenge. After treatment, 
lymphocytes were left to proliferate in culture for 4 days before measuring proliferation 
using flow cytometry, performed as single replicates (n=6-8). Statistical significance was 
determined by comparing the co-infected, swIAV, or PRRSV treated samples to the 
negative control (non-stimulated cells) within each group. Values were reported with 
statistical significance if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = ***. *MoMΦs were 
added at a 1:5 ratio to T cells on day 17. 
 
Proliferation of an uncharacterized lymphocyte population:  
During the analysis of the lymphocyte and CD3+ T cell proliferation levels, we noticed a 
difference in the percentage of cells that were CD3+ within the proliferating populations 
depending on the administered treatment (Figure 14a, 14b, 14c). We chose to show 
results from Group B, from the later time point of the infection, in order to have a 
comparison to the level of proliferation to both swIAV and PRRSV within the same 
group. Levels of CD3+ T cell proliferation in the cell culture assays are indicated in Table 
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5 below. The results indicate that over 50% of the proliferating lymphocyte population in 
Group B (from the PBMC culture) in response to the PRRSV treatment, were not CD3+ T 
cells. Similarly, in the swIAV+PRRSV co-infected treated PBMCs, nearly 47% of the 
proliferating lymphocyte population was not CD3+, as indicated in Table 6.5. On the 
other hand, in the swIAV treated PBMCs less than 20% of the proliferating population 
was not CD3+. These results, although not as statistically significant as those in the 
PBMC cell culture, were reflected in the MoMΦ-T cell and MoDC-T cell co-cultures 
(Table 6.5). 
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Figure 6-12: The percentages of CD3+ T cells (right y-axis) that proliferated within the 
total lymphocyte population (left y-axis) of the PBMC (Figure 14A), MoMΦ-T cell co-
culture (Figure 14B), and MoDC-T cell co-culture (Figure 14C), from Group B, in 
response to either media, ConA, Co-infected, PRRSV, or swIAV treatments. The percent 
proliferation of CD3+ T cells is represented as red “X”s while the percent proliferation of 
the entire lymphocyte population is represented as black triangles. The Shapiro-Wilk 
normality test confirmed Gaussian distribution and an ordinary one-way ANOVA of 
multiple comparisons was utilized to describe statistical significance. Data was acquired 
as single replicates (n=8). Values were reported with statistical significance as P = 0.0453 
= *; P < 0.0001 = ****; ns = not significant. 
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Table 6.5: The mean percentage of CD3+ lymphocytes that proliferated in response to the 
indicated administered treatments in the PBMC or APC-T cell co-culture assays from 
Group B animals.  
 PBMCs (CD3) MoMΦs (CD3) MoDCs (CD3) 
ConA 98.5% 94.4% 96.1% 
Co-infected 53.7% 64.1% 63.4% 
PRRSV 49.3% 57.0% 59.0% 
swIAV 79.6% 77.7% 75.4% 
 
6.4 Discussion: 
 
The adaptive immune response to PRRSV can be characterized by the early appearance 
of non-neutralizing antibodies (within a week), a delayed appearance of IFN-γ secreting 
cells in PBMCs (2 weeks), which is likely associated with a delayed induction of T cell 
immunity, and a delayed appearance of neutralizing antibodies (3-4 weeks) (Loving et al., 
2015). The resolution of an infection is attributable to both IFN-γ secreting cells and the 
induction of neutralizing antibodies, although PRRSV persists in the tonsils of pigs for up 
to a year. As of late, the T cell response to PRRSV has garnered more attention, with 
studies indicating T cell epitope cross-reactivity amongst strains, and it seems to be 
generally accepted that the T cell response is being geared towards Th1 type immunity  
(Correas et al., 2017; Rahe and Murtaugh, 2017). But, there has not yet been an 
explanation for the delayed induction of T cell immunity. A potential explanation for the 
delayed induction of T cell immunity has been proposed to be associated with the 
induction of PRRSV specific regulatory T cells (Silva-Campa et al., 2009; Wongyanin et 
al., 2012; Wongyanin et al., 2010), but this is under debate (Rodriguez-Gomez et al., 
2015). In addition to atrophy and apoptosis in observed in peripheral lymphoid organs, 
and the thymus, of PRRSV infected animals, another potential explanation for the 
delayed induction of T cell immunity could be associated with the manipulation of 
antigen processing and presentation in the target cells of PRRSV infection, CD163+ 
myeloid derived APCs (Calvert et al., 2007) (Gomez-Laguna et al., 2013b). Therefore, 
we chose to investigate the induction of T cell immunity over the course of an infection 
to PRRSV, comparing the immune response to animals immunized with a commercially 
distributed swine-influenza A vaccine (FluSure XP), in addition to comparing the 
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immunostimulatory capacity of MoDCs and MoMΦs to induce the proliferation of 
specific T cell subsets in response to PRRSV infection or swIAV (H1N1) stimulation. 
 
Humoral response and IFN-γ secreting cells: 
To confirm the immunization with FluSure XP and the infection with PRRSV of the 
animals, we first tested for antibodies in the serum of the animals. As expected, PRRSV 
antibodies were detectable 9 days post challenge and increased over the course of the trial 
(Figure 6-2a). The antibody response to swIAV immunization was apparent throughout 
the course of the trial. Of note, in order to increase the level of T lymphocyte 
proliferation to swIAV, animals received a booster (double dose) of the FluSure vaccine 
21 days post-PRRSV infection. On day 32 post-PRRSV infection the levels of antibodies 
against swIAV increased drastically (Figure 6-2b). Additionally, it’s possible that 
PRRSV infection may have an effect on the antibody response to swIAV, as the antibody 
titres in Group A to swIAV are slightly higher than in Group B, although these 
differences were not found to be statistically significant. Lastly, Group A may have been 
exposed to PRRSV later during the trial, as antibody titres to PRRSV became detectable 
32 days post-PRRSV infection. In addition to serum ELISAs to measure antibody 
secretion, we utilized IFN-γ ELISpots to detect IFN-γ secreting cells in PBMCs. 
Our results indicate that IFN-γ secreting cells to PRRSV are detectable 14 days post 
infection and the amount of IFN-γ secreting cells in PBMCs increased at 28 days post-
PRRSV infection (Figure 6-3). The detection of IFN-γ secreting cells to PRRSV 2 weeks 
post infection reflects results from a recent study (Correas et al., 2017). Although IFN-γ 
secretion to swIAV was detectable over the course of the trial, the amount of IFN-γ 
secreting cells was not as prominent as that PRRSV. The lower IFN-γ response to the 
swIAV immunization could be an efficacy issue associated the vaccine formulation, 
being attributable to a weak T cell stimulation. It doesn’t seem that PRRSV infection 
influenced the level of IFN-γ secretion to swIAV in the immunized animals (Group A vs 
Group B, Figure 6-3). Similarly, the swIAV immunization did not have an effect on the 
IFN-γ response to PRRSV (Group B vs Group C, Figure 6-3). Overall, based on these 
results, the T cell response to PRRSV is functional and there may be a slight delay in the 
induction of T cell immunity.  
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Lymphocyte and CD3+ T cells: 
We first measured the overall levels of lymphocyte proliferation in response to either 
swIAV, PRRSV, or a combination of both PRRSV and swIAV within PBMCs or 
MoMΦs or MoDCs co-cultured with an enriched population of T cells. During the first 
week of infection, we were unable to detect any T cell or lymphocyte proliferation in 
PBMCs in response to any of the viral treatments administered to the cell cultures (Figure 
6-4). As a result, we decided to increase the MOI of swIAV from 1.0 to 10.0 in the 
PBMC cell cultures, and in the APC treatments prior to co-culturing with the enriched T 
cells. As Figure 6-5a demonstrates, we were able to induce lymphocyte proliferation in 
response to the swIAV, PRRSV, and co-infection treatments in the lymphoproliferation 
assay cell cultures during the second week of PRRSV infection. Overall, there wasn’t a 
noteworthy difference in the level of lymphocyte proliferation between the MoMΦ-T cell 
or MoDC-T cell co-cultures. The highest percentage of lymphocyte proliferation was 
recorded in the PBMC cell culture, while the MoDC-T cell co-culture had the lowest 
percentage of lymphocyte proliferation (Figure 6-5a, Supplementary Table 6.6). These 
results were reflected later in the animal trial, as the percentage of lymphocyte 
proliferation to PRRSV was higher in the PBMCs than in the APC-T cell co-cultures, 
with an overall increase as the trial continued (Figure 6-5a vs 6-5b). A recent study 
indicates that plasmacytoid DCs (pDCs) may have a role in up-regulating the expression 
of co-stimulatory molecules on DC subsets, including MoDCs  (in response to TLR-7 and 
TLR-9 stimulation) (Auray et al., 2016). This could potentially explain the higher level of 
lymphocyte proliferation in our PBMC proliferation cultures in comparison to the APC-T 
cell co-cultures. The percentage of CD3+ T cell proliferation, in response to the viral 
treatments, reflects the proliferation profiles recorded in the previous total lymphocyte 
proliferation figures (Figures 6-6a and 6-6b). During the earlier time point of the animal 
trial, we observed lymphocyte and T cell proliferation in response to the media alone 
treatments in Groups B and C in the APC-T cell co-cultures, but not in the PBMCs. 
During the later time point of the animal trial, we did not record any proliferation in the 
media alone treatments in the APC-T cell co-cultures (Figure 6-6b). 
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Monocytes are potentially infected in vivo: 
To address the lymphocyte proliferation in the APC-T cell co-culture assays, in Groups B 
and C, in the media alone treatments, we hypothesize that the animals were viremic 
during the first few weeks of infection. If that were the case, a portion of monocytes that 
we isolated from whole blood of the PRRSV infected pigs may have been infected with 
PRRSV. As a result, while the monocytes were differentiating into MoMΦs or MoDCs, 
PRRSV would have been replicating within the cell cultures. This could have had an 
impact on the differentiation of monocytes into MoDCs and MoMΦs during the viremic 
stage of infection. In order to confirm whether or not monocytes are infected in vivo, 
future experiments are needed. A recent study indicates that the monocyte population in 
the peripheral blood of pigs infected with PRRSV decreases, potentially indicating the 
susceptibility of monocytes to infection (Ferrari et al., 2018). Based on our results, it is 
possible that monocytes are infected by PRRSV, lending an explanation to the 
proficiency by which PRRSV is able to migrate to peripheral lymphoid organs and to the 
uterus.  
 
Naïve and activated CD4α+ Th cells: 
The purpose of the trial was to compare the immunostimulatory capacity of MoMΦs and 
MoDCs. In particular, we aimed to determine whether MoMΦs or MoDCs preferentially 
induced the proliferation of specific T lymphocyte subsets. The profiles of proliferation 
amongst the subsets reflect those results from the CD3+ T cell proliferation assays. We 
detected naïve Th cell proliferation mostly in the PBMC cell cultures, but it’s likely that 
these cells had a low/dim expression of CD8α and could have been transitioning towards 
an “activated” state, as we would not anticipate observing antigen specific proliferation 
within a naïve population of T cells (Figures 6-7a and 6-7b). The percentages of CD4α+ 
CD8α+ activated Th cell proliferation reflected previous results. Essentially, the PBMCs 
had a higher percentage of proliferation than the APC-T cell co-cultures and the amounts 
of Th cell proliferation increased over the course of the trial. The highest level of 
proliferation to PRRSV was observed in the Group C lymphocyte proliferation assays. 
And the highest level of activated Th cell proliferation to swIAV was observed in Group 
B from all three of the lymphocyte proliferation assays. Lastly, the MoDC-T cell co-
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cultures had higher levels of activated Th cell proliferation in response to both PRRSV 
and swIAV treatments than in the MoMΦ-T cell co-cultures. This may be attributable to 
MoDCs presenting a greater diversity of MHCII associate peptide sequences to T cells 
than MoMΦ as a result of the lower pH and higher protease activity in the endosomes of 
macrophages during antigen processing (Blum et al., 2013; Delamarre et al., 2005). This 
could explain the higher capacity of MoDCs to stimulate CD4+ Th cell proliferation. 
When comparing the level of Th cell proliferation to swIAV in Group A vs Group B 
(Figure 6-8), the level of Th cell proliferation was higher in the animals infected with 
PRRSV. Furthermore, we saw similar results in the gamma delta T cells (Figure 6-9b), in 
the central memory Th cells (6-11b) and the effector Th cells (6-12b). It’s possible that 
the PRRSV infection could be “training” monocytes to acquire an M1 phenotype 
(Bordon, 2014; Saeed et al., 2014).  
 
CD4α- CD8α+ T cells (CTL) response: 
The induction of CTL mediated immunity to a virus is highly important towards 
overcoming an infection (Elemans et al., 2014). Overall, the CTL proliferation profiles 
follow a similar trend as the other T cell subsets, in that CTL proliferation was recorded 
as early as 14 days post infection in the cell culture assays and continued to increase as 
the trial progressed (Figures 6-9a and 6-9b). The highest levels of CTL proliferation were 
observed in the PBMC cell cultures, and Group C had the highest mean percent CTL 
proliferation to PRRSV treatment, while Group B had the highest mean percent CTL 
proliferation to swIAV treatment. Upon further analysis, the differences between the 
treatments within the MoDC and MoMΦ- T cell co-cultures were not shown to be 
statistically significant. Overall, the induction of CTL proliferation seems to indicate that 
immunity to the PRRSV and the FluSure immunization are being directed towards a Th1 
type immune response. 
 
Central memory CD4α+ Th cells and effector CD4α+ Th cells: 
Central memory Th cells (CD4α+ CD8α+ CD27+) were detectable 14 days post PRRSV 
challenge in PBMCs, and in the APC-T cell co-cultures on days 17 and 20 (Figure 6-
11a). This was somewhat surprising, as we did not anticipate seeing central memory Th 
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cells until later during the infection (MacLeod et al., 2010; Pepper and Jenkins, 2011b). 
But, these results are relatively similar to those obtained in a recent study in which 
memory Th cells began to increase 17 days post infection (Ferrari et al., 2018). The 
highest level of central memory Th cell proliferation in response to PRRSV was recorded 
in Group C from the cell culture assays. Furthermore, the highest of level central memory 
Th cell proliferation to PRRSV was in the PBMC cell culture assay. In addition, higher 
levels of central memory Th cell proliferation were observed in the MoDC-T cell co-
culture assays compared to the MoMΦ-T cell co-cultures (Supplementary Table 6.12). 
These results indicate that MoDCs may possess a higher capacity to stimulate central 
memory Th cell proliferation than MoMΦs. This was also reflected in the proliferation 
profiles of the swIAV treatments, in which the highest level of central memory Th cell 
proliferation was again recorded in Group B for the cell culture assays (Supplementary 
Table 6.12). Statistically significant results indicating that MoDCs possessed a higher 
capacity than MoMΦs to stimulate central memory Th cell proliferation was found in 
Group C, in response to the PRRSV treatment (Supplementary Figure 6-33). The mean 
percent proliferation profiles of the effector Th cell responses to PRRSV and swIAV 
were very similar to that observed for the central memory Th cell proliferation profiles. 
The highest level of effector Th cell proliferation to PRRSV was recorded in the PBMC 
cultures, followed by the MoDC-T cell co-culture, and then the MoMΦ-T cell co-culture, 
all in Group C. And the highest proliferations in the effector Th cell population to swIAV 
were recorded in Groups B, with the MoDC-T cell co-cultures having higher levels of 
proliferation than both the PBMC and MoMΦ-T cell cultures (Supplementary Table 
6.13), although this was not found to be statistically significant. 
Comparing the mean percentage of lymphocyte proliferation amongst the T cell subsets, 
it becomes apparent that MoDCs may be more potent inducers of central memory Th 
cells. It’s plausible that this difference in immunostimulatory preference between MoDCs 
and MoMΦs highlights their attributes. Dendritic cells are often considered the 
professional APCs of the immune system, for many reasons including migration to the 
lymph node for antigen presentation to naïve T cells, and having a more diverse 
repertoire of peptide sequences than macrophages. In this case, DCs could play a crucial 
role in the induction of CD4α+ Th cells, aiding in the progression of the entire T cell 
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immune response and directly influencing the humoral immune response (Luckheeram et 
al., 2012b); (Swain, McKinstry, & Strutt, 2012a). In comparison, macrophages are often 
considered to be the sentinels of the immune system, being involved in the maintenance 
of homeostasis and tissue regeneration under non-pathogenic conditions, or playing 
significant roles in search and destroy phagocytosis when encountering a pathogen (Mills 
and Ley, 2014) (Varol et al., 2015). In the case of PRRSV, the induction of CTLs would 
be critical in overcoming an infectious state (Barry and Bleackley, 2002). The evidence 
thus far implies that the T cell response is being geared towards Th1 type immunity. To 
further support this, we assayed cell culture supernatants after the 4th day in culture for 
various cytokines. 
 
Cytokine response: 
We assayed for cytokine expression after 4 days and for the most part we were unable to 
detect cytokines in the majority of the supernatants from the cell cultures, reflecting 
results obtained previously (Reutner et al., 2013). Taking into consideration a viral 
infection and Th1 type immunity, we were particularly interested in type 1-interferons 
(IFN-α, IFN-β), IL-12, and IFN-γ. Our results indicate that both swIAV and to a lesser 
extent PRRSV stimulated IFN-α secretion (Supplementary Figures 6-19 and 6-20), 
although IFN-α was detected in some of the media alone treatments as well. More 
importantly, IFN-γ was detected in the cell cultures in response to swIAV, PRRSV, and 
the co-infection treatments. There wasn’t a notable difference amongst the treatments or 
the groups (Supplementary Figures 6-21 and 6-22). Lastly, there was an inconsistency in 
the detection of IL-12, IL-10, IL-13, and IL-17α amongst the various treatments and the 
different groups making it difficult to form any definitive conclusions regarding the afore 
mentioned cytokines expressions (Supplementary Figures 6-23 to 6-29). Overall, the 
detection of IFN-γ in the cell culture supernatants in response to both swIAV and 
PRRSV, in addition to the induced CTL proliferation, we feel that a protective immune 
response to PRRSV is associated with Th1 type immunity. 
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Unidentified lymphocyte population: 
Lastly, we noticed that the percentages of T cells within the total population of 
proliferating lymphocytes differed, depending on the treatment administered. 
Specifically, there was an unidentified population of lymphocytes that proliferated in 
response to the PRRSV treatment in all three of the cell culture assays, being most 
pronounced in the PBMC population (Figure 6-14). Furthermore, this was not the case in 
the ConA stimulated positive control treatment and to a much lesser extent in the swIAV 
treated lymphocyte proliferative cell culture assays. Today there is no anti-pig anti-CD19 
antibody available, as such we could only enrich the T cell population for our co-culture 
assays by depleting B cells that express CD21. Thus, we hypothesize that the unidentified 
lymphocyte population are CD19+ B cells in the APC-T cell co-cultures, and a mix of 
CD21+ and CD19+ B cells in the PBMC cell cultures. There is a robust non-NA response 
seen early during infection with PRRSV (within 3 days antibodies are detectable), and 
this may be attributable to hypergammaglobulinemia. It has been shown that the amount 
of immunoglobulin present in bronchoalveolar lavages (BAL) during a PRRSV infection 
was increased more than 10 fold in comparison to pigs infected with swIAV and porcine 
circovirus-2 (PCV-2). The study showed that the majority of the B cells, during the 
viremic stage of a PRRSV infection, express different isotypes (IgM, IgG, IgA) but 
nearly identical sequences in their 3rd complimentarity-determining region (HCDR3) of 
the antibody heavy chain. In other words, the authors showed that the non-NA response 
to PRRSV originated from similar B cell clones that had not undergone somatic 
hypermutation (Schroeder et al., 1998). If this is the case, it supports our hypothesis as to 
the portion of the lymphocytes proliferating in response to PRRSV in the PBMC cultures 
(Figure 6-14) being B cells. Further experiments are needed to identify the proliferating 
population of unidentified cells. 
 
6.5 Conclusion: 
 
In conclusion, there does not seem to be an overly remarkable difference between the 
immunostimulatory capacity of MoMΦs and MoDCs to induce CD3+ T cell proliferation. 
That being stated, our results indicate that MoDCs may be more potent stimulators of 
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central memory Th cell proliferation in response to both PRRSV. A major question in 
PRRSV immunology, considering the delayed induction of T cell immunity and skewed 
humoral response, has been what effect PRRSV has on the antigen-presenting/processing 
capability of APCs. Our results indicate that even though MoMΦs and MoDCs are being 
infected by PRRSV, they are able to present antigen to induce a robust T cell response. 
This response was markedly stronger than that to the swIAV treatment, which was 
administered at 10x the dose in comparison to PRRSV. And lastly, we have shown that it 
is plausible that PRRSV infects monocytes in vivo providing some clarity regarding the 
pathogenesis of the virus. Furthermore, the lymphoproliferative T cell response to swIAV 
in the animals infected with PRRSV was consistently stronger than the response to 
swIAV in the animals not exposed to PRRSV, hinting that PRRSV infection increased 
the immunostimulatory capacity of the monocyte population within those PRRSV 
infected animals. Our results indicate that there might be a slight delay in the induction of 
T cell immunity to PRRSV. Reasons for the delay could be attributable to PRRSV 
interfering with antigen processing/presentation in DCs or MΦs, atrophy and apoptosis of 
lymphoid populations in the lymph nodes, the induction of PRRSV specific Tregs, or 
potentially a combination of the three explanations. A recent study indicated that PRRSV 
specific Tregs are most prominent in peripheral lymphoid organs and tissue surrounding 
the lung (Nedumpun et al., 2018). Based on our results, CTLs and effector T cells are 
induced 14 days post-PRRSV infection. It’s plausible that these tissue specific Tregs 
could suppress T cell function at sites of infection, and once the T cell response breaches 
a threshold, the CTLs and effector T cells would be able to overcome the immune 
suppression by the Tregs. Overall we can conclude that the T cell immune response to 
PRRSV is functional, it is even more robust than the T cell response to the FluSure XP 
immunization, and it is being geared towards Th1 type immunity. 
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6.6 Supplementary Figures: 
 
 
Figure 6-13: Figure representing the peripheral blood mononuclear cell (PBMC) 
interferon-gamma ELISPOTs from the different treatment groups in the fifth week of 
PRRSV infection. Briefly, 5.0x10^5 PBMCs were isolated on the respective dates listed. 
Cells were treated with PRRSV (MOI 1.0) or swIAV (MOI 10.0) and the IFN-γ ELISpot 
plates were developed 20 hours post treatment. Statistical significance was determined by 
comparing the swIAV or PRRSV treated samples to the negative control (non-stimulated 
cells). Values were reported with statistical significance if P < 0.05 = *; P < 0.005 = **; 
P < 0.0005 = ***.  
 
 
Table 6.6: Mean percentage of lymphocyte proliferation in the indicated treatments, 
groups, cell cultures, on specific days post infection (DPI). 
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PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 1.40 7.78 3.11 5.33 6.54 19.88 12.76 16.00
Group	B 1.31 17.74 20.76 5.30 3.64 28.11 42.40 13.79
Group	C 2.80 19.34 27.44 1.83 3.63 28.94 44.30 3.35
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 5.81 13.07 5.99 12.37 3.69 5.56 1.59 7.28
Group	B 20.19 24.16 26.50 16.83 9.12 22.80 23.60 16.60
Group	C 23.54 25.78 26.09 14.95 11.37 9.99 20.31 2.05
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 2.39 4.54 2.17 4.11 2.16 11.08 5.12 10.48
Group	B 7.89 17.13 13.35 11.91 2.27 17.68 17.95 13.15
Group	C 8.63 16.71 11.88 9.35 5.20 11.66 23.90 9.27
20	DPI 30	DPI
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Table 6.7: Mean percentage of CD3+ T cell proliferation in the indicated treatments, 
groups, cell cultures, on specific days post infection (DPI). 
 
 
 
 
 
 
Table 6.8: Mean percentage of naïve (CD3+ CD4α+ CD8α-) T cell proliferation in the 
indicated treatments, groups, cell cultures, on specific days post infection (DPI). 
 
 
 
 
 
 
 
PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 1.39 7.58 3.00 5.51 2.66 15.40 9.08 12.46
Group	B 0.83 13.38 14.21 4.83 1.90 15.68 24.63 11.27
Group	C 2.58 14.92 20.16 1.63 1.61 16.84 27.23 1.26
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 4.10 11.30 4.19 10.72 3.09 5.05 1.14 6.95
Group	B 13.22 14.34 13.99 10.88 7.32 16.28 15.36 13.76
Group	C 15.65 15.76 15.20 8.89 10.35 6.43 14.79 1.44
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 1.69 3.44 1.56 3.33 0.92 7.66 2.42 7.32
Group	B 7.30 15.62 12.14 10.69 1.02 11.57 10.02 9.88
Group	C 8.10 15.62 11.09 8.75 4.06 7.18 12.73 5.72
20	DPI 30	DPI
PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.226 1.265 0.437 0.898 0.350 1.016 0.917 0.806
Group	B 0.178 4.385 5.973 0.989 0.149 1.011 2.234 0.819
Group	C 0.300 5.075 7.347 0.206 0.107 1.227 2.080 0.124
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.254 0.249 0.169 0.307 0.551 0.445 0.292 0.565
Group	B 0.895 0.543 0.656 0.740 0.650 0.957 1.206 0.942
Group	C 0.702 0.597 0.444 0.435 1.172 0.597 1.078 0.324
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.259 0.282 0.255 0.304 0.044 0.261 0.145 0.311
Group	B 0.589 0.723 0.647 0.684 0.073 0.741 0.774 0.668
Group	C 0.477 0.632 0.532 0.501 0.141 0.469 0.797 0.394
20	DPI 30	DPI
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Table 6.9: Mean percentage of activated (CD3+ CD4α+ CD8α+) T helper cell 
proliferation in the indicated treatments, groups, cell cultures, on specific days post 
infection (DPI). 
 
 
 
 
 
 
Table 6.10: Mean percentage of cytotoxic lymphocyte (CD3+ CD4α- CD8α+) 
proliferation in the indicated treatments, groups, cell cultures, on specific days post 
infection (DPI). 
 
 
 
 
 
 
 
PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.010 0.171 0.081 0.130 0.079 2.570 0.997 1.746
Group	B 0.007 0.871 1.022 0.096 0.075 3.052 5.417 1.948
Group	C 0.015 1.124 1.755 0.020 0.064 3.561 6.720 0.138
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.516 1.178 0.315 1.208 0.534 0.897 0.210 1.135
Group	B 3.405 3.231 3.737 1.824 1.144 3.355 2.848 2.360
Group	C 4.488 3.819 3.754 2.017 2.384 1.456 3.116 0.250
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.129 0.388 0.139 0.394 0.142 2.341 0.613 2.274
Group	B 0.838 1.800 1.356 1.422 0.235 4.670 3.138 3.598
Group	C 0.947 1.857 1.301 1.192 1.550 2.893 4.947 2.492
20	DPI 30	DPI
PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.171 1.234 0.465 0.933 0.357 5.759 2.925 4.460
Group	B 0.068 1.826 2.071 0.492 0.691 5.658 9.355 3.965
Group	C 0.215 2.764 3.182 0.133 0.627 7.053 11.598 0.548
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 2.162 6.606 2.217 6.162 1.040 1.532 0.307 2.352
Group	B 5.877 6.155 6.277 5.069 2.850 6.286 6.527 5.715
Group	C 6.137 6.152 6.821 4.942 4.628 2.377 6.435 0.450
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.301 0.600 0.306 0.713 0.298 3.740 1.317 3.391
Group	B 1.850 3.181 3.165 2.646 0.289 3.728 4.538 3.126
Group	C 1.924 3.475 3.062 2.377 0.985 1.802 4.895 1.173
20	DPI 30	DPI
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Table 6.11: Mean percentage of gamma delta T cell (CD3+ γδ+) proliferation in the 
indicated treatments, groups, cell cultures, on specific days post infection (DPI). 
 
 
 
 
 
 
Table 6.12: Mean percentage of central memory T helper cell (CD3+ CD4α+ CD8α+ 
CD27+) proliferation in the indicated treatments, groups, cell cultures, on specific days 
post infection (DPI). 
 
 
 
 
 
 
 
 
 
PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.420 2.629 0.764 1.800 0.183 1.745 0.945 1.147
Group	B 0.242 3.485 2.217 1.586 0.169 1.642 2.231 1.187
Group	C 0.511 1.942 1.723 0.462 0.094 1.473 2.165 0.091
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 2.797 9.386 3.415 8.755 0.145 0.243 0.076 0.579
Group	B 7.345 8.899 7.797 7.406 0.575 0.947 0.804 1.129
Group	C 6.980 8.276 7.868 6.720 0.919 0.334 0.571 0.118
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.266 0.248 0.127 0.333 0.203 0.860 0.233 0.837
Group	B 2.032 3.130 3.402 2.503 0.232 1.266 1.039 1.289
Group	C 1.842 2.643 2.607 1.972 0.314 0.433 0.963 0.305
20	DPI 30	DPI
PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.008 0.088 0.049 0.073 0.050 0.612 0.348 0.425
Group	B 0.005 0.267 0.440 0.039 0.044 1.369 2.850 0.502
Group	C 0.011 0.452 0.797 0.011 0.038 2.153 3.597 0.081
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.251 0.315 0.112 0.468 0.225 0.170 0.071 0.361
Group	B 2.029 1.611 2.319 0.763 0.673 1.209 1.570 0.738
Group	C 2.863 1.896 2.259 0.973 1.618 0.820 1.603 0.157
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.080 0.208 0.094 0.191 0.116 0.828 0.438 0.863
Group	B 0.329 0.878 0.716 0.753 0.118 1.704 1.958 1.057
Group	C 1.082 2.122 1.301 1.192 0.957 1.524 2.960 1.360
20	DPI 30	DPI
	 140	
Table 6.13: Mean percentage of effector T helper cell (CD3+ CD4α+ CD8α+ CD27-) 
proliferation in the indicated treatments, groups, cell cultures, on specific days post 
infection (DPI). 
 
 
 
 
 
 
 
 
 
Figure 6-14: Figure indicating the percentage of CD3+ T cells that proliferated within 
the total lymphocyte population of the PBMC cultures from all of the groups over the 
course of the trial. 
PBMCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.002 0.082 0.033 0.058 0.029 1.957 0.649 1.322
Group	B 0.003 0.604 0.582 0.057 0.031 1.684 2.568 1.446
Group	C 0.004 0.673 0.958 0.010 0.026 1.407 3.123 0.057
14	DPI 24	DPI
Macrophages
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.285 0.839 0.212 0.740 0.309 0.727 0.139 0.774
Group	B 1.198 1.730 1.414 1.024 0.487 2.190 1.164 1.687
Group	C 1.518 1.791 1.416 1.159 0.870 0.653 1.410 0.096
17	DPI 27	DPI
MoDCs
Media Co-infected PRRSV SIV Media Co-infected PRRSV SIV
Group	A 0.048 0.235 0.045 0.203 0.026 1.513 0.175 1.411
Group	B 0.509 1.053 0.640 0.669 0.117 2.966 1.180 2.541
Group	C 0.452 0.896 0.546 0.554 0.593 1.369 1.987 1.132
20	DPI 30	DPI
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Figure 6-15: Figure indicating the percentage of CD3+ T cells that proliferated within 
the total lymphocyte population of the MoMΦ-T cell co-cultures from all of the groups 
over the course of the trial. 
 
 
 
Figure 6-16: Figure indicating the percentage of CD3+ T cells that proliferated within 
the total lymphocyte population of the MoDC-T cell co-cultures from all of the groups 
over the course of the trial. 
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Figure 6-17: Figure indicating the level of CD3+ T cell proliferation from PBMC 
cultures in response to PRRSV (MOI 1.0), swIAV (MOI 10.0), or co-infected treatments 
from their respective groups during the fifth week of infection. After treatment, 
lymphocytes were left in culture for 4 days before measuring proliferation using flow 
cytometry. Statistical significance was determined by comparing the co-infected, swIAV, 
or PRRSV treated samples to the negative control (non-stimulated cells). Values were 
reported with statistical significance if P < 0.05 = *; P < 0.005 = **; P < 0.0005 = ***.  
 
 
 
 
Figure 6-18: Representation of the FMIA cytokine ELISAs measuring IFN-α during the 
2nd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-19: Representation of the FMIA cytokine ELISAs measuring IFN-α during the 
3rd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-20: Representation of the FMIA cytokine ELISAs measuring IFN-γ during the 
2nd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-21: Representation of the FMIA cytokine ELISAs measuring IFN-γ during the 
3rd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-22: Representation of the FMIA cytokine ELISAs measuring IL-10 during the 
2nd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-23: Representation of the FMIA cytokine ELISAs measuring IL-10 during the 
3rd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
 
 
 
 
Figure 6-24: Representation of the FMIA cytokine ELISAs measuring IL-12 during the 
2nd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-25: Representation of the FMIA cytokine ELISAs measuring IL-13 during the 
2nd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-26: Representation of the FMIA cytokine ELISAs measuring IL-13 during the 
3rd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-27: Representation of the FMIA cytokine ELISAs measuring IL-17α during the 
2nd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-28: Representation of the FMIA cytokine ELISAs measuring IL-17α during the 
3rd week post-PRRSV infection. Supernatants from the cell culture assays were removed 
after 4 days in culture to measure cytokine secretion in response to the administered 
treatments indicated in the graphs. Samples were analyzed in duplicate. 
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Figure 6-29: Schematic demonstrating the gating strategy utilized for CD4α+ CD8α+ 
CD27+ T cells from a PRRSV treated PBMC cell culture (pig 343). Briefly, a gate was 
established around singlets before drawing a gate surrounding lymphocytes. A gate was 
then drawn on live cells, before gating on CD3+ T cell expression. After gating on the 
proliferating cell population, a gate established for the CD4α+ CD8α+ T cell subset, before 
gating on CD27- (Effector Th cells, in blue) and CD27+ (Central memory Th cells, in red) 
to measure Th cell subset proliferation. 
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Figure 6-30: Comparison between the immunostimulatory capacity of MoDCs and 
MoMΦs to stimulate central memory Th cell proliferation during the later time point of 
the animal trial to the specific treatments within their respective groups. The mean 
percent proliferation of the indicated treatment was subtracted from the mean 
proliferation of the media alone treatment, according to each separate animal. The percent 
proliferation was then compared between MoMΦs and MoDCs according to each 
treatment. Statistical analysis was based on non-Gaussian distribution and the Kruskal-
Wallis test of multiple comparisons was used to test for significance. P < 0.05 = *; P < 
0.005 = **; P < 0.0005 = ***. 
 
 
 
Contributions: JD, Stacy Strom, and JVK isolated PBMCs, monocytes, and T cells. JVK 
and JD cell trace violet stained the T cells. Stacy Strom, JVK, and JD performed the 
ELISpot assays. JD performed serum ELISAs. JD and Donna Dent performed FMIA 
ELISAs. JD performed macrophage and MoDC cell differentiation cultures. JD 
performed the flow cytometry. JD, JVK, and Stacy Strom co-cultured APCs with T cells. 
JD did statistical analysis. JD and VG designed experiments. 
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Chapter 7  GENERAL DISCUSSION 
 
The PRRSV is an enveloped, positive sense, single stranded, RNA virus that infects 
APCs of the porcine immune system. Cell susceptibility is restricted to cells that express 
the hemoglobin/haptoglobin scavenger molecule CD163 (Calvert et al., 2007). Animals 
infected with PRRSV are subject to an array of clinical syndromes such as respiratory 
difficulty and pneumonia, weight loss, and the infection of the fetus leading to 
spontaneous abortions and fetal mummification, accounting for the majority of the 
economic losses (Butler et al., 2014). Outcomes of disease range from being 
asymptomatic to upwards of 100% mortality in pig herds, being largely attributable to the 
pathogenicity of the PRRSV strain, secondary co-infections with opportunistic pathogens, 
in addition to the age, sex, and breed of the pig. The initial site of PRRSV replication is 
within PAMs in the alveolar space (Chen, Trible, Kerrigan, Tian, & Rowland, 2016). 
Shortly after which PRRSV becomes viremic spreading to peripheral lymphoid organs 
and establishing a persistent state in the tonsils (Lunney et al., 2016). The innate immune 
system is subject to regulation by PRRSV in a strain specific manner, according to 
pathogenicity. The highly virulent Chinese strains of PRRSV seem to induce a cytokine 
storm, whereas the less virulent strains suppress the expression of innate immune 
cytokines. Innate immune suppression and a depletion of the myeoloid phagocyte 
population lead to an immunocompromised state, leaving animals susceptible to 
secondary infections. Regarding the adaptive immune response, antibodies to the PRRSV 
are detected within a week of infection, although the antibodies are non-neutralizing. 
There is a delayed induction of T cell immunity to the PRRSV and roughly 4 weeks post 
infection, neutralizing antibodies become detectable leading to the resolution of the 
infection (Loving et al., 2015). There is a high demand for novel vaccines as the currently 
live attenuated vaccines are limited in cross-protectiveness and pose a risk of reverting to 
virulence. Understanding the delayed induction of T cell immunity and the dysregulated 
humoral immune response will be critical in the development of novel vaccine platforms. 
The aim of this thesis was to understand the role that APCs play during the pathogenesis 
of the virus and to shed light upon the interaction of PRRSV infected APCs with T cells. 
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We hypothesized that specific subsets of DCs were susceptible to PRRSV. We decided to 
utilize FMS-related tyrosine kinase 3 ligand (Flt3L) to differentiate DCs from 
hematopoetic progenitor cells, isolated from the bone marrow. In chapter 3, we 
successfully differentiated BMDCs and we showed that CD163+ BMDCs were 
susceptible to PRRSV infection and that the CD163- BMDCs were not susceptible. We 
continued our investigation by comparing the susceptibility of CD163+ BMDCs to MΦs 
and MoDCs infected with PRRSV. Our results indicated that PRRSV infects MoDCs and 
MoMΦs more efficiently than CD163+ BMDCs. Lastly, our results indicated that the 
CD163+ BMDCs remained healthy 48 hours post infection, whereas the MoMΦs and 
MoDCs were essentially dead after 48 hours. This difference in APC viability may be 
attributable to a less severe rate of infection, but it could also be an indication of a 
defense mechanism that CD163+ BMDCs possess not seen in the myeloid derived MΦs 
or MoDCs.  
An aspect of major interest in our lab is the progression to T cell immunity during a 
PRRSV infection, and a major strategy that viruses have developed for immune evasion 
has been the compromisation of antigen presentation and maturation of DCs (Kruse et al., 
2000; Mahanty et al., 2003; Wang et al., 2007). Thus, in chapter 3 we investigated the 
expression of cell surface markers associated with antigen presentation in the APC 
populations. When comparing the levels of MHCI and MHCII expression on the APC 
populations, PRRSV infected, non-stimulated MoMΦs showed clear downregulations in 
both MHCI and MHCII cell surface expression. Our results demonstrated that even 
though there is a downregulation of MHC molecules on the surface of MoMΦs infected 
with PRRSV, it did not abrogate their stimulatory capacity, as the MoMΦs clearly 
retained their capacity to stimulate a recall response in T cells from PRRSV immunized 
animals. Ultimately, we were left questioning why there was a delayed induction of T cell 
immunity to PRRSV. To further address the delayed induction of T cell immunity after 
PRRSV infection, we decided to investigate the maturation of the invariant chain in 
MoDCs and PAMs. 
Dendritic cells (DCs) are often referred to as the professional APCs of the immune 
system, being largely attributable to their capacity to stimulate naïve T cells, driving the 
adaptive immune response in a particular direction. The pathway in which MHCII is 
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synthesized and loaded with peptide has been largely deduced, but the trafficking of 
peptide loaded MHCII to the plasma membrane in APCs is not completely resolved 
(Blum et al., 2013; ten Broeke et al., 2013). Originally we sought to investigate whether 
PRRSV has an influence on the maturation of the invariant chain. Theoretically, if 
PRRSV were to interfere with the maturation of the invariant chain, it would result in the 
occupation of the MHCII binding groove with CLIP. This in turn would prevent the 
loading of a PRRSV peptide sequences into the MHCII binding groove for antigen 
presentation (Blum et al., 2013; Mellins and Stern, 2014). To determine whether PRRSV 
influences the maturation of the invariant chain, in chapter 4 we infected cells and 
immunoprecipitated MHCII. 
We successfully immunoprecipitated MHCII from infected and non-infected MoDCs and 
PAMs, as we identified the alpha chain (SLA-DRA1) and the beta chain (SLA-DRB1) of 
MHCII. There was one major discernable difference in the levels of MHCII associated 
molecules amongst the infected and non-infected cell populations, and it was not 
associated with the invariant chain. At this time, it is difficult to conclude whether 
PRRSV infection alters the maturation of the invariant chain, as we could not identify an 
antibody for its identification in pigs. Interestingly the band of interest within the infected 
cell population was practically diminished, which we identified to be gamma actin 1. The 
role of the cytoskeleton during a PRRSV infection has gone largely unstudied. Our 
results seem to indicate that the association of gamma actin 1 with MHCII is present in 
MoDCs and to a much lesser extent in PAMs. Furthermore, the gamma actin 1 
association with MHCII was largely diminished when MoDCs were infected with 
PRRSV. We are thus left questioning why gamma actin 1 was immunoprecipitaed with 
MHCII, and why gamma actin 1 was not as pronounced in the PRRSV infected MoDCs 
or the PAMs, regardless of infection status. It’s plausible that gamma actin 1 could play a 
prominent role during antigen presentation, potentially in the transport of peptide loaded 
MHCII molecules (pMHCII) to the cell surface, or possibly in sequestering pMHCII to 
lipid rafts at immunological synaptic junctions during T cell stimulation. Further studies 
investigating the role of the actin cytoskeleton during a PRRSV infection, and during 
antigen presentation in MoDCs, could be beneficial towards understanding the 
pathogenesis of PRRSV. To draw any sort of conclusions regarding the relationship of 
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APCs with T cells during a PRRSV infection, it was essential to develop a method to 
culture the APCs with T cells, so we established an assay by modifying the mixed 
leukocyte reaction (MLR) in chapter 5. 
We hypothesized that IFN-γ stimulated (M1) macrophages would possess a greater 
capacity to stimulate T lymphocyte proliferation than non-stimulated (M0) or IL-4 
stimulated (M2) macrophages. Using an MLR, we demonstrated that M1 macrophages 
possessed a greater capability to promote T lymphocyte proliferation than M0 or M2 
macrophages derived from blood monocytes. Furthermore, we modified the MLR in 
Chapter 6 to assess antigen specific T cell responses. Overall, the stimulation of APCs 
towards specific phenotypes had clear implications on both the robustness of the T cell 
response and type of T cell immunity that will be induced. The results obtained from the 
MLR gave us the confidence to study the stimulation of antigen specific T lymphocyte 
populations in vitro isolated from PRRSV infected animals.  
The purpose of the animal trial in Chapter 6 was to investigate and characterize the T cell 
response to PRRSV infection, and to compare the immunostimulatory capacity of 
MoMΦs and MoDCs to promote the proliferation of specific T cell subsets. We utilized 
the FluSure XP vaccine to swine-influenza as a positive control and a comparative 
measure of immunity to PRRSV infection. We detected IFN-γ secreting cells in PBMCs 
from PRRSV infected animals 2 weeks post infection, in addition to T cell proliferation 
in both the PBMC and APC-T cell co-cultures in all of the Groups to both PRRSV and 
swIAV treatments. For the most part, the highest level of T lymphocyte proliferation to 
both PRRSV infection and swIAV treatment was detected in the PBMC 
lymphoproliferation cell cultures. Overall, our main findings included the following: A) 
PRRSV infection of animals in Group B may have enhanced the T cell response to 
swIAV immunization in the MoMΦ-T cell co-culture and MoDC-T cell co-culture, being 
potentially attributable to monocyte training in PRRSV infected animals. B) The 
stimulatory capacity between MoMΦs and MoDCs to induce overall lymphocyte 
proliferation did not differ significantly. Although MoDCs may be more potent inducers 
of central memory Th cells as exhibited in response to both PRRSV and swIAV 
treatments. C) During the second week of infection, we observed proliferation in the 
media alone treatments in the APC-T cell co-cultures from the animal groups that were 
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infected with PRRSV. We hypothesize that the monocytes that we isolated for the 
MoMΦ and MoDC differentiation were infected with PRRSV. D) Lastly, more than 50% 
the population of cells that proliferated in response to PRRSV which were not CD3+ T 
cells in the PBMC culture. We hypothesize that the unidentified population of cells could 
be CD19+/CD21+ B cells. If the population consists of B cells it lends support to our 
overall theory regarding PRRSV induction of hypergammaglobulinemia, which will be 
discussed in more detail below. 
In conclusion, we have shown that the susceptibility of APCs is restricted to those cells 
that express CD163. Furthermore, the rate of replication of PRRSV is slower in CD163+ 
BMDCs, and potentially in MoDCs, than in MOMϕs. The infection of APCs by PRRSV 
does not abrogate their antigen-presenting and immunostimulatory capacity to promote T 
lymphocyte proliferation. Furthermore PRRSV infection appears to be altering the 
association of gamma actin 1 with MHCII. We are unable to draw a definitive conclusion 
as to whether the lack of gamma actin 1 association is attributable to the maturation of 
DCs and the transport of peptide loaded MHCII to the plasma membrane, or is occurring 
as a result of PRRSV hijacking the actin cytoskeleton for its own replication and 
assembly. Regarding the induction of T cell immunity to PRRSV, although the induction 
of T cell immunity may be delayed, the T cell response is functional. We demonstrated 
that both MoMϕs and MoDCs were capable of stimulating Th cell and CTL proliferation 
in an antigen specific manner to PRRSV and swIAV. Lastly, a distinguishing feature of 
MoDCs in comparison to MoMΦs could be an increased potency to induce central 
memory Th cell proliferation.  
 
Theory regarding the delayed induction of T cell immunity to PRRSV: 
This thesis in its entirety allowed us to propose a theory regarding the delayed induction 
of T cell immunity and the dysregulated humoral immune response (being the induction 
of non-neutralizing antibodies and delayed appearance of neutralizing antibodies). We 
believe that a specific subset of DCs, those being derived from hematopoietic progenitor 
cells with Flt3L, is responsible for the initiation of the CD4α+ T cell response to PRRSV. 
Our results indicate that the pathogenesis of the virus or the rate of replication within 
MoMΦs and DCs is different. The virus replicates more quickly in MoMΦs than CD163+ 
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BMDCs, and the virus seems to kill the MoMΦs and MoDCs more quickly than it does 
the CD163+ BMDCs. Theoretically, APCs would need around 24 hours to stimulate a 
naïve T cell to become activated for its particular antigen (Jelley-Gibbs et al., 2000). We 
feel that macrophages and MoDCs may simply not have enough time to present antigen 
to the T cell specific for its specific derived viral peptide sequence. Given the likelihood 
that the BMDC population isn’t as prominent as MoDCs and MoMΦs in vivo, the 
CD163+ BMDCs could be the APC population responsible for driving T cell immunity. 
Thus, the delayed induction of T cell immunity could be attributable to the rarity of this 
specific DC population in addition to time constraint of that DC population reaching the 
lymph node for antigen presentation to naïve T cells. The delayed induction of CD4α+ Th 
cells would also result in a lack of follicular Th cell induction. A recent report indicates 
that γδ T cells play a significant role during the differentiation of follicular Th cells 
(Rezende et al., 2018). Therefore the induction of γδ T cells could be relevant when 
considering the induction of follicular Th cells. Overall, in the absence of follicular Th 
cells, B cells would not be able to undergo proper somatic hypermutation. Additionally, 
B cells would enter a state of hypergammaglobulinemia in which they would proliferate 
and plasma cell synthesis of antibodies would go undirected, as discussed in the humoral 
immunity section of the literature review. Thus, once follicular Th cells are active (likely 
2 weeks post infection when IFN-γ secreting cells become detectable in PBMCs and γδ T 
cell proliferation is at its highest point) the B cells would undergo somatic hypermutation 
(roughly a week’s time) and the synthesis of neutralizing antibodies would follow (4 
weeks post infection), which is what we see in vivo (Loving et al., 2015).  
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7.1 Future work 
There are several directions that the work from this thesis can take. Investigating the 
pathogenesis of PRRSV within Flt3L-derived CD163+ BMDCs could provide useful 
information into the mechanisms surrounding the decreased susceptibility to PRRSV of 
the CD163+ BMDCs. Additionally, investigating the peptide sequences being presented 
in association with MHCII by the CD163+ BMDC population, if our theory is correct, has 
the potential to aid in the development of a novel vaccine. Continuing, the mechanisms 
surrounding the transport of peptide loaded MHCII to the plasma membrane are not 
completely understood. Understanding the role of the cytoskeleton during MHCII 
trafficking to the plasma membrane would contribute to the general knowledge 
surrounding antigen presentation and processing for the field of immunology. 
Furthermore, investigating the role of the actin cytoskeleton during a PRRSV infection, 
and whether PRRSV manipulates the cytoskeleton, could provide a deeper understanding 
of the pathogenesis of virus and would contribute to the general knowledge for the field 
of virology. Lastly, explanations for the delayed induction of T cell immunity and the 
delayed induction of neutralizing antibodies do no exist. Although it would be difficult to 
investigate, determining the point in time that follicular T helper cells migrate into 
germinal centers could provide insight into the process of somatic hyptermutation in B 
cells during a PRRSV infection. Ultimately, this could provide an answer as to whether 
or not the delayed induction of neutralizing antibodies is attributable to a lack of 
follicular Th cells coordinating somatic hypermutation.  
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